Prof Timothy Hughes
School of Medicine
College of Health
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
Professor Timothy P. Hughes, MD, FRACP, FRCPA, MBBS, FAAHMS - TITLEHOLDER. Professor Timothy Hughes is Precision Medicine Theme Leader at SAHMRI Professor Timothy Hughes is the Precision Medicine Theme Leader at SAHMRI; Beat Cancer Professor at the University of Adelaide and Consultant Haematologist at the RAH. He is also Chair of the International Chronic Myeloid Leukemia Foundation (iCMLf); an inaugural Fellow of the Australian Academy of Health and Medical Sciences (AAHMS) Professor Hughes had a significant leadership role in the establishment of the molecular response criteria and kinase domain mutation screening guidelines that are used world-wide to monitor response and resistance in chronic myeloid leukaemia (CML). He has been a principal investigator on many of the key Global and Australian CML trials that have shaped the way tyrosine-kinase inhibitors (TKI's) are selected and sequenced. He has been a leader in the area of treatment-free remission (TFR) and influential in the recent recommendations to make TFR a mainstream goal of therapy. He has published over 300 papers with over 54,000 citations.In recognition of his outstanding contributions to the field, Professor Hughes was awarded an L3 Investigator Grant from the NHMRC (2022-2026) for his project "A curative approach for chronic myeloid leukaemia".
Chronic Myeloid Leukaemia (CML) - Precision Medicine Theme, SAHMRI
Lead: Professor Tim Hughes.
Brief description of research area.
The treatment of chronic myeloid leukaemia (CML) has been one of the most remarkable cancer success stories this century, heralding the widespread application of small molecules to target oncogenic kinases. Insights from CML research in this era have provided guidance for the targeted therapy programs in many other cancers. The improvement in 10-year survival for CML patients from 20% in the 1990s to over 80% today has been achieved with the clinical application of tyrosine kinase inhibitor (TKI) therapy targeting BcrAbl. Despite the improvements in outcomes achieved with TKI therapy, major challenges still confront the CML clinician. Transformation to blast crisis is still seen in -10%, similar numbers are resistant to all TKls and only -50% overall achieve deep molecular responses (DMR). Furtherme>re most CML patients will remain dependent on TKI therapy for life with current approaches. As well as the massive cost burden, this longterm dependence on TKI therapy often leads to impaired quality of life and, in some cases, significant organ damage. Pioneering work from the Bordeaux and Adelaide trial groups has shown that around half of the patients who achieve stable DMR can cease TKI therapy without evidence of molecular relapse, even with long-term follow-up ( defined as achieving treatment-free remission -TFR). By contrast the other half have molecular evidence of recurrence, usually within 6 months of stopping, and have to restart TKI therapy. We have made excellent progress in understanding some of the key drivers of DMR and TFR and are already translating some of these findings into clinical trials to expand opportunity for these optimal outcomes. This emerging knowledge will provide urgently needed criterio for safe TKI cessation and guide the design of future trials to maximise TFR with consequent major benefits for many CML patients. CML is projected to become the most prevalent leukaemia by 2040, so for f'he thousands of CML patients in Australia who are facing lifelong dependence on expensive and debilitating therapy, support for this work is critical.
Research Project 1 – Dr Ilaria Pagani
Title: Identifying and exploiting metabolic dependencies for improved therapeutic outcomes in chronic myeloid leukaemia.
While the treatment of BCR-ABL1 driven chronic myeloid leukaemia (CML) with tyrosine kinase inhibitors (TKI) has been a success story of modern medicine, not all patients respond optimally, with a small but significant minority progressing to fatal blast crisis.
The inability of TKIs to eradicate leukaemic stem and progenitor cells (LSPC) provides a potential pool for subsequent relapse. This is exemplified by the dependence of most CML patients on lifelong TKI treatment, even in patients who achieve molecular responses. Universally, the presence of an activated tyrosine kinase drives metabolic changes, and the perturbation of these metabolic pathways provides potential avenues for exploration of therapeutic interventions. Targeting metabolic pathways may potentiate the effect of TKI therapies particularly in the LSPC compartment.
The aim of the project will be to investigate the metabolic pathways that exists within normal haematopoietic cells (important knowledge to avoid toxicity), and in LSPC including cases sensitive and resistant to TKIs to enable a clear understanding of whether the metabolome of LSPC can be targeted to sensitise this pool to TKI therapy.
This novel and innovative approach will likely provide a combinational treatment strategy with greater efficacy than current approaches, specifically in CML blast crisis.
Project available for: Honours / Mphil / PhD
Location: SAHMRI
Research project start: Semester 1
Special requirements: Police Clearance
Research Project 2 – Dr Ilaria Pagani
Title: Monitoring of minimal residual disease on chronic myeloid leukaemia patients in a setting of treatment free remission.
For patients who have achieved deep molecular responses and have minimal residual disease after treatment, the new goal for clinicians today is to identify candidate patients that can safely cease TKI therapy achieving treatment free remission (TFR). It is estimated that approximately 50% of CML patients may be eligible to stop TKIs, however half of them experience molecular relapse, usually within 6 months, and have to restart therapy. CML is projected to become the most prevalent leukaemia by 2040, therefore is critical to maximise the number of patients achieving TFR. However, unravelling the critical mediators of TFR is a major challenge.
The aim of the project will be to characterise the residual leukaemia population in TFR patients, and understand why some patients relapse and others don’t. One possible line of inquiry involves identifying the lineage of residual CML cells, through a highly sensitive DNA approach. This will involve a characterization of the genomic breakpoint and the development of a patient-specific assay to monitor residual leukaemia on sorted cell populations.
Project available for: Honours / Mphil / PhD
Location: SAHMRI
Research project start: Semester 1
Special requirements: Police Clearance
Research Project 3 - Dr David Yeung, Dr Liu Lu and Dr Ilaria Pagani
Title: Investigating the efficacy of a combination of TKI and a novel allosteric inhibitor asciminib in chronic myeloid leukaemia.
Clinical trials for the treatment of CML are currently underway using asciminib (ABL001), an allosteric inhibitor, alone and in combination with ATP-competitive tyrosine kinase inhibitors (TKIs: imatinib, nilotinib or dasatinib), to inhibit the constitutively active tyrosine kinase Bcr-Abl. The aims of this project are:
- Investigation of the synergistic effect of the combination of TKI and asciminib.
- Understand the signalling pathway changes in BCR-ABL+ cell lines and CML patient cells when combination therapy is given.
- Generation of resistant cell lines in the laboratory setting. This provides a useful tool for predicting and studying patient responses in vivo.
Understanding how these drugs work in synergy will enhance our ability to predict whether patients are likely to respond to combination therapy, and clarify ways to maximise synergism between these agents. In this project, BCR-ABL1+ cell lines will be exposed long term to gradually increasing concentrations of asciminib in combination with TKI. Mechanisms of resistance will be interrogated during resistance development and once overt resistance is observed. We will then examine mechanisms of treatment resistance in vitro, in an attempt to predict emergent disease resistance mechanisms that may arise.
Project available for: Honours / Mphil / PhD
Location: SAHMRI
Research project start: Semester 1
Special requirements: Police Clearance
Research Project 4 - Dr Chung Kok
Title: Developing an artificial intelligence-based algorithm to enable a risk-adapted approach to frontline therapy in chronic myeloid leukaemia (CML).
Chronic myeloid leukaemia (CML) is a model cancer for targeted therapy, driven by an activated mutant kinase. BCR-ABL1 is both necessary and sufficient to cause CML, through the expression of the constitutively active tyrosine kinase Bcr-Abl, targetable using tyrosine kinase inhibitors (TKIs). Despite the excellent progress we have made, major challenges remain. Even with our current choice of 5 TKIs, 15-20% respond poorly to TKI therapy and half of these patients will die from CML-related causes. Approximately 10% patients still fail to respond despite receiving second generation TKIs frontline, which are more potent than the first generation TKI imatinib. This very high-risk (VHR) group would likely be more effectively managed with a “dual targeted” approach from the start of therapy. For this reason, we have focused on developing baseline predictors of treatment failure to first and second generation TKIs, so that subsequent adverse outcomes can be minimized in high-risk cases by using a more intensive approach upfront. However, this approach would not be beneficial for most patients - adding toxicity without clinical benefit in the low-risk (LR) setting. Predictors that are capable of identifying the patients most likely to benefit from the use of a more potent TKI (high-risk (HR)) and the patients who will do poorly with any of the currently available TKIs (VHR) are urgently needed. We have previously published several bioassays that are predictive of response to frontline therapy in CML, however no single assay allows a sufficiently precise classification of patient risk groups to be clinically actionable.
We propose that the most effective approach will be to utilise all of these biomarkers to develop an artificial intelligence (AI) based algorithm to guide front-line therapy. This will enable up-front triaging of CML patients, tailoring therapy to the most appropriate risk-adapted approach. The theme of this proposal, therefore, is maximising the clinical effectiveness of rationally targeted therapies in CML.
HYPOTHESES
High-risk and very high-risk patients can be identified using an artificial-intelligence derived predictive algorithm based on informative biomarkers to
- enable optimal risk-adapted treatment decisions and
- maximise the clinical effectiveness of rationally targeted therapies.
SPECIFIC AIMS
Aim 1. Develop and validate an artificial intelligence (AI) based algorithm by integrating clinical and laboratory information to predict therapy-specific risk of failure in CML
Aim 2. Design interventions in patients identified as very high-risk based on pathways identified as potential actionable targets
Aim 3. Explore the potential use of the AI algorithm in a dynamic setting to enhance clinical utility
Project available for: Honours / Mphil / PhD
Location: SAHMRI
Research project start: Semester 1
Special requirements: Police Clearance
| Date | Position | Institution name |
|---|---|---|
| 2019 - ongoing | Precision Medicine Theme Leader | South Australian Health and Medical Research Institute (SAHMRI) |
| 2015 - 2020 | Chair | SA Comprehensive Cancer Collaborative (SACCC) |
| 2015 - 2018 | Cancer Theme Leader | South Australian Health and Medical Research Institute |
| 2013 - ongoing | Cancer Council Professor | SAHMRI |
| 2013 - ongoing | Chair | International CML Foundation (iCMLf) |
| 2008 - ongoing | Co-founder | International CML Foundation (iCMLf) |
| 2008 - 2014 | Head, Department of Haematology | SA Pathology |
| 1993 - ongoing | Consultant Haematologist, , Division of Haematology | Royal Adelaide Hospital & SA Pathology |
| 1991 - 1993 | Post-Doctoral Fellow | Howard Hughes Medical Institute, UCLA, California USA |
| 1989 - 1991 | Leukaemia Research Fellow | Adult Leukaemia Research Centre, Royal Postgraduate Medical School, Hammersmith Hospital, London UK |
| 1987 - 1988 | Haematology Registrar | Prince Henry Hospital, Sydney |
| Date | Type | Title | Institution Name | Country | Amount |
|---|---|---|---|---|---|
| 2019 | Award | Ramaciotti Medal for Excellence in Biomedical Research | Ramaciotti | Australia | - |
| 2018 | Achievement | Clarivate top 1% of cited scientists in their field internationally | Clarivate | Australia | - |
| 2017 | Award | GSK Award for Research Excellence, Research Australia Health & Medical Research Awards | Research Australia Health & Medical Research | Australia | - |
| 2017 | Award | Goldman Prize, International CML Foundation (iCMLf) – outstanding lifetime contribution to the management of CML | International CML Foundation (iCMLf) | Australia | - |
| 2015 | Research Award | CIC on Top Ranked NHMRC Program Grant assessed in 2013 | NHMRC | Australia | - |
| 2015 | Fellowship | Inaugural Fellow of the Australian Academy of Health and Medical Sciences (AAHMS) | Australian Academy of Health and Medical Sciences (AAHMS) | Australia | - |
| 2015 | Achievement | Carl De Gruchy Award, HSANZ for lifetime achievements | HSANZ | Australia | - |
| 2015 | Award | The World’s Most Influential Scientific Minds 2015, “Clinical Medicine” | Thomson Reuters | Australia | - |
| 2014 | Award | Top 1% of highly cited Scientists in 2014 | Thomson Reuters | Australia | - |
| 2011 | Research Award | NHMRC Ten of the Best Research Projects | NHMRC | Australia | - |
| Date | Institution name | Country | Title |
|---|---|---|---|
| 1993 | University of New South Wales | Australia | Doctor of Medicine |
| 1988 | Fellowship of the Royal Australasian College of Physicians | Australia | FRACP |
| 1988 | Fellowship of the Royal College of Pathologists of Australia | Australia | FRCPA |
| 1981 | The University of New South Wales | Australia | MBBS Hons |
| Year | Citation |
|---|---|
| 2026 | Maqsood, M., Toubia, J., Wadham, C., Shanmuganathan, N., Shahrin, N. H., Fernandes, A., . . . Branford, S. (2026). Enhanced Detection of Splice-Altering Variants in Hematologic Malignancies Using Targeted RNA-Sequencing Data. Journal of Molecular Diagnostics, 28(1), 39-52. |
| 2025 | Beckmann, K., Kearney, B. J., Shanmuganathan, N., Yeung, D., & Hughes, T. (2025). Disease-specific survival for people with chronic myeloid leukaemia, South Australia, 1980–2020: a retrospective cohort study. Medical Journal of Australia, 223(11), 643-645. |
| 2025 | Yeung, D. T., Shanmuganathan, N., Reynolds, J., Branford, S., Walia, M., Yong, A. S. M., . . . Hughes, T. P. (2025). Australasian Leukaemia and Lymphoma Group. Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study (vol 144, pg 1993, 2024). BLOOD, 146(22), 2729. |
| 2025 | Yeung, D. T., Grigg, A. P., Reynolds, J., Branford, S., Mazumdar, D., Cunningham, I., . . . Hughes, T. (2025). The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-α2b in newly diagnosed chronic phase chronic myeloid leukaemia. British Journal of Haematology, 9 pages. |
| 2025 | Hughes, T. P., White, D. L., & Yeung, D. T. (2025). Asciminib for Philadelphia chromosome-positive leukemias. Haematologica, 110(10), 2273-2280. |
| 2025 | Apperley, J. F., Milojkovic, D., Cross, N. C. P., Hjorth-Hansen, H., Hochhaus, A., Kantarjian, H., . . . Hehlmann, R. (2025). 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Leukemia, 39(8), 1797-1813. Scopus24 WoS25 Europe PMC23 |
| 2025 | Fong, N. F. T., Ross, D. M., Yeung, D. T., Hughes, T. P., & Shanmuganathan, N. (2025). Do all patients with chronic phase CML require a diagnostic bone marrow biopsy in the modern TKI era?. Blood Neoplasia, 2(4), 100138. |
| 2025 | Shanmuganathan, N., Yeung, D. T., Wadham, C., Fernandes, A., Maqsood, M., Shahrin, N. H., . . . Branford, S. (2025). Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations. Blood, 146(23), 2821-2832. Scopus2 WoS2 |
| 2025 | Tolland, M., Ross, D. M., White, D., Hughes, T. P., & Pagani, I. S. (2025). Lipid Storage and Therapy Resistance in Chronic Myeloid Leukaemia: A Novel Perspective on Targeting Metabolic Vulnerabilities. Cancers, 17(18), 21 pages. Scopus1 WoS1 |
| 2025 | Hughes, T. P., Yong, A. S., & Ross, D. M. (2025). The Evolution of Treatment-Free Remission. Blood, 145(9), 921-930. Scopus9 WoS6 Europe PMC5 |
| 2025 | Cortes, J. E., Lang, F., Rea, D., Hochhaus, A., Breccia, M., Goh, Y. T., . . . Mauro, M. J. (2025). Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results. Leukemia, 39(5), 1124-1134. Scopus7 WoS6 Europe PMC3 |
| 2025 | Hochhaus, A., Kim, D. W., Cortes, J. E., Sasaki, K., Mauro, M. J., Hughes, T. P., . . . Rea, D. (2025). Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results. Leukemia, 39(5), 1114-1123. Scopus6 WoS4 Europe PMC3 |
| 2025 | Lagonik, E., Page, E. C., Bruning, J. B., Eadie, L. N., Heatley, S. L., Greenwood, M., . . . White, D. L. (2025). Activity of STAMP inhibitors in ABL2 rearranged Acute Lymphoblastic Leukemia is dependent on the Abl2 SH3 domain. Blood Neoplasia, 2(3), 100109. Scopus1 Europe PMC1 |
| 2025 | Mauro, M. J., Minami, Y., Hochhaus, A., Lomaia, E., Voloshin, S., Turkina, A., . . . Rea, D. (2025). Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL. Blood Advances, 9(16), 4248-4259. Scopus6 Europe PMC1 |
| 2024 | Kantarjian, H., Branford, S., Breccia, M., Cortes, J., Haddad, F. G., Hochhaus, A., . . . Xavier-Mahon, F. (2024). Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?. Leukemia, 38(5), 947-950. Scopus12 WoS10 Europe PMC8 |
| 2024 | Cortes, J. E., Sasaki, K., Kim, D. W., Hughes, T. P., Etienne, G., Mauro, M. J., . . . Rea, D. (2024). Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results. Leukemia, 38(7), 1522-1533. Scopus38 WoS35 Europe PMC30 |
| 2024 | Holmgren, A., Akkouh, I., O'Connell, K. S., Osete, J. R., Bjornstad, P. M., Djurovic, S., & Hughes, T. (2024). Bipolar patients display stoichiometric imbalance of gene expression in post-mortem brain samples. MOLECULAR PSYCHIATRY, 29(4), 1128-1138. WoS4 |
| 2024 | Kok, C. H., Irani, Y., Clarson, J., Saunders, V., Dang, P., Shanmuganathan, N., . . . Hughes, T. P. (2024). CD302 predicts achievement of deep molecular response in chronic myeloid leukemia patients treated with imatinib. Blood Neoplasia, 1(2, article no. 100014), 1-11. Scopus1 Europe PMC1 |
| 2024 | Eadie, L. N., Lagonik, E., Page, E. C., Schutz, C. E., Heatley, S. L., McClure, B. J., . . . White, D. L. (2024). Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy. Blood, 144(9), 1022-1026. Scopus6 WoS6 Europe PMC6 |
| 2024 | Hochhaus, A., Wang, J., Kim, D. W., Kim, D. D. H., Mayer, J., Goh, Y. T., . . . Hughes, T. P. (2024). Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. New England Journal of Medicine, 391(10), 885-898. Scopus103 WoS97 Europe PMC73 |
| 2024 | Chee, L., Lee, N., Grigg, A., Chen, M., Schwarer, A., Szer, J., . . . Shanmuganathan, N. (2024). Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia. Internal Medicine Journal, 54(7), 1214-1218. Scopus4 WoS4 Europe PMC4 |
| 2024 | Yeung, D. T., Shanmuganathan, N., Reynolds, J., Branford, S., & Hughes, T. P. (2024). Asciminib Monotherapy as frontline treatment of chronic-phase chronic Myeloid Leukemia: results from the ASCEND Study. Blood Journal, 144(9), 1933-2001. Scopus19 WoS20 Europe PMC15 |
| 2024 | Lim, K., Kan, W. L., Nair, P. C., Kutyna, M., Lopez, A. F., Hercus, T., . . . Thomas, D. (2024). CBL mutations in chronic myelomonocytic leukemia often occur in the RING domain with multiple subclones per patient: Implications for targeting. PLoS One, 19(9), e0310641-1-e0310641-19. Scopus1 Europe PMC1 |
| 2024 | Hochhaus, A., Cortes, J. E., & Hughes, T. P. (2024). Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.. New England Journal of Medicine, 391(23), 2275-2276. Scopus1 Europe PMC3 |
| 2024 | Hughes, T. P., Saglio, G., Geissler, J., Kim, D. W., Lomaia, E., Mayer, J., . . . Cortes, J. E. (2024). Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study. Journal of Hematology and Oncology, 17(1), 12 pages. Scopus6 WoS8 Europe PMC6 |
| 2023 | Osete, J. R., Akkouh, I. A., Ievglevskyi, O., Vandenberghe, M., de Assis, D. R., Ueland, T., . . . Djurovic, S. (2023). Characterization of lithium (Li) treated human cortical spheroids (hCS). MOLECULAR PSYCHIATRY, 28(7), 2621. |
| 2023 | Leow, B. C. S., Kok, C. H., Yeung, D. T., Hughes, T. P., White, D. L., & Eadie, L. N. (2023). The acquisition order of leukemic drug resistance mutations is directed by the selective fitness associated with each resistance mechanism. Sci Rep, 13(1), 1-12. Scopus2 WoS2 Europe PMC1 |
| 2023 | Pagani, I. S., Shanmuganathan, N., Dang, P., Saunders, V. A., Grose, R., Kok, C. H., . . . Ross, D. M. (2023). Lineage-specific detection of residual disease predicts relapse in chronic myeloid leukemia patients stopping therapy. Blood, 142(25), 2192-2197. Scopus9 WoS8 Europe PMC7 |
| 2023 | Kok, C. H., Saunders, V. A., Dang, P., Shanmuganathan, N., White, D., Branford, S., . . . Hughes, T. P. (2023). Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib. Blood Cancer Journal, 13(1), 1-9. Scopus2 WoS2 Europe PMC1 |
| 2023 | Shanmuganathan, N., & Hughes, T. P. (2023). Accelerated-phase CML: de novo and transformed. Hematology United States, 2023(1), 459-468. WoS1 |
| 2023 | Osete, J. R., Akkouh, I. A. A., Ievglevskyi, O., Vandenberghe, M., de Assis, D. R., Ueland, T., . . . Djurovic, S. (2023). Transcriptional and functional effects of lithium in bipolar disorder iPSC-derived cortical spheroids. MOLECULAR PSYCHIATRY, 28(7), 3033-3043. WoS32 Europe PMC32 |
| 2023 | Irani, Y. D., Hughes, A., Kok, C. H., Clarson, J., Yeung, D. T., Ross, D. M., . . . Yong, A. S. M. (2023). Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon-alpha. British Journal of Haematology, 202(6), 1127-1136. Scopus6 WoS4 Europe PMC4 |
| 2023 | Cortes, J. E., Hochhaus, A., Takahashi, N., Larson, R. A., Issa, G. C., Bombaci, F., . . . Hughes, T. P. (2023). Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial. Future Oncology, 18(38), 4161-4170. Scopus12 WoS11 Europe PMC5 |
| 2023 | Irani, Y. D., Kok, C. H., Clarson, J., Shanmuganathan, N., Branford, S., Yeung, D. T., . . . Yong, A. S. (2023). Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia. Blood Advances, 7(11), 2364-2374. Scopus15 WoS15 Europe PMC13 |
| 2023 | Radich, J. P., Wall, M., Branford, S., Campbell, C. D., Chaturvedi, S., DeAngelo, D. J., . . . Druker, B. J. (2023). Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis. Haematologica, 108(6), 1567-1578. Scopus4 WoS5 Europe PMC4 |
| 2023 | Hochhaus, A., Réa, D., Boquimpani, C., Minami, Y., Cortes, J. E., Hughes, T. P., . . . Mauro, M. J. (2023). Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia, 37(3), 617-626. Scopus120 WoS112 Europe PMC90 |
| 2023 | Shanmuganathan, N., Wadham, C., Shahrin, N., Feng, J., Thomson, D., Wang, P., . . . Branford, S. (2023). Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention. Haematologica, 108(9), 2380-2395. Scopus22 WoS23 Europe PMC15 |
| 2023 | Mauro, M. J., Hughes, T. P., Kim, D. W., Rea, D., Cortes, J. E., Hochhaus, A., . . . Lang, F. (2023). Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results. Leukemia, 37(5), 1048-1059. Scopus42 WoS42 Europe PMC40 |
| 2023 | Torsvik, A., Brattbakk, H. -R., Trentani, A., Holdhus, R., Stansberg, C., Bartz-Johannessen, C. A., . . . Steen, V. M. (2023). Patients with schizophrenia and bipolar disorder display a similar global gene expression signature in whole blood that reflects elevated proportion of immature neutrophil cells with association to lipid changes. TRANSLATIONAL PSYCHIATRY, 13(1), 12 pages. WoS11 Europe PMC18 |
| 2022 | Holmgren, A., Hansson, L., Bjerkaas-Kjeldal, K., Impellizzeri, A. A. R., Gilfillan, G. D., Djurovic, S., & Hughes, T. (2022). Mapping the expression of an <i>ANK3</i> isoform associated with bipolar disorder in the human brain. TRANSLATIONAL PSYCHIATRY, 12(1), 8 pages. WoS4 Europe PMC3 |
| 2022 | O'Connell, K. S., Sonderby, I. E., Frei, O., van der Meer, D., Athanasiu, L., Smeland, O. B., . . . Djurovic, S. (2022). Association between complement component 4A expression, cognitive performance and brain imaging measures in UK Biobank. PSYCHOLOGICAL MEDICINE, 52(15), 3497-3507. WoS17 Europe PMC23 |
| 2022 | Krull, F., Akkouh, I., Hughes, T., Bettella, F., Athanasiu, L., Smeland, O. B., . . . Andreassen, O. A. (2022). Dose-dependent transcriptional effects of lithium and adverse effect burden in a psychiatric cohort. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 112, 8 pages. WoS6 Europe PMC5 |
| 2022 | Krishnan, V., Kim, D. D. H., Hughes, T. P., Branford, S., & Ong, S. T. (2022). Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers. Haematologica, 107(2), 358-370. Scopus18 WoS15 Europe PMC14 |
| 2022 | Hughes, T. P., Cortes, J. E., Réa, D., Mauro, M. J., Hochhaus, A., Kim, D. W., . . . Mahon, F. X. (2022). CML-466 Asciminib Provides Durable Molecular Responses in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With the T315I Mutation: Updated Efficacy and Safety Data From a Phase I Trial. Clinical Lymphoma Myeloma and Leukemia, 22, S300. Scopus1 |
| 2022 | Réa, D., Hochhaus, A., Mauro, M. J., Minami, Y., Lomaia, E., Voloshin, S., . . . Boquimpani, C. (2022). CML-395 Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update. Clinical Lymphoma Myeloma and Leukemia, 22, S295-S296. Scopus2 WoS2 |
| 2022 | Hughes, T. P., Cortes, J., Takahashi, N., Larson, R., Issa, G. C., Bombaci, F., . . . Hochhaus, A. (2022). CML-423 Trial in Progress: A Phase III Study of Asciminib vs an Investigator-Selected Tyrosine Kinase Inhibitor (TKI) in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Clinical Lymphoma Myeloma and Leukemia, 22, S297-S298. |
| 2022 | Hughes, T. P., & Shanmuganathan, N. (2022). Management of TKI-resistant chronic phase CML. Hematology. American Society of Hematology. Education Program, 2022(1), 129-137. Scopus16 WoS15 Europe PMC15 |
| 2022 | Page, E. C., Heatley, S. L., Eadie, L. N., McClure, B. J., de Bock, C. E., Omari, S., . . . White, D. L. (2022). HMGN1 plays a significant role in CRLF2 driven Down Syndrome leukemia and provides a potential therapeutic target in this high-risk cohort. Oncogene, 41(6), 797-808. Scopus18 WoS17 Europe PMC15 |
| 2022 | Shirazi, P. T., Eadie, L. N., Heatley, S. L., Page, E. C., François, M., Hughes, T. P., . . . White, D. L. (2022). Exploring the oncogenic and therapeutic target potential of the MYB-TYK2 fusion gene in B-cell acute lymphoblastic leukemia. Cancer Gene Therapy, 29(8-9), 1140-1152. Scopus7 WoS7 Europe PMC7 |
| 2022 | Réa, D., & Hughes, T. P. (2022). Development of asciminib, a novel allosteric inhibitor of BCR-ABL1. Critical Reviews in Oncology Hematology, 171, 11 pages. Scopus53 WoS46 Europe PMC36 |
| 2022 | Adnan Awad, S., Brück, O., Shanmuganathan, N., Jarvinen, T., Lähteenmäki, H., Klievink, J., . . . Mustjoki, S. (2022). Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation. Blood Cancer Journal, 12(4, article no. 69), 4 pages. Scopus23 WoS21 Europe PMC17 |
| 2022 | Yeung, D. T., Shanmuganathan, N., & Hughes, T. P. (2022). Asciminib: a new therapeutic option in chronic-phase CML with treatment failure. Blood, 139(24), 3474-3479. Scopus44 WoS36 Europe PMC27 |
| 2022 | Shanmuganathan, N., Wadham, C., Thomson, D., Shahrin, N. H., Vignaud, C., Obourn, V., . . . Branford, S. (2022). RNA-Based Targeted Gene Sequencing Improves the Diagnostic Yield of Mutant Detection in Chronic Myeloid Leukemia.. The Journal of molecular diagnostics : JMD, 24(7), 803-822. Scopus9 WoS8 Europe PMC5 |
| 2022 | Lu, L., Kok, C. H., Dang, P., Branford, S., Saunders, V. A., Shanmuganathan, N., . . . Yeung, D. T. O. (2022). Highly sensitive droplet digital polymerase chain reaction for BCR::ABL1 messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment-free remission. British Journal of Haematology, 198(3), 600-603. Scopus9 WoS8 Europe PMC7 |
| 2022 | Shanmuganathan, N., & Hughes, T. P. (2022). Asciminib for chronic myeloid leukaemia: Next questions. British Journal of Haematology, 199(3), 322-331. Scopus11 WoS9 Europe PMC5 |
| 2022 | Poudel, G., Tolland, M. G., Hughes, T. P., & Pagani, I. S. (2022). Mechanisms of Resistance and Implications for Treatment Strategies in Chronic Myeloid Leukaemia. Cancers, 14(14), 18 pages. Scopus52 WoS44 Europe PMC43 |
| 2022 | Kutyna, M. M., Kok, C. H., Lim, Y., Tran, E. N. H., Campbell, D., Paton, S., . . . Hiwase, D. K. (2022). A senescence stress secretome is a hallmark of therapy-related myeloid neoplasm stromal tissue occurring soon after cytotoxic exposure. Leukemia, 36(11), 2678-2689. Scopus18 WoS17 Europe PMC17 |
| 2021 | Heatley, S. L., Asari, K., Schutz, C. E., Leclercq, T. M., McClure, B. J., Eadie, L. N., . . . White, D. L. (2021). In-vitro modeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion gene RANBP2-ABL1 - implications for targeted therapy. Leukemia and Lymphoma, 62(5), 1157-1166. Scopus4 WoS3 Europe PMC3 |
| 2021 | Kantarjian, H. M., Hughes, T. P., Larson, R. A., Kim, D. W., Issaragrisil, S., le Coutre, P., . . . Hochhaus, A. (2021). Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia, 35(2), 440-453. Scopus282 WoS265 Europe PMC220 |
| 2021 | Reis de Assis, D., Szabo, A., Requena Osete, J., Puppo, F., O'Connell, K. S., A. Akkouh, I., . . . Djurovic, S. (2021). Using iPSC Models to Understand the Role of Estrogen in Neuron-Glia Interactions in Schizophrenia and Bipolar Disorder. CELLS, 10(2), 33 pages. WoS7 Europe PMC8 |
| 2021 | Hughes, T. P., Clementino, N. C. D., Fominykh, M., Lipton, J. H., Turkina, A. G., Moiraghi, E. B., . . . Mahon, F. -X. (2021). Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update.. Leukemia, 35(6), 1631-1642. Scopus36 WoS35 Europe PMC31 |
| 2021 | García-Montolio, M., Ballaré, C., Blanco, E., Gutiérrez, A., Aranda, S., Gómez, A., . . . Di Croce, L. (2021). Polycomb Factor PHF19 Controls Cell Growth and Differentiation Toward Erythroid Pathway in Chronic Myeloid Leukemia Cells. Frontiers in Cell and Developmental Biology, 9, 13 pages. Scopus9 WoS9 Europe PMC10 |
| 2021 | Kantarjian, H. M., Hughes, T. P., Larson, R. A., Kim, D. W., Issaragrisil, S., le Coutre, P., . . . Hochhaus, A. (2021). Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (Leukemia, (2021), 35, 2, (440-453), 10.1038/s41375-020-01111-2). Leukemia, 35(7), 2142-2143. Scopus12 WoS10 Europe PMC6 |
| 2021 | Shanmuganathan, N., Pagani, I. S., Ross, D. M., Park, S., Yong, A. S., Braley, J. A., . . . Hughes, T. P. (2021). Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia. Blood, 137(9), 1196-1207. Scopus73 WoS65 Europe PMC51 |
| 2021 | Ross, D. M., & Hughes, T. P. (2021). Counterpoint: There is a best duration of deep molecular response for treatment-free remission, but it is patient-specific, and that is the challenge. British Journal of Haematology, 192(1), 24-27. Scopus3 WoS4 Europe PMC3 |
| 2021 | El Khawanky, N., Hughes, A., Yu, W., Myburgh, R., Matschulla, T., Taromi, S., . . . Zeiser, R. (2021). Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia. Nat Commun, 12(1), 6436-1-6436-20. Scopus91 WoS89 Europe PMC86 |
| 2021 | Réa, D., Mauro, M. J., Boquimpani, C., Minami, Y., Lomaia, E., Voloshin, S., . . . Hochhaus, A. (2021). A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood, 138(21), 2031-2041. Scopus269 WoS247 Europe PMC210 |
| 2021 | Akkouh, I. A., Hughes, T., Steen, V. M., Glover, J. C., Andreassen, O. A., Djurovic, S., & Szabo, A. (2021). Transcriptome analysis reveals disparate expression of inflammation-related miRNAs and their gene targets in iPSC-astrocytes from people with schizophrenia. BRAIN BEHAVIOR AND IMMUNITY, 94, 235-244. WoS24 Europe PMC26 |
| 2021 | Szabo, A., Akkouh, I. A., Vandenberghe, M., Osete, J. R., Hughes, T., Heine, V., . . . Djurovic, S. (2021). A human iPSC-astroglia neurodevelopmental model reveals divergent transcriptomic patterns in schizophrenia. TRANSLATIONAL PSYCHIATRY, 11(1), 13 pages. WoS21 Europe PMC26 |
| 2021 | Osete, J. R., Akkouh, I. A., de Assis, D. R., Szabo, A., Frei, E., Hughes, T., . . . Djurovic, S. (2021). Lithium increases mitochondrial respiration in iPSC-derived neural precursor cells from lithium responders. MOLECULAR PSYCHIATRY, 26(11), 6789-6805. WoS47 Europe PMC42 |
| 2021 | Kelly, L., Dreher, D., Kim, G., Hughes, T., & Sabouri, A. S. (2021). Placement of a Peripherally Inserted Central Catheter in a Prone Patient With COVID-19 Feasibility and Case Report. JOURNAL OF INFUSION NURSING, 44(4), 199-202. WoS1 |
| 2020 | Schmitz, U., Shah, J. S., Dhungel, B. P., Monteuuis, G., Luu, P. -L., Petrova, V., . . . Rasko, J. E. J. (2020). Widespread aberrant alternative splicing despite molecular remission in chronic myeloid leukaemia patients. Cancers, 12(12), 3738-1-3738-19. Scopus10 WoS10 Europe PMC11 |
| 2020 | Pagani, I. S., Dang, P., Saunders, V. A., Braley, J., Thieleke, A., Branford, S., . . . Ross, D. M. (2020). Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid leukemia. Leukemia and Lymphoma, 61(10), 2527-2529. Scopus9 WoS6 Europe PMC4 |
| 2020 | McClure, B. J., Heatley, S. L., Rehn, J., Breen, J., Sutton, R., Hughes, T. P., . . . White, D. L. (2020). High-risk B-cell acute lymphoblastic leukaemia presenting with hypereosinophilia and acquiring a novel PAX5 fusion on relapse. British Journal of Haematology, 191(2), 301-304. Scopus4 WoS3 Europe PMC3 |
| 2020 | Hochhaus, A., Boquimpani, C., Rea, D., Minami, Y., Lomaia, E., Voloshin, S., . . . Mauro, M. J. (2020). Efficacy and safety results from ASCEMBL, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib (BOS) in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs). Blood, 136(Supplement_2), 5 pages. Scopus21 WoS17 |
| 2020 | Turkina, A., Wang, J., Mathews, V., Saydam, G., Jung, C. W., Al Hashmi, H. H., . . . Hughes, T. P. (2020). TARGET: a survey of real-world management of chronic myeloid leukaemia across 33 countries. British Journal of Haematology, 190(6), 869-876. Scopus34 WoS38 Europe PMC38 |
| 2020 | Mauro, M. J., & Hughes, T. P. (2020). Asciminib in Relapsed Chronic Myeloid Leukemia Reply. NEW ENGLAND JOURNAL OF MEDICINE, 382(14), 1379. WoS3 Europe PMC2 |
| 2020 | Irani, Y. D., Hughes, A., Clarson, J., Kok, C. H., Shanmuganathan, N., White, D. L., . . . Yong, A. S. M. (2020). Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells. British Journal of Haematology, 191(3), 433-441. Scopus67 WoS63 Europe PMC59 |
| 2020 | Ross, D. M., & Hughes, T. P. (2020). Treatment-free remission in patients with chronic myeloid leukaemia.. Nature Reviews Clinical Oncology, 17(8), 493-503. Scopus45 WoS44 Europe PMC35 |
| 2020 | Thomson, D. W., Shahrin, N. H., Wang, P. P. S., Wadham, C., Shanmuganathan, N., Scott, H. S., . . . Branford, S. (2020). Aberrant RAG-mediated recombination contributes to multiple structural rearrangements in lymphoid blast crisis of chronic myeloid leukemia. Leukemia, 34(8), 2051-2063. Scopus36 WoS35 Europe PMC30 |
| 2020 | Shanmuganathan, N., & Hughes, T. P. (2020). What's NEXT for CML-NGS mutation screening. Blood, 135(8), 515-516. Scopus1 WoS1 Europe PMC1 |
| 2020 | Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., . . . Hehlmann, R. (2020). European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia, 34(4), 966-984. Scopus1247 WoS1115 Europe PMC951 |
| 2020 | Pagani, I. S., Dang, P., Saunders, V. A., Grose, R., Shanmuganathan, N., Kok, C. H., . . . Ross, D. M. (2020). Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission. Leukemia, 34(4), 1052-1061. Scopus42 WoS41 Europe PMC33 |
| 2020 | Akkouh, I. A., Ueland, T., Hansson, L., Inderhaug, E., Hughes, T., Steen, N. E., . . . Djurovic, S. (2020). Decreased IL-1β-induced CCL20 response in human iPSC-astrocytes in schizophrenia: Potential attenuating effects on recruitment of regulatory T cells. BRAIN BEHAVIOR AND IMMUNITY, 87, 634-644. WoS44 Europe PMC48 |
| 2020 | Hughes, T., Hansson, L., Akkouh, I., Hajdarevic, R., Bringsli, J. S., Torsvik, A., . . . Djurovic, S. (2020). Runaway multi-allelic copy number variation at the α-defensin locus in African and Asian populations. SCIENTIFIC REPORTS, 10(1), 8 pages. WoS5 Europe PMC6 |
| 2020 | Akkouh, I. A., Skrede, S., Holmgren, A., Ersland, K. M., Hansson, L., Bahrami, S., . . . Hughes, T. (2020). Exploring lithium's transcriptional mechanisms of action in bipolar disorder: a multi-step study. NEUROPSYCHOPHARMACOLOGY, 45(6), 947-955. WoS30 Europe PMC30 |
| 2020 | Zhang, Z., Yu, Y., Xie, Y., Hughes, T., Xu, J., Huang, F., & Huang, H. (2020). Catalytic C-C coupling of diazo compounds with arylboronic acids: Using surface modified sewage sludge as catalyst. Green Chemistry, 22(13), 4165-4173. Scopus8 WoS10 |
| 2019 | Dipietro, L., Campbell, W. W., Buchner, D. M., Erickson, K., Powell, K. E., Bloodgood, B., . . . Whitt-Glover, M. C. (2019). Physical Activity, Injurious Falls, and Physical Function in Aging: An Umbrella Review. MEDICINE & SCIENCE IN SPORTS & EXERCISE, 51(6), 1303-1313. WoS206 Europe PMC174 |
| 2019 | Tavakoli Shirazi, P., Eadie, L. N., Heatley, S. L., Hughes, T. P., Yeung, D. T., & White, D. L. (2019). The effect of co-occurring lesions on leukaemogenesis and drug response in T-ALL and ETP-ALL.. British journal of cancer, 122(4), 455-464. Scopus12 WoS12 Europe PMC11 |
| 2019 | Shanmuganathan, N., & Hughes, T. P. (2019). Early Management of CML. Current Hematologic Malignancy Reports, 14(6), 480-491. Scopus2 WoS3 |
| 2019 | Hughes, T. P., Mauro, M. J., Cortes, J. E., Minami, H., Rea, D., DeAngelo, D. J., . . . Kim, D. -W. (2019). Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.. The New England journal of medicine, 381(24), 2315-2326. Scopus405 WoS361 Europe PMC305 |
| 2019 | Heraud, C., Basuki, J., Hughes, T. C., & Mueller, M. (2019). Copolymerization of Pentafluorophenylmethacrylate with Hydrophilic Methacrylamide Monomers Induces Premature Hydrolytic Cleavage. Macromolecular Rapid Communications, 40(19), 7 pages. Scopus5 WoS3 Europe PMC3 |
| 2019 | Shanmuganathan, N., Braley, J. A., Yong, A. S. M., Hiwase, D. K., Yeung, D. T., Ross, D. M., . . . Branford, S. (2019). Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission. Blood, 134(1), 85-89. Scopus28 WoS25 Europe PMC21 |
| 2019 | Kok, C. H., Yeung, D. T., Lu, L., Watkins, D. B., Leclercq, T. M., Dang, P., . . . Hughes, T. P. (2019). Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib. Blood Advances, 3(10), 1610-1621. Scopus31 WoS28 Europe PMC30 |
| 2019 | Branford, S., Kim, D. D. H., Apperley, J. F., Eide, C. A., Mustjoki, S., Ong, S. T., . . . International CML Foundation Genomics Alliance. (2019). Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia, 33(8), 1835-1850. Scopus121 WoS106 Europe PMC94 |
| 2019 | Chhetri, R., Wee, L. Y. A., Sinha, R., Kutyna, M. M., Pham, A., Stathopoulos, H., . . . Hiwase, D. K. (2019). Red cell autoimmunization and alloimmunization in myelodysplastic syndromes: Prevalence, characteristic and significance. Haematologica, 104(10), E451-E454. Scopus19 WoS19 Europe PMC12 |
| 2019 | Shanmuganathan, N., Branford, S., Hughes, T. P., & Hiwase, D. (2019). Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI. Blood Advances, 3(3), 370-374. Scopus7 WoS7 Europe PMC3 |
| 2019 | Ross, D. M., Pagani, I. S., Irani, Y. D., Clarson, J., Leclercq, T., Dang, P., . . . Yong, A. S. M. (2019). Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia. British Journal of Haematology, 186(3), e56-e60. Scopus13 WoS12 Europe PMC13 |
| 2019 | Hughes, T. P., Laneuville, P., Rousselot, P., Snyder, D. S., Rea, D., Shah, N. P., . . . Cortes, J. E. (2019). Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for philadelphia chromosome-positive leukemia. Haematologica, 104(1), 93-101. Scopus74 WoS75 Europe PMC58 |
| 2018 | Nair, S. S., Luu, P. -L., Qu, W., Maddugoda, M., Huschtscha, L., Reddel, R., . . . Clark, S. J. (2018). Guidelines for whole genome bisulphite sequencing of intact and FFPET DNA on the Illumina HiSeq X Ten. Epigenetics & Chromatin, 11(1), 24. Scopus41 WoS38 Europe PMC36 |
| 2018 | Ross, D. M., Burbury, K. L., Grigg, A. P., Hughes, T. P., & Seymour, J. F. (2018). Management of pregnancy in women with chronic myeloid leukemia. Journal of Clinical Oncology, 36(25), 2657-2658. Scopus2 WoS2 Europe PMC2 |
| 2018 | Branford, S., Wang, P., Yeung, D. T., Thomson, D., Purins, A., Wadham, C., . . . Hughes, T. P. (2018). Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. Blood, 132(9), 948-961. Scopus171 WoS164 Europe PMC146 |
| 2018 | Lu, L., Kok, C. H., Saunders, V., Wang, J., McLean, J., Hughes, T. P., . . . White, D. L. (2018). Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant BCR-ABL1+ cell lines. Oncotarget, 9(78), 34735-34747. Scopus17 Europe PMC11 |
| 2018 | Pagani, I. S., Dang, P., Kommers, I. O., Goyne, J. M., Nicola, M., Saunders, V. A., . . . Ross, D. M. (2018). BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia. Haematologica, 103(12), 2026-2032. Scopus36 WoS28 Europe PMC24 |
| 2018 | Eadie, L. N., Hughes, T. P., & White, D. L. (2018). Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapy. Leukemia, 32(10), 2288-2291. Scopus11 WoS10 Europe PMC8 |
| 2018 | Eadie, L., Saunders, V., Branford, S., White, D., & Hughes, T. (2018). The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro. Oncotarget, 9(17), 13423-13437. Scopus50 Europe PMC36 |
| 2018 | Hiwase, D., Tan, P., D'Rozario, J., Taper, J., Powell, A., Irving, I., . . . Hughes, T. (2018). Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: results from the Phase IIIb ENESTswift study. Leukemia Research, 67, 109-115. Scopus15 WoS15 Europe PMC9 |
| 2018 | McClure, B., Heatley, S., Kok, C., Sadras, T., An, J., Hughes, T., . . . White, D. (2018). Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression. British Journal of Cancer, 118(7), 1000-1004. Scopus34 WoS29 Europe PMC27 |
| 2018 | Cortes, J. E., Kim, D. -W., Pinilla-Ibarz, J., le Coutre, P. D., Paquette, R., Chuah, C., . . . Kantarjian, H. M. (2018). Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.. Blood, 132(4), 1-13. Scopus503 WoS456 Europe PMC397 |
| 2018 | Eadie, L., Dang, P., Goyne, J., Hughes, T., & White, D. (2018). ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells. PLoS ONE, 13(1), e0192180-1-e0192180-18. Scopus23 WoS19 Europe PMC18 |
| 2018 | Broughton, S., Hercus, T., Nero, T., Kan, W., Barry, E., Dottore, M., . . . Parker, M. (2018). A dual role for the N-terminal domain of the IL-3 receptor in cell signalling. Nature Communications, 9(1), 386-1-386-15. Scopus34 WoS34 Europe PMC27 |
| 2018 | Mahon, F. X., Boquimpani, C., Kim, D. W., Benyamini, N., Clementino, N. C. D., Shuvaev, V., . . . Hughes, T. P. (2018). Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase results from a single-group, phase 2, open-label study. Annals of Internal Medicine, 168(7), 461-470. Scopus131 WoS115 Europe PMC94 |
| 2018 | Hercus, T., Kan, W., Broughton, S., Tvorogov, D., Ramshaw, H., Sandow, J., . . . Lopez, A. (2018). Role of the β common (βc) family of cytokines in health and disease. Cold Spring Harbor Perspectives in Biology, 10(6), a028514. Scopus42 WoS33 Europe PMC32 |
| 2018 | Witoelar, A., Rongve, A., Almdahl, I. S., Ulstein, I. D., Engvig, A., White, L. R., . . . Andreassen, O. A. (2018). Meta-analysis of Alzheimer's disease on 9,751 samples from Norway and IGAP study identifies four risk loci. SCIENTIFIC REPORTS, 8(1), 8 pages. WoS36 Europe PMC53 |
| 2018 | Ross, D., Pagani, I., Shanmuganathan, N., Kok, C., Seymour, J., Mills, A., . . . Hughes, T. (2018). Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells. Leukemia, 32(12), 2572-2579. Scopus72 WoS65 Europe PMC58 |
| 2018 | Shanmuganathan, N., & Hughes, T. P. (2018). Molecular monitoring in CML: how deep? How often? How should it influence therapy?. Blood, 132(20), 2125-2133. Scopus15 WoS13 Europe PMC12 |
| 2018 | Tvorogov, D., Thomas, D., Liau, N. P. D., Dottore, M., Barry, E. F., Lathi, M., . . . Lopez, A. F. (2018). Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis. Science Advances, 4(11), 1-12. Scopus48 WoS49 Europe PMC52 |
| 2018 | Shanmuganathan, N., & Hughes, T. P. (2018). Molecular monitoring in CML: how deep? How often? How should it influence therapy?. Hematology, 2018(1), 168-176. Scopus27 WoS21 Europe PMC17 |
| 2018 | Mahon, F. X., & Hughes, T. P. (2018). Treatment-free remission after second-line nilotinib treatment: In response. Annals of Internal Medicine, 169(7), 510. Scopus1 WoS1 |
| 2018 | Chesterman, J. P., Hughes, T. C., & Amsden, B. G. (2018). Reversibly photo-crosslinkable aliphatic polycarbonates functionalized with coumarin. European Polymer Journal, 105, 186-193. Scopus36 WoS31 |
| 2018 | Li, L., Lu, C., Wang, L., Chen, M., White, J., Hao, X., . . . Hughes, T. C. (2018). Gelatin-Based Photocurable Hydrogels for Corneal Wound Repair. ACS Applied Materials and Interfaces, 10(16), 13283-13292. Scopus170 WoS168 Europe PMC113 |
| 2018 | Whinton, M., Hughes, T. C., Peng, S., & Brook, M. A. (2018). Silicone Microemulsion Structures Are Maintained during Polymerization with Reactive Surfactants. Langmuir, 34(14), 4374-4381. Scopus10 WoS7 Europe PMC3 |
| 2018 | Hughes, T., Sønderby, I. E., Polushina, T., Hansson, L., Holmgren, A., Athanasiu, L., . . . Djurovic, S. (2018). Elevated expression of a minor isoform of ANK3 is a risk factor for bipolar disorder. Translational Psychiatry, 8(1), 12 pages. Scopus23 WoS19 Europe PMC23 |
| 2018 | Akkouh, I. A., Ueland, T., Andreassen, O. A., Brattbakk, H. -R., Steen, V. M., Hughes, T., & Djurovic, S. (2018). Expression of <i>TCN1</i> in Blood is Negatively Associated with Verbal Declarative Memory Performance. SCIENTIFIC REPORTS, 8(1), 11 pages. WoS12 Europe PMC13 |
| 2018 | Segorbe, D., Wilkinson, D., Mizeranschi, A., Hughes, T., Aalokken, R., Vachova, L., . . . Gilfillan, G. D. (2018). An optimized FAIRE procedure for low cell numbers in yeast. YEAST, 35(8), 507-512. WoS4 Europe PMC4 |
| 2018 | Fan, L., Martynenko, A., Doucette, C., Hughes, T., & Fillmore, S. (2018). Microbial Quality and Shelf Life of Blueberry Puree Developed Using Cavitation Technology. JOURNAL OF FOOD SCIENCE, 83(3), 732-739. WoS15 Europe PMC6 |
| 2017 | Marsikova, J., Wilkinson, D., Hlavacek, O., Gilfillan, G. D., Mizeranschi, A., Hughes, T., . . . Palkova, Z. (2017). Metabolic differentiation of surface and invasive cells of yeast colony biofilms revealed by gene expression profiling. BMC GENOMICS, 18(1), 16 pages. WoS15 Europe PMC19 |
| 2017 | Ge, C., Basuki, J. S., White, J., Hou, R., Peng, Y., Hughes, T. C., & Tan, T. (2017). Photothermal triggered protein release from an injectable polycaprolactone-based microspherical depot. Journal of Materials Chemistry B, 5(20), 3634-3639. Scopus1 WoS1 |
| 2017 | Hu, S., Ren, W., Cai, D., Hughes, T. C., Qin, P., & Tan, T. (2017). A mixed matrix membrane for butanol pervaporation based on micron-sized silicalite-1 as macro-crosslinkers. Journal of Membrane Science, 533, 270-278. Scopus60 WoS51 |
| 2017 | Basuki, J. S., Qie, F., Mulet, X., Suryadinata, R., Vashi, A. V., Peng, Y. Y., . . . Hughes, T. C. (2017). Photo-Modulated Therapeutic Protein Release from a Hydrogel Depot Using Visible Light. Angewandte Chemie International Edition, 56(4), 966-971. Scopus93 WoS91 Europe PMC51 |
| 2017 | Hughes, T., & Saglio, G. (2017). Expert opinion on the treatment of refractory chronic phase chronic myeloid leukaemia. European Oncology and Haematology, 13(1), 17-23. Scopus1 |
| 2017 | Nicolini, F. E., Basak, G. W., Kim, D. W., Olavarria, E., Pinilla-Ibarz, J., Apperley, J. F., . . . Cortes, J. E. (2017). Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer, 123(15), 2875-2880. Scopus93 WoS84 Europe PMC75 |
| 2017 | Pagani, I. S., Kok, C. H., Saunders, V. A., Van der Hoek, M. B., Heatley, S. L., Schwarer, A. P., . . . Ross, D. M. (2017). A method for next-generation sequencing of paired diagnostic and remission Samples to detect mitochondrial DNA mutations associated with leukemia. The Journal of molecular diagnostics : JMD, 19(5), 711-721. Scopus6 WoS5 Europe PMC7 |
| 2017 | Hughes, T. P., Munhoz, E., Aurelio Salvino, M., Ong, T. C., Elhaddad, A., Shortt, J., . . . Lipton, J. H. (2017). Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd. British Journal of Haematology, 179(2), 219-228. Scopus22 WoS19 Europe PMC17 |
| 2017 | Sadras, T., Heatley, S., Kok, C., McClure, B., Yeung, D., Hughes, T., . . . White, D. (2017). A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH. Cancer Genetics, 216-217, 86-90. Scopus13 WoS13 Europe PMC13 |
| 2017 | Sadras, T., Heatley, S., Kok, C., Dang, P., Galbraith, K., McClure, B., . . . White, D. (2017). Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions. Cancer Letters, 408, 92-101. Scopus19 WoS21 Europe PMC20 |
| 2017 | Marum, J., Yeung, D., Purins, L., Reynolds, J., Parker, W., Stangl, D., . . . Branford, S. (2017). ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure. Blood Advances, 1(18), 1369-1381. Scopus22 WoS19 Europe PMC20 |
| 2017 | Hughes, T. P., Leber, B., Cervantes, F., Spector, N., Pasquini, R., Clementino, N. C. D., . . . Lipton, J. H. (2017). Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: Final ENESTcmr randomized trial results. Leukemia, 31(11), 2529-2531. Scopus42 WoS42 Europe PMC31 |
| 2017 | Rasko, J. E. J., & Hughes, T. P. (2017). First Approved Kinase Inhibitor for AML. Cell, 171(5), 981. Scopus10 WoS8 Europe PMC9 |
| 2017 | Heatley, S. L., Sadras, T., Kok, C. H., Nievergall, E., Quek, K., Dang, P., . . . White, D. L. (2017). High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment. Haematologica, 102(12), e490-e493. Scopus57 WoS55 Europe PMC52 |
| 2017 | Eadie, L., Hughes, T., & White, D. (2017). Response to 'Overexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics?'. Leukemia, 31(3), 769-770. |
| 2017 | Hughes, A. E., Clarson, J., Gargett, T., Yu, W., Brown, M. P., Lopez, A. F., . . . Yong, A. S. M. (2017). Comment on 'KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study'. Leukemia research, 55, 55-57. Scopus3 WoS3 Europe PMC3 |
| 2017 | Hughes, T. P., & Ross, D. M. (2017). Targeted therapies: Remembrance of things past - Discontinuation of second-generation TKI therapy for CML. Nature Reviews Clinical Oncology, 14(4), 201-202. Scopus6 WoS2 Europe PMC5 |
| 2017 | Wang, J., Lu, L., Kok, C., Saunders, V., Goyne, J., Dang, P., . . . White, D. (2017). Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells. Haematologica, 102(5), 843-853. Scopus12 WoS13 Europe PMC7 |
| 2017 | Hochhaus, A., Larson, R., Guilhot, F., Radich, J., Branford, S., Hughes, T., . . . Druker, B. (2017). Long-term outcomes of imatinib treatment for chronic myeloid leukemia. New England Journal of Medicine, 376(10), 917-927. Scopus1073 WoS964 Europe PMC810 |
| 2017 | Wylie, A. A., Schoepfer, J., Jahnke, W., Cowan Jacob, S. W., Branford, S., & Sellers, W. R. (2017). The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature, 543(7647), 733-737. Scopus494 WoS477 Europe PMC411 |
| 2017 | Sopper, S., Mustjoki, S., White, D., Hughes, T., Valent, P., Burchert, A., . . . Wolf, D. (2017). Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia. Journal of Clinical Oncology, 35(2), 175-184. Scopus36 WoS30 Europe PMC25 |
| 2017 | Barratt, D., Cox, H., Menelaou, A., Yeung, D., White, D., Hughes, T., & Somogyi, A. (2017). CYP2C8 genotype significantly alters imatinib metabolism in chronic myeloid leukaemia patients. Clinical Pharmacokinetics, 56(8), 977-985. Scopus22 WoS23 Europe PMC20 |
| 2017 | Hughes, A., Clarson, J., Tang, C., Vidovic, L., White, D., Hughes, T., & Yong, A. (2017). CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. Blood, 129(9), 1166-1176. Scopus166 WoS155 Europe PMC145 |
| 2017 | Banjar, H., Ranasinghe, D., Brown, F., Adelson, D., Kroger, T., Leclercq, T., . . . Chaudhri, N. (2017). Modelling predictors of molecular response to frontline imatinib for patients with chronic myeloid leukaemia. PLoS ONE, 12(1), 1-23. Scopus8 WoS7 Europe PMC5 |
| 2017 | Eadie, L. N., Dang, P., Saunders, V. A., Yeung, D. T., Osborn, M. P., Grigg, A. P., . . . White, D. L. (2017). The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment. Leukemia, 31(1), 75-82. Scopus58 WoS60 Europe PMC54 |
| 2016 | Lipton, J., Chuah, C., Guerci-Bresler, A., Rosti, G., Simpson, D., Assouline, S., . . . Deininger, M. (2016). Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncology, 17(5), 612-621. Scopus246 WoS215 Europe PMC183 |
| 2016 | Deininger, M., Hodgson, J., Shah, N., Cortes, J., Kim, D., Nicolini, F., . . . Branford, S. (2016). Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood, 127(6), 703-712. Scopus94 WoS91 Europe PMC70 |
| 2016 | le Coutre, P., Hughes, T., Mahon, F., Kim, D., Steegmann, J., Shah, N., . . . Cortes, J. (2016). Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials. Leukemia, 30(7), 1593-1596. Scopus11 WoS12 Europe PMC11 |
| 2016 | Parker, W., Yeung, D., Yeoman, A., Altamura, H., Jamison, B., Field, C., . . . Branford, S. (2016). The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib. Blood, 127(15), 1870-1880. Scopus60 WoS57 Europe PMC51 |
| 2016 | Hochhaus, A., Saglio, G., Hughes, T., Larson, R., Kim, D., Issaragrisil, S., . . . Kantarjian, H. (2016). Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia, 30(5), 1044-1054. Scopus705 WoS654 Europe PMC579 |
| 2016 | Latham, S., Bartley, P., Budgen, B., Ross, D., Hughes, E., Branford, S., . . . Morley, A. (2016). BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia. Journal of Clinical Pathology, 69(9), 817-821. Scopus9 WoS9 Europe PMC7 |
| 2016 | Nievergall, E., Reynolds, J., Kok, C., Watkins, D., Biondo, M., Busfield, S., . . . White, D. (2016). TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy. Leukemia, 30(6), 1263-1272. Scopus48 WoS43 Europe PMC37 |
| 2016 | Mughal, T., Radich, J., Deininger, M., Apperley, J., Hughes, T., Harrison, C., . . . Daley, G. (2016). Chronic myeloid leukemia: reminiscences and dreams. Haematologica, 101(5), 541-558. Scopus97 WoS97 Europe PMC78 |
| 2016 | Hughes, T., & Ross, D. (2016). Moving treatment-free remission into mainstream clinical practice in CML. Blood, 128(1), 17-23. Scopus288 WoS263 Europe PMC235 |
| 2016 | Eadie, L., Hughes, T., & White, D. (2016). ABCB1 Overexpression Is a key initiator of resistance to tyrosine kinase inhibitors in CML cell lines. PLoS ONE, 11(8), e0161470-1-e0161470-18. Scopus39 WoS35 Europe PMC31 |
| 2016 | Gurr, P. A., Zhang, Z., Hao, X., Hughes, T. C., & Qiao, G. G. (2016). Highly Ordered Honeycomb Film Formation of Linear Polymers by the Breath Figure Technique. Australian Journal of Chemistry, 69(10), 1130-1139. Scopus5 WoS4 |
| 2016 | Luan, B., Friedrich, T., Zhai, J., Streltsov, V. A., Lindsey, B. W., Kaslin, J., . . . Hao, X. (2016). A library of AuNPs modified by RAFT polymers of different charge and chain length: high throughput synthesis and synchrotron XFM imaging using a zebrafish larvae model. RSC Advances, 6(28), 23550-23563. Scopus7 WoS6 |
| 2016 | Sundaram, A. Y. M., Hughes, T., Biondi, S., Bolduc, N., Bowman, S. K., Camilli, A., . . . Gilfillan, G. D. (2016). A comparative study of ChIP-seq sequencing library preparation methods. BMC GENOMICS, 17(1), 12 pages. WoS20 Europe PMC22 |
| 2016 | Tesli, M., Wirgenes, K. V., Hughes, T., Bettella, F., Athanasiu, L., Hoseth, E. S., . . . Andreassen, O. A. (2016). <i>VRK2</i> gene expression in schizophrenia, bipolar disorder and healthy controls. BRITISH JOURNAL OF PSYCHIATRY, 209(2), 114-120. WoS16 Europe PMC19 |
| 2016 | Baroy, T., Pedurupillay, C. R. J., Bliksrud, Y. T., Rasmussen, M., Holmgren, A., Vigeland, M. D., . . . Misceo, D. (2016). A novel mutation in <i>FBXL4</i> in a Norwegian child with encephalomyopathic mitochondrial DNA depletion syndrome 13. EUROPEAN JOURNAL OF MEDICAL GENETICS, 59(6-7), 342-346. WoS19 Europe PMC16 |
| 2016 | Hughes, T., Hansson, L., Sonderby, I. E., Athanasiu, L., Zuber, V., Tesli, M., . . . Djurovic, S. (2016). A Loss-of-Function Variant in a Minor Isoform of <i>ANK3</i> Protects Against Bipolar Disorder and Schizophrenia. BIOLOGICAL PSYCHIATRY, 80(4), 323-330. WoS30 Europe PMC33 |
| 2015 | Baroy, T., Koster, J., Stromme, P., Ebberink, M. S., Misceo, D., Ferdinandusse, S., . . . Frengen, E. (2015). A novel type of rhizomelic chondrodysplasia punctata, RCDP5, is caused by loss of the PEX5 long isoform. HUMAN MOLECULAR GENETICS, 24(20), 5845-5854. WoS60 Europe PMC55 |
| 2015 | Barlow, K. J., Bernabeu, V., Hao, X., Hughes, T. C., Hutt, O. E., Polyzos, A., . . . Moad, G. (2015). Triphenylphosphine-grafted, RAFT-synthesised, porous monoliths as catalysts for Michael addition in flow synthesis. Reactive and Functional Polymers, 96, 89-96. Scopus20 WoS19 |
| 2015 | Fawcett, A. S., Hughes, T. C., Zepeda-Velazquez, L., & Brook, M. A. (2015). Phototunable Cross-Linked Polysiloxanes. Macromolecules, 48(18), 6499-6507. Scopus49 WoS45 |
| 2015 | Peng, S., Hartley, P. G., Hughes, T. C., & Guo, Q. (2015). Enhancing thermal stability and mechanical properties of lyotropic liquid crystals through incorporation of a polymerizable surfactant. Soft Matter, 11(31), 6318-6326. Scopus10 WoS10 Europe PMC4 |
| 2015 | Liu, Y., Muir, B. W., Waddington, L. J., Hinton, T. M., Moffat, B. A., Hao, X., . . . Hughes, T. C. (2015). Colloidally stabilized magnetic carbon nanotubes providing MRI contrast in mouse liver tumors. Biomacromolecules, 16(3), 790-797. Scopus18 WoS17 Europe PMC10 |
| 2015 | Wan, W., Zhao, Z., Hughes, T. C., Qian, B., Peng, S., Hao, X., & Qiu, J. (2015). Graphene oxide liquid crystal Pickering emulsions and their assemblies. Carbon, 85, 16-23. Scopus53 WoS50 |
| 2015 | Qie, F., Astolfo, A., Wickramaratna, M., Behe, M., Evans, M. D. M., Hughes, T. C., . . . Tan, T. (2015). Self-assembled gold coating enhances X-ray imaging of alginate microcapsules. Nanoscale, 7(6), 2480-2488. Scopus13 WoS11 Europe PMC6 |
| 2015 | Yeung, D., Tang, C., Vidovic, L., White, D., Branford, S., Hughes, T., & Yong, A. (2015). KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy. Blood, 126(25), 2720-2723. Scopus27 WoS24 Europe PMC23 |
| 2015 | Lickliter, J. D., Taylor, K., Szer, J., Grigg, A., Arthur, C., Hughes, T. P., . . . Bradstock, K. (2015). An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: Long-term results of the CMLALL1 trial. Leukemia and Lymphoma, 56(3), 630-638. Scopus2 WoS2 Europe PMC2 |
| 2015 | Ong, J., Yeung, D., Filshie, R., Hughes, T. P., & Nandurkar, H. (2015). Imatinib-induced gastric antral vascular ectasia in three patients with chronic myeloid leukaemia. International Journal of Hematology, 102(5), 639-642. Scopus6 WoS5 Europe PMC4 |
| 2015 | White, D. L., & Hughes, T. P. (2015). Living with CML: Is death no longer the end (point)?. Blood, 126(1), 2-4. Scopus1 WoS2 Europe PMC3 |
| 2015 | le Coutre, P. D., Cortes, J. E., Kim, D. -W., Pinilla-Ibarz, J., Paquette, R., Chuah, C., . . . Kantarjian, H. M. (2015). Ponatinib efficacy and safety in heavily pretreated leukemia patients (Pts) in the PACE trial at 3 years. ONCOLOGY RESEARCH AND TREATMENT, 38, 182-183. |
| 2015 | Watkins, D., Hughes, T., & White, D. (2015). OCT1 and imatinib transport in CML: Is it clinically relevant?. Leukemia, 29(10), 1960-1969. Scopus50 WoS45 Europe PMC37 |
| 2015 | Hughes, T., Saglio, G., Quintás-Cardama, A., Mauro, M., Kim, D., Lipton, J., . . . Hochhaus, A. (2015). BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase. Leukemia, 29(9), 1832-1838. Scopus68 WoS67 Europe PMC55 |
| 2015 | Lu, L., Saunders, V., Leclercq, T., Hughes, T., & White, D. (2015). Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells. Leukemia, 29(8), 1792-1794. Scopus20 WoS23 Europe PMC19 |
| 2015 | Yeung, D., Osborn, M., White, D., Branford, S., Braley, J., Herschtal, A., . . . Hughes, T. (2015). TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood, 125(6), 915-923. Scopus91 WoS77 Europe PMC67 |
| 2015 | Bartley, P., Latham, S., Budgen, B., Ross, D., Hughes, E., Branford, S., . . . Morley, A. (2015). A DNA real-time quantitative PCR method suitable for routine monitoring of low levels of minimal residual disease in chronic myeloid leukemia. The Journal of Molecular Diagnostics, 17(2), 185-192. Scopus23 WoS18 Europe PMC17 |
| 2015 | Yeung, D. T., Moulton, D. J., Heatley, S. L., Nievergall, E., Dang, P., Braley, J., . . . White, D. L. (2015). Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment. Leukemia, 29(1), 230-232. Scopus27 WoS22 Europe PMC21 |
| 2015 | Schafranek, L., Nievergall, E., Powell, J., Hiwase, D., Leclercq, T., Hughes, T., & White, D. (2015). Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia. Leukemia, 29(1), 76-85. Scopus30 WoS29 Europe PMC26 |
| 2014 | Branford, S., Yeung, D., Parker, W., Roberts, N., Purins, L., Braley, J., . . . Hughes, T. (2014). Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood, 124(4), 511-518. Scopus193 WoS160 Europe PMC145 |
| 2014 | Ross, D. M., & Hughes, T. P. (2014). How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia. British Journal of Haematology, 166(1), 3-11. Scopus44 WoS44 Europe PMC41 |
| 2014 | Roberts, K., Li, Y., Payne-Turner, D., Harvey, R., Yang, Y., Pei, D., . . . Mullighan, C. (2014). Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. New England Journal of Medicine, 371(11), 1005-1015. Scopus1215 WoS1095 Europe PMC1020 |
| 2014 | Kok, C. H., Leclercq, T., Watkins, D. B., Saunders, V., Wang, J., Hughes, T. P., & White, D. L. (2014). Elevated PTPN2 expression is associated with inferior molecular response in de-novo chronic myeloid leukaemia patients. Leukemia, 28(3), 702-705. Scopus7 WoS6 Europe PMC7 |
| 2014 | Jabbour, E. J., Hughes, T. P., Cortés, J. E., Kantarjian, H. M., & Hochhaus, A. (2014). Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leukemia & Lymphoma, 55(7), 1451-1462. Scopus36 WoS35 Europe PMC32 |
| 2014 | Parker, W., Phillis, S., Yeung, D., Hughes, T., Scott, H., & Branford, S. (2014). Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination. Blood, 124(1), 153-155. Scopus28 WoS27 Europe PMC23 |
| 2014 | Hughes, T., Lipton, J., Spector, N., Cervantes, F., Pasquini, R., Clementino, N., . . . Leber, B. (2014). Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. Blood, 124(5), 729-736. Scopus85 WoS76 Europe PMC70 |
| 2014 | Hughes, T., Hochhaus, A., Kantarjian, H., Cervantes, F., Guilhot, F., Niederwieser, D., . . . Saglio, G. (2014). Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. Haematologica, 99(7), 1204-1211. Scopus36 WoS31 Europe PMC27 |
| 2014 | Hughes, T., Saglio, G., Kantarjian, H., Guilhot, F., Niederwieser, D., Rosti, G., . . . Hochhaus, A. (2014). Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood, 123(9), 1353-1360. Scopus235 WoS212 Europe PMC185 |
| 2014 | Olshen, A., Tang, M., Cortes, J., Gonen, M., Hughes, T., Branford, S., . . . Michor, F. (2014). Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib. Haematologica, 99(11), 1701-1709. Scopus14 WoS9 Europe PMC10 |
| 2014 | Branford, S., Ross, D. M., Yeung, D. T., Braley, J., & Hughes, T. P. (2014). Achieving the deep molecular response levels required for an imatinib discontinuation trial is strongly associated with the BCR-ABL level at the first qualifying timepoint. Abstract of power point presentation at 56th ASH Annual Meeting, published in Blood, 124(21), 4561. WoS2 |
| 2014 | Pritchard, J. R., Lustgarten, S., Hodgson, G., Baccarani, M., Cortes, J. E., Deininger, M. W., . . . Rivera, V. M. (2014). High-Resolution Analysis of the Relationship Between Dose and Molecular Response in CP-CML Patients Treated with Ponatinib or Imatinib. BLOOD, 124(21), 4 pages. |
| 2014 | Baccarani, M., Druker, B., Branford, S., Kim, D., Pane, F., Mongay, L., . . . Guilhot, F. (2014). Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. International Journal of Hematology, 99(5), 616-624. Scopus45 WoS39 Europe PMC36 |
| 2014 | Eadie, L., Hughes, T., & White, D. (2014). Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib. Clinical Pharmacology & Therapeutics, 95(3), 294-306. Scopus75 WoS73 Europe PMC69 |
| 2014 | Nievergall, E., Ramshaw, H., Yong, A., Biondo, M., Busfield, S., Vairo, G., . . . Hiwase, D. (2014). Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells. Blood, 123(8), 1218-1228. Scopus91 WoS84 Europe PMC77 |
| 2014 | Astolfo, A., Qie, F., Kibleur, A., Hao, X., Menk, R. H., Arfelli, F., . . . Hughes, T. C. (2014). A simple way to track single gold-loaded alginate microcapsules using x-ray CT in small animal longitudinal studies. Nanomedicine Nanotechnology Biology and Medicine, 10(8), 1821-1828. Scopus19 WoS16 Europe PMC14 |
| 2014 | Yang, R., Peng, S., Wan, W., & Hughes, T. C. (2014). Azobenzene based multistimuli responsive supramolecular hydrogels. Journal of Materials Chemistry C, 2(43), 9122-9131. Scopus56 WoS54 |
| 2014 | Peng, S., Xu, C., Hughes, T. C., & Zhang, X. (2014). From Nanodroplets by the ouzo effect to interfacial nanolenses. Langmuir, 30(41), 12270-12277. WoS28 Europe PMC14 |
| 2014 | Guidi, G., Hughes, T. C., Whinton, M., Brook, M. A., & Sheardown, H. (2014). The effect of silicone hydrogel contact lens composition on dexamethasone release. Journal of Biomaterials Applications, 29(2), 222-233. Scopus20 WoS17 Europe PMC11 |
| 2014 | Peng, S., Guo, Q., Hartley, P. G., & Hughes, T. C. (2014). Azobenzene moiety variation directing self-assembly and photoresponsive behavior of azo-surfactants. Journal of Materials Chemistry C, 2(39), 8303-8312. Scopus48 WoS43 |
| 2014 | Wan, W., Li, L., Zhao, Z., Hu, H., Hao, X., Winkler, D. A., . . . Qiu, J. (2014). Ultrafast fabrication of covalently cross-linked multifunctional graphene oxide monoliths. Advanced Functional Materials, 24(31), 4915-4921. Scopus122 WoS112 |
| 2014 | Wan, W., Zhao, Z., Hu, H., Hao, X., Hughes, T. C., Ma, H., . . . Qiu, J. (2014). Folding of graphene into elastic nanobelts. Carbon, 76, 46-53. Scopus12 WoS11 |
| 2014 | Yang, R., Peng, S., & Hughes, T. C. (2014). Multistimuli responsive organogels based on a reactive azobenzene gelator. Soft Matter, 10(13), 2188-2196. Scopus68 WoS68 Europe PMC33 |
| 2014 | Peng, S., Guo, Q., Hughes, T. C., & Hartley, P. G. (2014). Reversible photorheological lyotropic liquid crystals. Langmuir, 30(3), 866-872. Scopus55 WoS45 Europe PMC24 |
| 2014 | Barlow, K. J., Hao, X., Hughes, T. C., Hutt, O. E., Polyzos, A., Turner, K. A., & Moad, G. (2014). Porous, functional, poly(styrene-co-divinylbenzene) monoliths by RAFT polymerization. Polymer Chemistry, 5(3), 722-732. Scopus49 WoS47 |
| 2014 | Liu, Y., Hao, X., Waddington, L. J., Qiu, J., & Hughes, T. C. (2014). Surface modification of multiwalled carbon nanotubes with engineered self-assembled raft diblock coatings. Australian Journal of Chemistry, 67(1), 151-158. Scopus7 WoS6 |
| 2014 | Liu, Y., Hughes, T. C., Muir, B. W., Waddington, L. J., Gengenbach, T. R., Easton, C. D., . . . Qiu, J. (2014). Water-dispersible magnetic carbon nanotubes as T2-weighted MRI contrast agents. Biomaterials, 35(1), 378-386. Scopus61 WoS52 Europe PMC29 |
| 2014 | Seymour, J. F., Kim, D. W., Rubin, E., Haregewoin, A., Clark, J., Watson, P., . . . Giles, F. J. (2014). A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Cancer Journal, 4(8), e238. Scopus62 WoS60 Europe PMC43 |
| 2014 | Wirgenes, K. V., Tesli, M., Inderhaug, E., Athanasiu, L., Agartz, I., Melle, I., . . . Djurovic, S. (2014). <i>ANK3</i> gene expression in bipolar disorder and schizophrenia. BRITISH JOURNAL OF PSYCHIATRY, 205(3), 244-+. WoS31 Europe PMC34 |
| 2013 | Zhang, Z., Hughes, T. C., Gurr, P. A., Blencowe, A., Uddin, H., Hao, X., & Qiao, G. G. (2013). The behaviour of honeycomb film formation from star polymers with various fluorine content. Polymer, 54(17), 4446-4454. Scopus34 WoS31 |
| 2013 | Gallipoli, P., Stobo, J., Heaney, N., Nicolini, F. E., Clark, R., Wilson, G., . . . Holyoake, T. L. (2013). Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up. British Journal of Haematology, 163(5), 674-676. Scopus10 WoS10 Europe PMC9 |
| 2013 | Cortes, J. E., Kim, D. W., Pinilla-Ibarz, J., Le Coutre, P., Paquette, R., Chuah, C., . . . Kantarjian, H. (2013). A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. New England Journal of Medicine, 369(19), 1783-1796. Scopus1025 WoS892 Europe PMC784 |
| 2013 | Abboud, C., Berman, E., Cohen, A., Cortes, J., DeAngelo, D., Deininger, M., . . . Ohno, R. (2013). The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: From the perspective of a large group of CML experts. Blood, 121(22), 4439-4442. Scopus547 WoS374 Europe PMC418 |
| 2013 | Giles, F. J., Le Coutre, P. D., Pinilla-Ibarz, J., Larson, R. A., Gattermann, N., Ottmann, O. G., . . . Kantarjian, H. M. (2013). Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia, 27(1), 107-112. Scopus209 WoS185 Europe PMC161 |
| 2013 | Hochhaus, A., Saglio, G., Larson, R., Kim, D., Etienne, G., Rosti, G., . . . Hughes, T. (2013). Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood, 121(18), 3703-3708. Scopus86 WoS73 Europe PMC60 |
| 2013 | Parker, W., Yeoman, A., Jamison, B., Yeung, D., Scott, H., Hughes, T., & Branford, S. (2013). BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance. British Journal of Cancer, 109(6), 1593-1598. Scopus22 WoS18 Europe PMC16 |
| 2013 | Ross, D., Branford, S., Seymour, J., Schwarer, A., Arthur, C., Yeung, D., . . . Hughes, T. (2013). Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood, 122(4), 515-522. Scopus644 WoS605 Europe PMC552 |
| 2013 | Baccarani, M., Deininger, M., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J., . . . Hehlmann, R. (2013). European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood, 122(6), 872-884. Scopus1741 WoS1520 Europe PMC1354 |
| 2013 | Branford, S., Yeung, D., Ross, D., Prime, J., Field, C., Altamura, H., . . . Hughes, T. (2013). Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood, 121(19), 3818-3824. Scopus153 WoS145 Europe PMC131 |
| 2013 | Kok, C., Watkins, D., Leclercq, T., D'Andrea, R., Hughes, T., & White, D. (2013). Low GFI1 expression in white blood cells of CP-CML patients at diagnosis is strongly associated with subsequent blastic transformation. Leukemia, 27(6), 1427-1430. Scopus12 WoS13 Europe PMC12 |
| 2013 | White, H., Hedges, J., Bendit, I., Branford, S., Colomer, D., Hochhaus, A., . . . Labourier, E. (2013). Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale. Clinical Chemistry, 59(6), 938-948. Scopus46 WoS39 Europe PMC35 |
| 2013 | Hiwase, D., Saunders, V., Nievergall, E., Ross, D., White, D., & Hughes, T. (2013). Dasatinib targets chronic myeloid leukemia-CD34⁺ progenitors as effectively as it targets mature cells. Haematologica, 98(6), 896-900. Scopus8 WoS9 Europe PMC7 |
| 2013 | White, D., Eadie, L., Saunders, V., Hiwase, D., & Hughes, T. (2013). Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells. Leukemia, 27(5), 1201-1204. Scopus8 WoS7 Europe PMC6 |
| 2013 | Thomas, D., Powell, J., Green, B., Barry, E., Ma, Y., Woodcock, J., . . . Guthridge, M. (2013). Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survival. PLoS Biology, 11(3), 1-14. Scopus20 WoS17 Europe PMC21 |
| 2013 | Watkins, D., Hughes, T., White, D., & D'Andrea, R. (2013). NPM1 mutations occur rarely or not at all in chronic myeloid leukaemia patients in chronic phase or blast crisis. Leukemia, 27(2), 489-490. Scopus11 WoS9 Europe PMC9 |
| 2013 | Vandyke, K., Fitter, S., Drew, J., Fukumoto, S., Schultz, C., Sims, N., . . . Zannettino, A. (2013). Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: Evidence for site-specific skeletal effects. Journal of Clinical Endocrinology and Metabolism, 98(1), 67-76. Scopus26 WoS26 Europe PMC23 |
| 2013 | Eadie, L., Saunders, V., Hughes, T., & White, D. (2013). Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2. Leukemia & Lymphoma, 54(3), 569-578. Scopus24 WoS22 Europe PMC23 |
| 2013 | Schafranek, L., Leclercq, T., White, D., & Hughes, T. (2013). Clarithromycin enhances dasatinib-induced cell death in chronic myeloid leukemia cells, by inhibition of late stage autophagy. Leukemia & Lymphoma, 54(1), 198-201. Scopus29 WoS23 Europe PMC19 |
| 2013 | Stein, A., Martinelli, G., Hughes, T., Muller, M., Beppu, L., Gottardi, E., . . . Radich, J. (2013). Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia. BMC Cancer, 13(1), 1-10. Scopus15 WoS14 Europe PMC13 |
| 2013 | Hughes, T., & White, D. (2013). Which TKI? An embarrassment of riches for chronic myeloid leukemia patients. Hematology, 2013(1), 168-175. Scopus46 WoS40 Europe PMC31 |
| 2013 | Angelini, S., Soverini, S., Ravegnini, G., Barnett, M., Turrini, E., Thornquist, M., . . . Martinelli, G. (2013). Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica, 98(2), 193-200. Scopus96 WoS94 Europe PMC87 |
| 2013 | Hercus, T., Dhagat, U., Kan, W., Broughton, S., Nero, T., Perugini, M., . . . Lopez, A. (2013). Signalling by the βc family of cytokines. Cytokine & Growth Factor Reviews, 24(3), 189-201. Scopus87 WoS79 Europe PMC74 |
| 2013 | Schafranek, L., Nievergall, E., Powell, J., Hiwase, D., White, D., Hughes, T., & Leclercq, T. (2013). STAT5 is a critical component of the time-dependent sensitivity of CML cells to TKI treatment in a BCR-ABL-dependent, but JAK2-independent manner. Blood, 122(21), 2705. WoS1 |
| 2013 | Jabbour, E., Le Coutre, P., Cortes, J., Giles, F., Bhalla, K., Pinilla-Ibarz, J., . . . Kantarjian, H. (2013). Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia, 27(4), 907-913. Scopus20 WoS15 Europe PMC16 |
| 2013 | Ross, D., O'Hely, M., Bartley, P., Dang, P., Score, J., Goyne, J., . . . Morley, A. (2013). Distribution of genomic breakpoints in chronic myeloid leukemia: analysis of 308 patients. Leukemia, 27(10), 2105-2107. Scopus23 WoS18 Europe PMC17 |
| 2012 | Hiwase, D. K., & Hughes, T. P. (2012). Sudden blast crisis in chronic myeloid leukemia treated with tyrosine kinase inhibitors. Leukemia and Lymphoma, 53(7), 1251-1252. Scopus3 WoS1 Europe PMC2 |
| 2012 | Larson, R., Hochhaus, A., Hughes, T., Clark, R., Etienne, G., Kim, D., . . . Kantarjian, H. (2012). Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia, 26(10), 2197-2203. Scopus382 WoS344 Europe PMC311 |
| 2012 | Branford, S. (2012). Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia, 26(9), 2096-2102. Scopus368 WoS337 Europe PMC309 |
| 2012 | Yin, O., Giles, F., Baccarani, M., le Coutre, P., Chiparus, O., Gallagher, N., . . . Larson, R. (2012). Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemotherapy and Pharmacology, 70(2), 345-350. Scopus29 WoS24 Europe PMC18 |
| 2012 | Blake, S., Hughes, T., & Lyons, A. (2012). Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A. Experimental Hematology, 40(8), 612-621. Scopus13 WoS10 Europe PMC11 |
| 2012 | White, D., Radich, J., Soverini, S., Saunders, V., Frede, A., Dang, P., . . . Hughes, T. (2012). Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib. Haematologica, 97(6), 907-914. Scopus53 WoS47 Europe PMC43 |
| 2012 | Yeung, D., & Hughes, T. (2012). Therapeutic targeting of BCR-ABL: prognostic markers of response and resistance mechanism in chronic myeloid leukaemia. Critical Reviews in Oncogenesis, 17(1), 17-30. Scopus25 Europe PMC20 |
| 2012 | Wang, J., Hughes, T., Kok, C., Saunders, V., Frede, A., Groot Obbink, K., . . . White, D. (2012). Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells. British Journal of Cancer, 106(11), 1772-1778. Scopus21 WoS19 Europe PMC17 |
| 2012 | Branford, S., Yeung, D., Prime, J., Choi, S., Bang, J., Park, J., . . . Hughes, T. (2012). BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management. Blood, 119(18), 4264-4271. Scopus44 WoS44 Europe PMC38 |
| 2012 | Nieborowska-Skorska, M., Kopinski, P., Ray, R., Hoser, G., Ngaba, D., Flis, S., . . . Skorski, T. (2012). Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood, 119(18), 4253-4263. Scopus157 WoS153 Europe PMC140 |
| 2012 | Jabbour, E., Saglio, G., Hughes, T., & Kantarjian, H. (2012). Suboptimal responses in chronic myeloid leukemia: implications and management strategies. Cancer, 118(5), 1181-1191. Scopus17 WoS19 Europe PMC18 |
| 2012 | Larson, R., Yin, O., Hochhaus, A., Saglio, G., Clark, R., Nakamae, H., . . . le Coutre, P. (2012). Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph plus chronic myeloid leukemia in chronic phase. European Journal of Clinical Pharmacology, 68(5), 723-733. Scopus101 WoS95 Europe PMC80 |
| 2012 | Hercus, T., Broughton, S., Ekert, P., Ramshaw, H., Perugini, M., Grimbaldeston, M., . . . Lopez, A. (2012). The GM-CSF receptor family: mechanism of activation and implications for disease. Growth Factors, 30(2), 63-75. Scopus63 WoS59 Europe PMC55 |
| 2012 | Parker, W., Ho, M., Scott, H., Hughes, T., & Branford, S. (2012). Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile. Blood, 119(10), 2234-2238. Scopus64 WoS58 Europe PMC51 |
| 2012 | White, D., & Hughes, T. (2012). Classification of patients with chronic myeloid leukemia on basis of BCR-ABL transcript level at 3 months fails to identify patients with low organic cation transporter-1 activity destined to have poor imatinib response. Journal of Clinical Oncology, 2012(10), 1144-1145. Scopus14 WoS9 Europe PMC10 |
| 2012 | Guilhot, F., Hughes, T., Cortes, J., Druker, B., Baccarani, M., Gathmann, I., . . . Wang, Y. (2012). Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial. Haematologica, 2012(5), 731-738. Scopus118 WoS114 Europe PMC102 |
| 2012 | Branford, S., Kim, D., Soverini, S., Haque, A., Shou, Y., Woodman, R., . . . Muller, M. (2012). Initial molecular response at 3 months may predict both response and event-free survival at 24 months in Imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with Nilotinib. Journal of Clinical Oncology, 30(35), 4323-4329. Scopus87 WoS81 Europe PMC71 |
| 2012 | Cortes, J., Goldman, J. M., & Hughes, T. (2012). Current issues in chronic myeloid leukemia: Monitoring, resistance, and functional cure. Jnccn Journal of the National Comprehensive Cancer Network, 10(SUPPL.3), S1-S13. Scopus44 WoS41 Europe PMC32 |
| 2012 | Larson, R. A., Hochhaus, A., Hughes, T. P., Clark, R. E., Etienne, G., Kim, D. W., . . . Kantarjian, H. M. (2012). Erratum: Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up (Leukemia (2012) 26, 2302; Doi:10.1038/leu.2012.175). Leukemia, 26(10), 2302. Scopus4 |
| 2012 | Peng, S., Hartley, P. G., Hughes, T. C., & Guo, Q. (2012). Controlling morphology and porosity of porous siloxane membranes through water content of precursor microemulsion. Soft Matter, 8(40), 10493-10501. Scopus30 WoS27 |
| 2012 | Zhang, Z., Hao, X., Gurr, P. A., Blencowe, A., Hughes, T. C., & Qiao, G. G. (2012). Honeycomb films from perfluoropolyether-based star and micelle architectures. Australian journal of chemistry, 65(8), 1186-1190. Scopus23 WoS22 |
| 2012 | Zhang, Z., Hughes, T. C., Gurr, P. A., Blencowe, A., Hao, X., & Qiao, G. G. (2012). Influence of polymer elasticity on the formation of non-cracking honeycomb films. Advanced materials, 24(31), 4327-4330. Scopus24 WoS23 Europe PMC7 |
| 2012 | Hao, X., Jeffery, J. L., Le, T. P. T., McFarland, G., Johnson, G., Mulder, R. J., . . . Hughes, T. C. (2012). High refractive index polysiloxane as Injectable, in situ curable accommodating intraocular lens. Biomaterials, 33(23), 5659-5671. Scopus52 WoS51 Europe PMC26 |
| 2012 | Wei, Z., Hao, X., Gan, Z., & Hughes, T. C. (2012). One-pot synthesis of hyperbranched glycopolymers by RAFT polymerization. Journal of Polymer Science Part A Polymer Chemistry, 50(12), 2378-2388. Scopus25 WoS21 |
| 2012 | Wei, Z., Hao, X., Kambouris, P. A., Gan, Z., & Hughes, T. C. (2012). One-pot synthesis of hyperbranched polymers using small molecule and macro RAFT inimers. Polymer, 53(7), 1429-1436. Scopus29 WoS28 |
| 2012 | Gilfillan, G. D., Hughes, T., Sheng, Y., Hjorthaug, H. S., Straub, T., Gervin, K., . . . Lyle, R. (2012). Limitations and possibilities of low cell number ChIP-seq. BMC GENOMICS, 13(1), 13 pages. WoS68 Europe PMC65 |
| 2012 | Selmer, K. K., Gilfillan, G. D., Stromme, P., Lyle, R., Hughes, T., Hjorthaug, H. S., . . . Undlien, D. E. (2012). A mild form of Mucopolysaccharidosis IIIB diagnosed with targeted next-generation sequencing of linked genomic regions. EUROPEAN JOURNAL OF HUMAN GENETICS, 20(1), 58-63. WoS21 Europe PMC18 |
| 2011 | Evans, M. D. M., Chaouk, H., Wilkie, J. S., Dalton, B. A., Taylor, S., Xie, R. Z., . . . McLean, K. M. (2011). The influence of surface topography of a porous perfluoropolyether polymer on corneal epithelial tissue growth and adhesion. Biomaterials, 32(34), 8870-8879. Scopus10 WoS11 Europe PMC5 |
| 2011 | Lv, Y., Hughes, T. C., Hao, X., Mei, D., & Tan, T. (2011). Preparation of monomeric and polymeric β-cyclodextrin functionalized monoliths for rapid isolation and purification of puerarin from Radix puerariae. Journal of Separation Science, 34(16-17), 2131-2137. Scopus10 WoS10 Europe PMC3 |
| 2011 | Peng, S., Guo, Q., Hughes, T. C., & Hartley, P. G. (2011). In situ synchrotron SAXS study of polymerizable microemulsions. Macromolecules, 44(8), 3007-3015. Scopus30 WoS29 |
| 2011 | Evans, M. D. M., Prakasam, R. K., Vaddavalli, P. K., Hughes, T. C., Knower, W., Wilkie, J. S., . . . Sweeney, D. F. (2011). A perfluoropolyether corneal inlay for the correction of refractive error. Biomaterials, 32(12), 3158-3165. Scopus16 WoS14 Europe PMC7 |
| 2011 | Esposito, N., Colavita, I., Quintarelli, C., Sica, A., Peluso, A., Luciano, L., . . . Pane, F. (2011). SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia. Blood, 118(13), 3634-3644. Scopus48 WoS41 Europe PMC38 |
| 2011 | Cortes, J., Hochhaus, A., Hughes, T., & Kantarjian, H. (2011). Front-Line and Salvage Therapies With Tyrosine Kinase Inhibitors and Other Treatments in Chronic Myeloid Leukemia. Journal of Clinical Oncology, 29(5), 524-531. Scopus83 WoS72 Europe PMC63 |
| 2011 | Stein, A., Bottino, D., Modur, V., Branford, S., Kaeda, J., Goldman, J., . . . Hochhaus, A. (2011). BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib teatment. Clinical Cancer Research, 17(21), 6812-6821. Scopus39 WoS36 Europe PMC33 |
| 2011 | Parker, W., Lawrence, R., Ho, M., Irwin, D., Scott, H., Hughes, T., & Branford, S. (2011). Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after Imatinib resistance is predictive of outcome during subsequent therapy. Journal of Clinical Oncology, 29(32), 4250-4259. Scopus83 WoS75 Europe PMC72 |
| 2011 | Tang, C., Schafranek, L., Watkins, D., Parker, W., Moore, S., Prime, J., . . . Hughes, T. (2011). Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways. Leukemia & Lymphoma, 52(11), 2139-2147. Scopus55 WoS51 Europe PMC47 |
| 2011 | Kantarjian, H., Hochhaus, A., Saglio, G., de Souza, C., Flinn, I., Stenke, L., . . . Hughes, T. (2011). Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. The Lancet Oncology, 12(9), 841-851. Scopus443 WoS404 Europe PMC354 |
| 2011 | Tang, M., Gonen, M., Quintas-Cardama, A., Cortes, J., Kantarjian, H., Field, C., . . . Michor, F. (2011). Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. Blood, 118(6), 1622-1631. Scopus58 WoS54 Europe PMC50 |
| 2011 | Branford, S., & Hughes, T. (2011). Mutational analysis in chronic myeloid leukemia: When and what to do?. Current Opinion in Hematology, 18(2), 111-116. Scopus20 WoS22 Europe PMC19 |
| 2011 | Engler, J., Hughes, T., & White, D. (2011). OCT-1 as a determinant of response to antileukemic treatment. Clinical Pharmacology & Therapeutics, 89(4), 608-611. Scopus10 WoS9 Europe PMC8 |
| 2011 | Engler, J., Zannettino, A., Bailey, C., Rasko, J., Hughes, T., & White, D. (2011). OCT-1 function varies with cell lineage but is not influenced by BCR-ABL. Haematologica: the haematology journal, 96(2), 1-33. Scopus13 WoS12 Europe PMC12 |
| 2011 | Ross, D., Hughes, T., & Vaz de Melo, J. (2011). Do we have to kill the last CML cell?. Leukemia, 25(2), 193-200. Scopus34 WoS31 Europe PMC26 |
| 2011 | Kantarjian, H., Giles, F., Bhalla, K., Pinilla-Ibarz, J., Larson, R., Gattermann, N., . . . le Coutre, P. (2011). Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood, 117(4), 1141-1145. Scopus329 WoS248 Europe PMC236 |
| 2011 | White, D., & Hughes, T. (2011). Predicting the response of CML patients to tyrosine kinase inhibitor therapy. Current Hematologic Malignancy Reports, 6(2), 88-95. Scopus7 WoS7 Europe PMC6 |
| 2011 | Ross, D. M., Hughes, T. P., & Melo, J. V. (2011). Erratum: Do we have to kill the last CML cell? (Leukemia (2010) (DOI:10.1038/leukemia.2010.197). Leukemia, 25(2), 386. |
| 2010 | White, D. L., Saunders, V. A., Dang, P., Engler, J., & Hughes, T. P. (2010). OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1. Leukemia, 24(11), 1962-1965. Scopus37 WoS35 Europe PMC29 |
| 2010 | Osborn, M., & Hughes, T. (2010). Managing imatinib resistance in chronic myeloid leukaemia. Current Opinion in Hematology, 17(2), 97-103. Scopus16 WoS13 Europe PMC10 |
| 2010 | Branford, S., & Hughes, T. (2010). Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood, 116(22), E111-E117. Scopus157 WoS123 Europe PMC99 |
| 2010 | Hughes, T., Hochhaus, A., Branford, S., Muller, M., Kaeda, J., Foroni, L., . . . Radich, J. (2010). Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood, 116(19), 3758-3765. Scopus434 WoS375 Europe PMC333 |
| 2010 | Bartley, P., Ross, D., Latham, S., Martin-Harris, M., Budgen, B., Wilczek, V., . . . Morley, A. (2010). Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA. International Journal of Laboratory Hematology (Print Edition), 32(6 Part 1), E222-E228. Scopus52 WoS42 Europe PMC38 |
| 2010 | Ross, D., Branford, S., Seymour, J., Schwarer, A., Arthur, C., Bartley, P., . . . Hughes, T. (2010). Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia, 24(10), 1719-1724. Scopus248 WoS214 Europe PMC199 |
| 2010 | Engler, J., Frede, A., Saunders, V., Zannettino, A., White, D., & Hughes, T. (2010). The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34⁺ cells. Blood, 116(15), 2776-2778. Scopus20 WoS18 Europe PMC16 |
| 2010 | Branford, S., & Hughes, T. (2010). Practical considerations for monitoring patients with chronic myeloid leukemia. Seminars in Hematology, 47(4), 327-334. Scopus7 WoS5 Europe PMC5 |
| 2010 | Fitter, S., Vandyke, K., Schultz, C., White, D., Hughes, T., & Zannettino, A. (2010). Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: A mechanism for improved insulin sensitivity in Type 2 diabetic CML patients?. Journal of Clinical Endocrinology and Metabolism, 95(8), 3763-3767. Scopus52 WoS50 Europe PMC46 |
| 2010 | Hiwase, D., White, D., Powell, J., Saunders, V., Zrim, S., Frede, A., . . . Hughes, T. (2010). Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors. Leukemia, 24(4), 771-778. Scopus48 WoS42 Europe PMC41 |
| 2010 | Cortes, A., Baccarani, M., Guilhot, F., Druker, B., Branford, S., Kim, D., . . . Hughes, T. (2010). Phase III, randomized, open-label study of daily Imatinib Mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study. Journal of Clinical Oncology, 28(3), 424-430. Scopus246 WoS231 Europe PMC205 |
| 2010 | Saglio, G., Kim, D., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., . . . Kantarjian, H. (2010). Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemia. New England Journal of Medicine, 362(24), 2251-2259. Scopus1496 WoS1349 Europe PMC1131 |
| 2010 | White, D., Dang, P., Engler, J., Frede, A., Osborn, M., Saunders, V., . . . Hughes, T. (2010). Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with Imatinib. Journal of Clinical Oncology, 28(16), 2761-2767. Scopus159 WoS144 Europe PMC128 |
| 2010 | Eadie, L., Hughes, T., & White, D. (2010). Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells. Leukemia, 24(4), 855-857. Scopus9 WoS9 Europe PMC9 |
| 2010 | Engler, J., Frede, A., Saunders, V., Zannettino, A., Hughes, T., & White, D. (2010). Chronic Myeloid Leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 Activity. Leukemia, 24(4), 765-770. Scopus55 WoS53 Europe PMC45 |
| 2010 | Vandyke, K., Fitter, S., Dewar, A., Hughes, T., & Zannettino, A. (2010). Dysregulation of bone remodeling by imatinib mesylate. Blood, 115(4), 766-774. Scopus130 WoS116 Europe PMC99 |
| 2010 | Fraser, C., Lousberg, E., Guerin, L., Hughes, T., Brown, M., Diener, K., & Hayball, J. (2010). Dasatinib alters the metastatic phenotype of B16-OVA melanoma in vivo. Cancer Biology & Therapy, 10(7), 715-727. Scopus11 WoS11 Europe PMC9 |
| 2010 | Hiwase, D., White, D., Zrim, S., Saunders, V., Vaz de Melo, J., & Hughes, T. (2010). Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy. Leukemia, 24(3), 658-660. Scopus27 WoS27 Europe PMC25 |
| 2010 | Hochhaus, A., O'Brien, S. G., Guilhot, F., Druker, B. J., Branford, S., Foroni, L., . . . Larson, R. A. (2010). Erratum: Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia(Leukemia (2009) 23 (1054-1061) DOI: 10.1038/leu.2009.38). Leukemia, 24(5), 1102. Scopus2 WoS7 |
| 2010 | Hochhaus, A., Saglio, A., Kantarjian, H., Haque, A., Shou, Y., Woodman, R. C., . . . Kim, D. (2010). Detection of new mutations in patients (pts) with imatinib-resistant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.. JOURNAL OF CLINICAL ONCOLOGY, 28(15), 1 page. |
| 2010 | Hughes, T. P., le Coutre, P. D., Clark, R. E., Saglio, G., Larson, R. A., Yin, Q., . . . Kantarjian, H. (2010). Population pharmacokinetic (PK) and exposure-response analysis of nilotinib in newly diagnosed Ph plus chronic myeloid leukemia in chronic phase: Results from ENESTnd. JOURNAL OF CLINICAL ONCOLOGY, 28(15), 1 page. WoS1 |
| 2010 | Kim, D., Saglio, G., Martinelli, G., Shou, Y., Stein, A. M., Woodman, R. C., . . . Hochhaus, A. (2010). BCR-ABL transcript analysis of patients (pts) with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.. JOURNAL OF CLINICAL ONCOLOGY, 28(15), 1 page. |
| 2010 | Larson, R. A., le Coutre, P. D., Reiffers, J., Hughes, T. P., Saglio, G., Edrich, P., . . . Hochhaus, A. (2010). Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in ehronic phase (CML-CP): ENESTnd beyond one year. JOURNAL OF CLINICAL ONCOLOGY, 28(15), 1 page. WoS9 |
| 2010 | Lv, Y., Hughes, T. C., Hao, X., Hart, N. K., Littler, S. W., Zhang, X., & Tan, T. (2010). A novel route to prepare highly reactive and versatile chromatographic monoliths. Macromolecular Rapid Communications, 31(20), 1785-1790. Scopus16 WoS16 Europe PMC4 |
| 2010 | Hao, X., Jeffery, J. L., Wilkie, J. S., Meijs, G. F., Clayton, A. B., Watling, J. D., . . . Hughes, T. C. (2010). Functionalised polysiloxanes as injectable, in situ curable accommodating intraocular lenses. Biomaterials, 31(32), 8153-8163. Scopus47 WoS43 Europe PMC20 |
| 2010 | Cass, P., Knower, W., Pereeia, E., Holmes, N. P., & Hughes, T. (2010). Preparation of hydrogels via ultrasonic polymerization. Ultrasonics Sonochemistry, 17(2), 326-332. Scopus75 WoS65 Europe PMC26 |
| 2009 | Elvin, C. M., Brownlee, A. G., Huson, M. G., Tebb, T. A., Kim, M., Lyons, R. E., . . . Werkmeister, J. A. (2009). The development of photochemically crosslinked native fibrinogen as a rapidly formed and mechanically strong surgical tissue sealant. Biomaterials, 30(11), 2059-2065. Scopus120 WoS106 Europe PMC75 |
| 2009 | Hughes, T., Marzo, S., & Leonetti, J. (2009). Cochlear Implant Surgery in the Chronic Draining Ear. LARYNGOSCOPE, 119(S1), S120. |
| 2009 | Drummond, M. W., Heaney, N., Kaeda, J., Nicolini, F. E., Clark, R. E., Wilson, G., . . . Holyoake, T. L. (2009). A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response. Leukemia, 23(6), 1199-1201. Scopus34 WoS30 Europe PMC25 |
| 2009 | Baccarani, M., Cortes, J., Pane, F., Niederwieser, D., Saglio, G., Apperley, J., . . . Hehlmann, R. (2009). Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet. Journal of Clinical Oncology, 27(35), 6041-6051. Scopus1163 WoS1049 Europe PMC884 |
| 2009 | Muller, M., Cortes, J., Kim, D., Druker, B., Erben, P., Pasquini, R., . . . Hochhaus, A. (2009). Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood, 114(24), 4944-4953. Scopus259 WoS263 Europe PMC208 |
| 2009 | Fraser, C., Lousberg, E., Kumar, R., Hughes, T., Diener, K., & Hayball, J. (2009). Dasatinib inhibits the secretion of TNF-α following TLR stimulation in vitro and in vivo. Experimental Hematology, 37(12), 1435-1444. Scopus38 WoS38 Europe PMC34 |
| 2009 | Hughes, T., & Branford, S. (2009). Measuring minimal residual disease in chronic myeloid leukemia: Fluorescence in situ hybridization and polymerase chain reaction. Clinical Lymphoma & Myeloma, 9(Supp 3), S266-S271. Scopus8 WoS3 Europe PMC4 |
| 2009 | Kantarjian, H., Pasquini, R., Levy, V., Jootar, S., Holowiecki, J., Hamerschlak, N., . . . Shah, N. (2009). Dasatinib or high-dose Imatinib for chronic-phase chronic myeloid leukemia resistant to Imatinib at a dose of 400 to 600 milligrams daily. Two-year follow-up of a randomized phase 2 study (START-R). Cancer, 115(18), 4136-4147. Scopus187 WoS164 Europe PMC137 |
| 2009 | Hughes, T., Saglio, G., Branford, S., Soverini, S., Kim, J., Muller, M., . . . Hochhaus, A. (2009). Impact of baseline BCR-ABL mutations on response to Nilotinib in patients with chronic myeloid leukemia in chronic phase. Journal of Clinical Oncology, 27(25), 4204-4210. Scopus281 WoS260 Europe PMC229 |
| 2009 | Hochhaus, A., Muller, M., Radich, J., Branford, S., Kantarjian, H., Hanfstein, B., . . . Hughes, T. (2009). Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. Leukemia, 23(9), 1628-1633. Scopus33 WoS32 Europe PMC28 |
| 2009 | Vandyke, K., Dewar, A., Menicanin, D., To, L., Hughes, T., Zannettino, A., & Fitter, S. (2009). Imatinib mesylate causes growth plate closure in vivo. Leukemia, 23(11), 2155-2159. Scopus37 WoS35 Europe PMC36 |
| 2009 | White, D., & Hughes, T. (2009). Predicting the response of CML patients to tyrosine kinase inhibitor therapy. Current Hematologic Malignancy Reports, 4(2), 59-65. Scopus8 Europe PMC6 |
| 2009 | Apperley, J., Cortes, J., Kim, D., Roy, L., Roboz, G., Rosti, G., . . . Stone, R. (2009). Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial. Journal of Clinical Oncology, 27(21), 3472-3479. Scopus174 WoS156 Europe PMC128 |
| 2009 | Viswanathan, S., Powers, J., Einhorn, W., Hoshida, Y., Ng, T., Toffanin, S., . . . Daley, G. (2009). Lin28 promotes transformation and is associated with advanced human malignancies. Nature Genetics, 41(7), 843-U109. Scopus744 WoS705 Europe PMC675 |
| 2009 | Hochhaus, A., O'Brien, S., Guilhot, F., Druker, B., Branford, S., Foroni, L., . . . Larson, R. (2009). Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia, 23(6), 1054-1061. Scopus765 WoS674 Europe PMC616 |
| 2009 | Tojo, A., Usuki, K., Urabe, A., Maeda, Y., Kobayashi, Y., Jinnai, I., . . . Naoe, T. (2009). A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph plus CML or relapsed/refractory Ph plus ALL. International Journal of Hematology, 89(5), 679-688. Scopus40 WoS38 Europe PMC31 |
| 2009 | Vandyke, K., Dewar, A., Farrugia, A., Fitter, S., To, B., Hughes, T., & Zannettino, A. (2009). Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia, 23(5), 994-997. Scopus49 WoS48 Europe PMC43 |
| 2009 | Hughes, T., & Hochhaus, A. (2009). Clinical strategies to achieve an early and successful response to tyrosine kinase inhibitor therapy. Seminars in Hematology, 46(2), S11-S15. Scopus4 WoS4 Europe PMC3 |
| 2009 | Blake, S., Lyons, A., & Hughes, T. (2009). Nilotinib inhibits the Src-family kinase LCK and T-cell function in vitro. Journal of Cellular and Molecular Medicine, 13(3), 599-601. Scopus28 WoS25 Europe PMC22 |
| 2009 | Khoury, H., Guilhot, F., Hughes, T., Kim, D., & Cortes, J. (2009). Dasatinib treatment for Philadelphia chromosome-positive Leukemias: practical considerations. Cancer, 115(7), 1381-1394. Scopus43 WoS39 Europe PMC37 |
| 2009 | Ross, D., Schafranek, L., Hughes, T., Nicola, M., Branford, S., & Score, J. (2009). Genomic translocation breakpoint sequences are conserved in BCR-ABL1 cell lines despite the presence of amplification. Cancer Genetics and Cytogenetics, 189(2), 138-139. Scopus6 WoS6 Europe PMC6 |
| 2009 | Fraser, C., Blake, S., Diener, K., Lyons, A., Brown, M., Hughes, T., & Hayball, J. (2009). Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo. Experimental Hematology, 37(2), 256-265. Scopus58 WoS56 Europe PMC51 |
| 2009 | Branford, S., Vaz de Melo, J., & Hughes, T. (2009). Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?. Blood, 114(27), 5426-5435. Scopus159 WoS136 Europe PMC130 |
| 2009 | Hughes, T. P., & Branford, S. (2009). Monitoring disease response to tyrosine kinase inhibitor therapy in CML.. Hematology the Education Program of the American Society of Hematology American Society of Hematology Education Program, 2009(1), 477-487. Scopus61 Europe PMC35 |
| 2009 | Ross, D., Branford, S., Melo, J., & Hughes, T. (2009). Reply to 'What do we mean by sensitivity when we talk about detecting minimal residual disease?' by Steinbach and Debatin. Leukemia, 23(4), 819-820. Scopus7 WoS8 Europe PMC5 |
| 2009 | Hiwase, D., White, D., Saunders, V., Kumar, S., Melo, J., & Hughes, T. (2009). Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL<sup>+</sup> cells. Leukemia, 23(6), 1205-1206. Scopus17 WoS16 Europe PMC13 |
| 2008 | Ross, D. M., & Hughes, T. P. (2008). How complete is "complete" molecular response in imatinib-treated chronic myeloid leukemia?. Leukemia and Lymphoma, 49(7), 1230-1231. Scopus2 WoS2 Europe PMC2 |
| 2008 | Sweeney, D. F., Vannas, A., Hughes, T. C., Evans, M. D., McLean, K. M., Xie, R. Z., . . . Prakasam, R. K. (2008). Synthetic corneal inlays: Invited Review. Clinical and Experimental Optometry, 91(1), 56-66. Scopus34 WoS27 Europe PMC19 |
| 2008 | Branford, S., Fletcher, L., Cross, N. C. P., Müller, M. C., Hochhaus, A., Kim, D. W., . . . Hughes, T. (2008). Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood, 112(8), 3330-3338. Scopus348 WoS317 Europe PMC284 |
| 2008 | Hughes, T. P., Branford, S., White, D. L., Reynolds, J., Koelmeyer, R., Seymour, J. F., . . . Grigg, A. (2008). Impact of early dose intensity on cytogenetic and molecular responses in chronicphase CMLpatients receiving 600 mg/day of imatinib as initial therapy. Blood, 112(10), 3965-3973. Scopus148 WoS137 Europe PMC131 |
| 2008 | le Coutre, P., Ottmann, O., Giles, F., Kim, D., Cortes, J., Gattermann, N., . . . Kantarjian, H. (2008). Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood, 111(4), 1834-1839. Scopus279 WoS242 Europe PMC188 |
| 2008 | Ross, D., Watkins, D., Hughes, T., & Branford, S. (2008). Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: Implications for defining sensitivity in minimal residual disease. Clinical Chemistry, 54(9), 1568-1571. Scopus11 WoS11 Europe PMC9 |
| 2008 | Blake, S., Hughes, T., Mayrhofer, G., & Lyons, A. (2008). The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clinical Immunology, 127(3), 330-339. Scopus111 WoS98 Europe PMC96 |
| 2008 | Ross, D., & Hughes, T. (2008). Current and emerging tests for the laboratory monitoring of chronic myeloid leukaemia and related disorders. Pathology, 40(3), 231-246. Scopus10 WoS10 Europe PMC8 |
| 2008 | Mullighan, C., Miller, C., Radtke, I., Philips, L., Dalton, J., Ma, J., . . . Downing, J. (2008). BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature, 453(7191), 110-114. Scopus910 WoS846 Europe PMC784 |
| 2008 | Giles, F., DeAngelo, D., Baccarani, M., Deininger, M., Guilhot, F., Hughes, T., . . . Cortes, J. (2008). Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia. Seminars in Oncology, 35(Supp. 1), S1-S17. Scopus31 WoS25 Europe PMC22 |
| 2008 | Blake, S., Lyons, A., Fraser, C., Hayball, J., & Hughes, T. (2008). Dasatinib suppresses in vitro natural killer cell cytotoxicity. Blood, 111(8), 4415-4416. Scopus69 WoS69 Europe PMC62 |
| 2008 | Cross, N., Hughes, T., Hochhaus, A., & Goldman, J. (2008). International standardisation of quantitative real-time RT-PCR for BCR-ABL. Leukemia Research, 32(3), 505-506. Scopus26 WoS24 Europe PMC24 |
| 2008 | Fitter, S., Dewar, A., Kostakis, P., To, L., Hughes, T., Roberts, M., . . . Zannettino, A. (2008). Long-term imatinib therapy promotes bone formation in CML patients. Blood, 111(5), 2538-2547. Scopus147 WoS135 Europe PMC123 |
| 2008 | Hui, C., Sia, H., Mangos, H., Horvath, N., Lewis, I., Hughes, T., . . . Bardy, P. (2008). Daclizumab has poor efficacy in steroid-refractory severe acute graft-versus-host disease: a single centre experience with 12 allograft patients. Bone Marrow Transplantation, 41(4), 409-410. Scopus6 WoS5 Europe PMC6 |
| 2008 | Hughes, T. (2008). Is drug treatment superior to allografting as first-line therapy in chronic myeloid leukemia?. Nature Clinical Practice Oncology, 5(1), 14-15. Scopus1 Europe PMC1 |
| 2008 | Hiwase, D., Saunders, V., Hewett, D., Frede, A., Zrim, S., Dang, P., . . . White, D. (2008). Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clinical Cancer Research, 14(12), 3881-3888. Scopus168 WoS152 Europe PMC140 |
| 2008 | Hochhaus, A., Baccarani, M., Deininger, M., Apperley, J. F., Lipton, J. H., Goldberg, S. L., . . . Kantarjian, H. M. (2008). Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia, 22(6), 1200-1206. Scopus326 WoS280 Europe PMC248 |
| 2008 | Cross, N. C. P., Daley, G. Q., Green, A. R., Hughes, T. P., Jamieson, C., Manley, P., . . . Goldman, J. M. (2008). BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: Some common and contrasting features. Leukemia, 22(11), 1975-1989. Scopus17 WoS17 Europe PMC14 |
| 2007 | Shah, N. P., Skaggs, B. J., Branford, S., Hughes, T. P., Nicoll, J. M., Paquette, R. L., & Sawyers, C. L. (2007). Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. Journal of Clinical Investigation, 117(9), 2562-2569. Scopus348 WoS331 Europe PMC297 |
| 2007 | Branford, S., Hughes, T., Milner, A., Koelmeyer, R., Schwarer, A., Arthur, C., . . . Taylor, K. (2007). Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-α. Cancer, 110(4), 801-808. Scopus6 WoS7 Europe PMC4 |
| 2007 | Kantarjian, H., Pasquini, R., Hamerschlak, N., Rousselot, P., Holowiecki, J., Jootar, S., . . . Shah, N. (2007). Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial. Blood, 109(12), 5143-5150. Scopus349 WoS284 Europe PMC240 |
| 2007 | Hochhaus, A., Kantarjian, H. M., Baccarani, M., Lipton, J. H., Apperley, J. F., Druker, B. J., . . . Shah, N. P. (2007). Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood, 109(6), 2303-2309. Scopus559 WoS472 Europe PMC391 |
| 2007 | Hughes, T., & Branford, S. (2007). Ph+ ALL: Resistance seeds sown early. Blood, 110(2), 472. |
| 2007 | Branford, S., Seymour, J., Grigg, A., Arthur, C., Rudzki, Z., Lynch, K., & Hughes, T. (2007). BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clinical Cancer Research, 13(23), 7080-7085. Scopus122 WoS110 Europe PMC100 |
| 2007 | White, D., Saunders, V., Dang, P., Engler, J., Venables, A., Zrim, S., . . . Hughes, T. (2007). Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood, 110(12), 4064-4072. Scopus281 WoS259 Europe PMC233 |
| 2007 | White, D., Saunders, V., Grigg, A., Arthur, C., Filshie, R., Leahy, M., . . . Hughes, T. (2007). Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. Journal of Clinical Oncology, 25(28), 4445-4451. Scopus54 WoS53 Europe PMC52 |
| 2007 | White, D., Saunders, V., Quinn, S., Manley, P., & Hughes, T. (2007). Imatinib increases the intracellular concentration of nilotinib which may explain the observed synergy between these drugs. Blood, 109(8), 3609-3610. Scopus41 WoS45 Europe PMC33 |
| 2007 | Hughes, T., Branford, S., & Goldman, J. (2007). Reliability of PCR for BCR-ABL transcripts. Blood, 109(5), 2263-2264. WoS1 |
| 2007 | Hughes, T. P., Gunderson, L. H., Folke, C., Baird, A. H., Bellwood, D., Berkes, F., . . . Worm, B. (2007). Adaptive management of the great barrier reef and the grand canyon world heritage areas. Ambio, 36(7), 586-592. Scopus81 WoS72 Europe PMC14 |
| 2006 | Luke, C., Nguyen, A. M., To, B., Seshadri, R., Hughes, T., Bardy, P., . . . Roder, D. M. (2006). Myeloid leukaemia treatment and survival--the South Australian experience, 1977 to 2002. Asian Pacific Journal of Cancer Prevention, 7(2), 227-233. Scopus9 Europe PMC10 |
| 2006 | Baccarani, M., Saglio, G., Goldman, J., Hochhaus, A., Simonsson, B., Appelbaum, F., . . . Hehlmann, R. (2006). Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 108(6), 1809-1820. Scopus1146 WoS990 Europe PMC831 |
| 2006 | Hui, C., & Hughes, T. (2006). Autologous stem cell collection and autograft for patients with chronic myeloid leukemia in the era of ABL kinase inhibitors: Back to the bench. Leukemia & Lymphoma, 47(9), 1721-1723. Scopus1 WoS1 Europe PMC1 |
| 2006 | Druker, B., Guilhot, F., O'Brien, S., Gathmann, I., Kantarjian, H., Gattermann, N., . . . Larson, R. (2006). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New England Journal of Medicine, 355(23), 2408-2417. Scopus3122 WoS2747 Europe PMC2394 |
| 2006 | Grigg, A., & Hughes, T. (2006). Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib era. Biology of Blood and Marrow Transplantation, 12(8), 795-807. Scopus27 WoS22 Europe PMC18 |
| 2006 | White, D., Saunders, V., Dang, P., Engler, J., Zannettino, A., Cambareri, A., . . . Hughes, T. (2006). OCT-1-mediated influx is a key determinant of the intraceflular uptake of imatinib but not nilotinib, (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood, 108(2), 697-704. Scopus392 WoS337 Europe PMC297 |
| 2006 | Dewar, A., Farrugia, A., Condina, M., To, L., Hughes, T., Vernon-Roberts, B., & Zannettino, A. (2006). Imatinib as a potential antiresorptive therapy for bone disease. Blood, 107(11), 4334-4337. Scopus70 WoS67 Europe PMC62 |
| 2006 | Hughes, T., & Branford, S. (2006). Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Reviews, 20(1), 29-41. Scopus133 WoS112 Europe PMC92 |
| 2006 | Ross, D., Branford, S., Moore, S., & Hughes, T. (2006). Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL. Leukemia, 20(4), 664-670. Scopus63 WoS57 Europe PMC54 |
| 2006 | Branford, S., Cross, N., Hochhaus, A., Radich, J., Saglio, G., Kaeda, J., . . . Hughes, T. (2006). Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia, 20(11), 1925-1930. Scopus178 WoS158 Europe PMC133 |
| 2006 | Branford, S., & Hughes, T. (2006). Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCR.. Methods in Molecular Medicine, 125, 69-92. Scopus50 Europe PMC39 |
| 2006 | Hughes, T. (2006). ABL kinase inhibitor therapy for CML: baseline assessments and response monitoring.. Hematology the Education Program of the American Society of Hematology American Society of Hematology Education Program, 2006(1), 211-218. Scopus38 Europe PMC21 |
| 2006 | Branford, S., & Hughes, T. (2006). Detection of BCR-ABL mutations and resistance to imatinib mesylate.. Methods in Molecular Medicine, 125, 93-106. Scopus71 Europe PMC45 |
| 2006 | Ruo, Z. X., Evans, M. D. M., Bojarski, B., Hughes, T. C., Chan, G. Y., Nguyen, X., . . . Sweeney, D. F. (2006). Two-year preclinical testing of perfluoropolyether polymer as a corneal inlay. Investigative Ophthalmology and Visual Science, 47(2), 574-581. Scopus31 WoS27 Europe PMC18 |
| 2006 | Grace, G. Y., Hughes, T. C., McLean, K. M., McFarland, G. A., Nguyen, X., Wilkie, J. S., & Johnson, G. (2006). Approaches to improving the biocompatibility of porous perfluoropolyethers for ophthalmic applications. Biomaterials, 27(8), 1287-1295. Scopus31 WoS29 Europe PMC7 |
| 2006 | Hughes, T., Deininger, M., Hochhaus, A., Branford, S., Radich, J., Kaeda, J., . . . Goldman, J. M. (2006). Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood, 108(1), 28-37. Scopus1078 WoS954 Europe PMC812 |
| 2005 | White, D., Saunders, V., Lyons, A., Branford, S., Grigg, A., To, L., & Hughes, T. (2005). In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de-novo CML.. Blood, 106(7), 2520-2526. Scopus124 WoS109 Europe PMC105 |
| 2005 | Dewar, A., Cambareri, A., Zannettino, A., Boog, B., Doherty, K., Hughes, T., & Lyons, A. (2005). Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood, 105(8), 3127-3132. Scopus276 WoS258 Europe PMC212 |
| 2005 | Dewar, A., Zannettino, A., Hughes, T., & Lyons, A. (2005). Inhibition of c-fms by imatinib - Expanding the spectrum of treatment. Cell Cycle, 4(7), 851-853. Scopus46 WoS45 Europe PMC39 |
| 2005 | Dewar, A., Doherty, K., Hughes, T., & Lyons, A. (2005). Imatinib inhibits the functional capacity of cultured human monocytes. Immunology and Cell Biology, 83(1), 48-56. Scopus38 WoS38 Europe PMC29 |
| 2005 | Michor, F., Hughes, T., Iwasa, Y., Branford, S., Shah, N., Sawyers, C., & Nowak, M. (2005). Dynamics of chronic myeloid leukaemia. Nature, 435(7046), 1267-1270. Scopus704 WoS646 Europe PMC539 |
| 2004 | Faderl, S., Hochhaus, A., & Hughes, T. (2004). Monitoring of minimal residual disease in chronic myeloid leukemia. Hematology-Oncology Clinics of North America, 18(3), 657-672. Scopus25 Europe PMC11 |
| 2004 | Mollee, P., Arthur, C., Hughes, T., Januszewicz, H., Grigg, A., Bradstock, K., . . . Taylor, K. (2004). Interferon-α-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia. Annals of Oncology, 15(12), 1810-1815. Scopus6 WoS7 Europe PMC4 |
| 2004 | Hochhaus, A., & Hughes, T. (2004). Clinical resistance to imatinib: mechanisms and implications. Hematology-Oncology Clinics of North America, 18(3), 641-657. Scopus83 WoS70 Europe PMC59 |
| 2004 | Branford, S., Rudzki, Z., Parkinson, I., Grigg, A., Taylor, K., Seymour, J., . . . Hughes, T. (2004). Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood, 104(9), 2926-2932. Scopus206 WoS179 Europe PMC154 |
| 2004 | Szer, J., Durrant, S., Schwarer, A., Bradstock, K., Gibson, J., Arthur, C., . . . Raunow, H. (2004). Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantation. Internal Medicine Journal, 34(3), 98-101. Scopus10 WoS7 Europe PMC5 |
| 2004 | Mullighan, C., Heatley, S., Doherty, K., Szabo, F., Grigg, A., Hughes, T., . . . Bardy, P. (2004). Non-HLA immunogenetic polymorphisms and the risk of complications after allogeneic hemopoietic stem-cell transplantation. Transplantation, 27(4), 587-596. Scopus80 WoS73 Europe PMC65 |
| 2004 | Ross, D. M., & Hughes, T. P. (2004). Cancer treatment with kinase inhibitors: What have we learnt from imatinib?. British Journal of Cancer, 90(1), 12-19. Scopus44 WoS36 Europe PMC24 |
| 2003 | Favre, G., Beksaç, M., Bacigalupo, A., Ruutu, T., Nagler, A., Gluckman, E., . . . Pagliuca, A. (2003). Differences between graft product and donor side effects following bone marrow or stem cell donation. Bone Marrow Transplantation, 32(9), 873-880. Scopus89 Europe PMC69 |
| 2003 | Hughes, T. (2003). Comments on the Hammersmith policy. Seminars in Hematology, 40(2), 111-112. |
| 2003 | O'Brien, S., Guilhot, F., Larson, R., Gathmann, I., Baccarani, M., Cervantes, F., . . . Druker, B. (2003). Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New England Journal of Medicine, 348(11), 994-1004. Scopus3230 WoS2813 Europe PMC2328 |
| 2003 | Branford, S., Rudzki, Z., Harper, A., Grigg, A., Taylor, K., Durrant, S., . . . Hughes, T. (2003). Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia, 17(12), 2401-2409. Scopus149 WoS124 Europe PMC100 |
| 2003 | Roberts, M., Dyson, P., Rawling, C., Thorp, D., Rawling, T., White, D., . . . Hughes, T. (2003). Selected CD34 blood cell allografts for older patients: low transplant-related mortality, graft failure and acute GvHD. Cytotherapy, 5(6), 534-541. Scopus2 WoS2 Europe PMC2 |
| 2003 | Hughes, T., & Branford, S. (2003). Molecular monitoring of chronic myeloid leukemia. Seminars in Hematology, 40(2), 62-68. Scopus75 WoS61 Europe PMC51 |
| 2003 | Branford, S., Rudzki, Z., Walsh, S., Parkinson, I., Grigg, A., Szer, J., . . . Hughes, T. (2003). Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood, 102(1), 276-283. Scopus693 WoS600 Europe PMC505 |
| 2003 | Dewar, A., Domaschenz, R., Doherty, K., Hughes, T., & Lyons, A. (2003). Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors. Leukemia, 17(9), 1713-1721. Scopus54 WoS50 Europe PMC42 |
| 2003 | Hughes, T., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M., . . . Radich, J. (2003). Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. New England Journal of Medicine, 349(15), 1423-1432. Scopus1118 WoS976 Europe PMC819 |
| 2003 | Hui, C., Goh, K., White, D., Branford, S., Grigg, A., Seymour, J., . . . Hughes, T. (2003). Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR. Leukemia, 17(5), 821-828. Scopus40 WoS33 Europe PMC31 |
| 2003 | Melo, J. V., Hughes, T. P., & Apperley, J. F. (2003). Chronic myeloid leukemia.. Hematology the Education Program of the American Society of Hematology American Society of Hematology Education Program, 2003(1), 132-152. Scopus119 Europe PMC54 |
| 2003 | Hui, C. -H., & Hughes, T. P. (2003). Strategies for the treatment of imatinib-resistant chronic myeloid leukemia.. Clinical advances in hematology & oncology : H&O, 1(9), 538-559. Europe PMC5 |
| 2002 | Branford, S., Rudzki, Z., Walsh, S., Grigg, A., Arthur, C., Taylor, K., . . . Hughes, T. (2002). High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood, 99(9), 3472-3475. Scopus592 WoS534 Europe PMC451 |
| 2002 | Mullighan, C., Heatley, S., Doherty, K., Szabo, F., Grigg, A., Hughes, T., . . . Bardy, P. (2002). Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation. Blood, 99(10), 3524-3529. Scopus188 WoS168 Europe PMC141 |
| 2002 | Frost, M., Ferrao, P., Hughes, T., & Ashman, L. (2002). Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Molecular Cancer Therapeutics, 1(12), 1115-1124. Scopus250 WoS234 Europe PMC167 |
| 2002 | Branford, S., Hughes, T., & Rudzki, Z. (2002). Dual transcription of b2a2 and b3a2 BCR-ABL transcripts in chronic myeloid leukaemia is confined to patients with a linked polymorphism within the BCR gene. British Journal of Haematology, 117(4), 875-877. Scopus28 WoS26 Europe PMC17 |
| 2002 | Borg, M., Hughes, T., Horvath, N., Rice, M., & Thomas, A. C. (2002). Renal toxicity after total body irradiation. International Journal of Radiation Oncology Biology Physics, 54(4), 1165-1173. Scopus56 Europe PMC35 |
| 2001 | Mullighan, C. G., Heatley, S., Doherty, K., Szabo, F., Grigg, A. P., Hughes, T. P., . . . Bardy, P. G. (2001). Non-HLA genetic polymorphisms influence risk of acute and chronic graft-versus-host disease, early death and infection following allogeneic haemopoietic stem cell transplantation.. BLOOD, 98(11), 739A-740A. WoS1 |
| 2001 | Branford, S., Rudzki, Z., Walsh, S., Grigg, A., Arthur, C., Taylor, K., . . . Hughes, T. (2001). Point mutations clustered within the ATP binding region of BCR-ABL are common in patients with emerging Glivec resistance but not in Glivec non-responsive cases of CML.. BLOOD, 98(11), 769A-770A. WoS4 |
| 2001 | Branford, S., Moore, S., Grigg, A., Szer, J., Arthur, C., Taylor, K., . . . Hughes, T. (2001). Early measurement of BCR-ABL mRNA blood levels may be predictive of subsequent achievement of major cytogenetic response to Glivec in chronic myeloid leukemia.. BLOOD, 98(11), 613A. WoS4 |
| 2001 | Hui, C., Bardy, P., Hughes, T., Horvath, N., & To, L. (2001). Successful salvage of RAEB/AML relapsing early post allograft with FLAG-Ida conditioned mini-allograft: a report of two cases. International Journal of Laboratory Hematology (Print Edition), 23(2), 135-138. Scopus1 |
| 2001 | Lutwyche, J., Keough, R., Hughes, T., & Gonda, T. (2001). Mutation screening of the c-MYB negative regulatory domain in acute and chronic myeloid leukaemia. British Journal of Haematology, 114(3), 632-634. Scopus9 WoS9 Europe PMC9 |
| 2001 | Evans, M. D. M., McLean, K. M., Hughes, T. C., & Sweeney, D. F. (2001). A review of the development of a synthetic corneal onlay for refractive correction. Biomaterials, 22(24), 3319-3328. Scopus29 WoS24 Europe PMC15 |
| 2000 | Collins, D. J., Hughes, T. C., & Johnson, W. M. (2000). Dihydro-1,2,4-triazin-6(1H)-ones. IV Chemical modification of 3-phenyl-4,5-dihydro-1,2,4-triazin-6(1H)-ones. Australian Journal of Chemistry, 53(2), 137-141. Scopus10 WoS9 |
| 2000 | Hughes, T., White, D., Bresatz, S., Forte, M., Lewis, I., & Lyons, A. (2000). Normal and leukemic engraftment in the nod/scid mouse model. Haematologica, 85, 10-11. |
| 2000 | Moore, S., McDiarmid, L., & Hughes, T. (2000). Stem cell factor and chronic myeloid leukemia CD34+ cells. Leukemia & Lymphoma, 38(3-4), 211-220. Scopus10 WoS9 Europe PMC8 |
| 2000 | Craddock, C., Bardy, P., Kreiter, S., Johnston, R., Apperley, J., Marks, D., . . . Derigs, G. (2000). Engraftment of T-cell-depleted allogeneic haematopoietic stem cells using a reduced intensity conditioning regimen. British Journal of Haematology, 111(3), 797-800. Scopus22 Europe PMC14 |
| 2000 | Branford, S., Rudzi, Z., & Hughes, T. (2000). A novel BCR-ABL transcript (e8a2) with the insertion of an inverted sequence of ABL intron 1b in a patient with Philadelphia-positive chronic myeloid leukaemia. British Journal of Haematology, 109(3), 635-637. Scopus45 WoS45 Europe PMC40 |
| 2000 | Szabo, F., Horvath, N., Seimon, S., & Hughes, T. (2000). Inappropriate antidiuretic hormone secretion, abdominal pain and disseminated varicella-zoster virus infection: an unusual triad in a patient 6 months post mini-allogeneic peripheral stem cell transplant for chronic myeloid leukemia. Bone Marrow Transplantation, 26(2), 231-233. Scopus23 Europe PMC20 |
| 1999 | Branford, S., Hughes, T., & Rudzki, Z. (1999). Monitoring chronic myeloid leukaemia therapy by real time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. British Journal of Haematology, 107(-), 587-599. Scopus210 |
| 1999 | Branford, S., Hughes, T. P., & Rudzki, Z. (1999). Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. BRITISH JOURNAL OF HAEMATOLOGY, 107(3), 587-599. WoS189 Europe PMC178 |
| 1999 | Gricg, A. P., Szer, J., Beresford, J., Doods, A., Braosiock, K., Durrant, S., . . . Mattiie, J. (1999). Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia. British Journal of Haematology, 107(2), 409-418. Scopus61 Europe PMC49 |
| 1999 | Collins, D. J., Hughes, T. C., & Johnson, W. M. (1999). Dihydro-1,2,4-triazin-6(1H)-ones. III oxidation products of 1-Methyl-3-phenyl-4,5-dihydro-1,2,4-triazin-6(1H)-one. Australian Journal of Chemistry, 52(10), 971-975. Scopus3 WoS3 |
| 1999 | Collins, D. J., Hughes, T. C., & Johnson, W. M. (1999). Dihydro-1,2,4-triazin-6(1H)-ones. II synthesis of several methylated 3-phenyl-4,5-dihydro-1,2,4-triazin-6(1H)-ones. Australian Journal of Chemistry, 52(5), 379-385. Scopus13 WoS8 |
| 1998 | Moore, S., Haylock, D. N., Lévesque, J. P., McDiarmid, L. A., Samels, L. M., To, L. B., . . . Hughes, T. P. (1998). Stem cell factor as a single agent induces selective proliferation of the philadelphia chromosome positive fraction of chronic myeloid leukemia CD34+ cells. Blood, 92(7), 2461-2470. Scopus40 WoS37 Europe PMC23 |
| 1998 | Moore, S., Haylock, D., Levesque, J. P., McDiarmid, L., Samels, L., To, L., . . . Hughes, T. (1998). Stem cell factor as a single agent induces marked proliferation of the philadelphia chromosome positive fraction of CML CD34+ cell. Blood, 92(7), 2461-2470. |
| 1998 | Lewis, I., McDiarmid, L., Samels, L., To, L., & Hughes, T. (1998). Establishment of a reproducible model of chronic-phase chronic myeloid leukemia in NOD/SCID mice using blood-derived mononuclear or CD34+ cells. Blood, 91(2), 630-640. Scopus59 WoS58 Europe PMC34 |
| 1997 | Iversen, P., Lewis, I., Turczynowicz, S., Hasle, H., Niemeyer, C., Schmiegelow, K., . . . Lopez, A. (1997). Inhibition of GM-CSF prevents dissemination and induces remission of human juvenile myelomonocytic leukemia in engrafted immunodeficient mice.. Blood, 90(12), 4910-4917. |
| 1997 | Hughes, T., Grigg, A., Szer, J., Ho, J., Ma, D., Dale, B., . . . Arthur, C. (1997). Mobilization of predominantly Philadelphia chromosome-negative blood progenitors using cyclophosphamide and rHUG-CSF in early chronic-phase chronic myeloid leukaemia: correlation with Sokal prognostic index and haematological control.. British Journal of Haematology, 96(3), 635-640. Scopus14 WoS13 Europe PMC8 |
| 1997 | White, D., Hutchins, C., Turczynowicz, S., Suttle, J., Haylock, D., Hughes, T., . . . To, L. (1997). Detection of minimal residual disease in an AML patient with trisomy 8 using interphase fish. Pathology, 29(3), 289-293. Scopus9 WoS10 Europe PMC8 |
| 1997 | Lewis, I., Haylock, D., Moore, S., To, L., & Hughes, T. (1997). Peripheral blood is a source of BCR-ABL-negative pre-progenitors in early chronic phase chronic myeloid leukemia.. Leukemia, 11(4), 581-587. Scopus11 WoS7 Europe PMC2 |
| 1997 | Iversen, P. O., Lewis, I. D., Turczynowicz, S., Hasle, H., Niemeyer, C., Schmiegelow, K., . . . Lopez, A. F. (1997). Inhibition of granulocyte-macrophage colony-stimulating factor prevents dissemination and induces remission of juvenile myelomonocytic leukemia in engrafted immunodeficient mice. Blood, 90(12), 4910-4917. Scopus51 WoS44 Europe PMC22 |
| 1996 | Collins, D. J., Hughes, T. C., & Johnson, W. M. (1996). Regiospecific syntheses of the monomethylated 3-phenyldihydro-1,2,4-triazin-6(1H)-ones. Australian Journal of Chemistry, 49(4), 463-468. Scopus18 WoS15 |
| 1996 | Collins, D. J., Hughes, T. C., Johnson, W. M., & Mackay, M. F. (1996). 2-methyl-3-phenyl-2,5-dihydro-1,2,4-triazin-6(1H)-one methanol solvate and 4-methyl-3-phenyl-4,5-dihydro-1,2,4-triazin-6(1H)-one. Acta Crystallographica Section C Crystal Structure Communications, 52(11), 2865-2868. Scopus2 WoS1 |
| 1995 | Kumar, S., White, D., Takai, S., Turczynowicz, S., Juttner, C., & Hughes, T. (1995). Apoptosis regulatory gene NEDD2 maps to human chromosome segment 7934-35, a region frequently affected in haematological neoplasms. Human Genetics, 95(6), 641-644. Scopus41 WoS39 Europe PMC26 |
| 1995 | White, D., Hutchins, C., Haylock, D., Turczynowics, S., Bishop, A., To, L., . . . Juttner, C. (1995). A direct analysis of FACS-sorted hemopoietic cell fractions using fish. Biotechniques, 18(5), 818-821. Scopus4 WoS3 |
| 1994 | Orr, S. L., Hughes, T. P., Sawyers, C. L., Kato, R. M., Quan, S. G., Williams, S. P., . . . Hood, L. (1994). Isolation of unknown genes from human bone marrow by differential screening and single-pass cDNA sequence determination. Proceedings of the National Academy of Sciences of the United States of America, 91(25), 11869-11873. Scopus13 Europe PMC9 |
| 1993 | Cross, N. C. P., Hughes, T. P., Feng, L., O'Shea, P., Bungey, J., Marks, D. I., . . . Goldman, J. M. (1993). Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft‐versus‐host disease and relapse. British Journal of Haematology, 84(1), 67-74. Scopus172 WoS181 Europe PMC85 |
| 1993 | Cross, N. C. P., Feng, L., Chase, A., Bungey, J., Hughes, T. P., & Goldman, J. M. (1993). Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood, 82(6), 1929-1936. Scopus377 WoS369 Europe PMC170 |
| 1993 | Marks, D. I., Cullis, J. O., Ward, K. N., Lacey, S., Szydlo, R., Hughes, T. P., . . . Goldman, J. M. (1993). Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors: A comparison of complications in the first 2 years. Annals of Internal Medicine, 119(3), 207-214. Scopus200 WoS203 Europe PMC119 |
| 1993 | HANAUER, S. B., KRAWITT, E. L., ROBINSON, M., RICK, G. G., SAFDI, M. A., ALPERT, E., . . . ROI, L. (1993). LONG-TERM MANAGEMENT OF CROHNS-DISEASE WITH MESALAMINE CAPSULES (PENTASA(R)). AMERICAN JOURNAL OF GASTROENTEROLOGY, 88(9), 1343-1351. WoS49 Europe PMC29 |
| 1992 | Marks, D. I., Hughes, T. P., Szydlo, R., Kelly, S., Cullis, J. O., Schwarer, A. P., . . . Goldman, J. M. (1992). HLA‐identical sibling donor bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: influence of GVHD prophylaxis on outcome. British Journal of Haematology, 81(3), 383-390. Scopus42 WoS44 Europe PMC19 |
| 1992 | Cullis, J. O., Schwarer, A. P., Hughes, T. P., Hows, J. M., Franklin, I., Morgenstern, G., & Goldman, J. M. (1992). Second transplants for patients with chronic myeloid leukaemia in relapse after original transplant with T‐depleted donor marrow: feasibility of using busulphan alone for re‐conditioning. British Journal of Haematology, 80(1), 33-39. Scopus43 WoS41 Europe PMC20 |
| 1992 | Bi, S., Hughes, T., Bungey, J., Chase, A., De Fabritiis, P., & Goldman, J. M. (1992). p53 in chronic myeloid leukemia cell lines. Leukemia, 6(8), 839-842. Scopus54 Europe PMC34 |
| 1992 | Cullis, J. O., Jiang, Y. Z., Schwarer, A. P., Hughes, T. P., Barrett, A. J., & Goldman, J. M. (1992). Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation [3]. Blood, 79(5), 1379-1381. Scopus138 WoS152 Europe PMC59 |
| 1990 | Morgan, G. J., Hernandez, A., Chan, L. C., Hughes, T., Martiat, P., & Wiedemann, L. M. (1990). The role of alternative splicing patterns of BCR/ABL transcripts in the generation of the blast crisis of chronic myeloid leukaemia. British Journal of Haematology, 76(1), 33-38. Scopus46 Europe PMC24 |
| 1990 | Mackinnon, S., Hows, J., Goldman, J., Arthur, C., Hughes, T., Apperley, J., . . . Waldman, H. (1990). Bone marrow transplantation for chronic myeloid leukemia: The use of histocompatible unrelated volunteer donors. Experimental Hematology, 18(5), 421-425. Scopus49 Europe PMC22 |
| 1990 | Hughes, T., & Goldman, J. M. (1990). Improved results with PCR for chronic myeloid leukaemia. Lancet, 336(8718), 812. Scopus17 Europe PMC9 |
| 1990 | Hughes, T., Janssen, J. W. G., Morgan, G., Martiat, P., Saglio, G., Pignon, J. M., . . . Goldman, J. M. (1990). False-positive results with PCR to detect leukaemia-specific transcript. Lancet, 335(8696), 1037-1038. Scopus54 Europe PMC39 |
| 1990 | Hughes, T., Martiat, P., Morgan, G., Sawyers, C., Witte, O. N., & Goldman, J. M. (1990). Significance of residual leukaemia transcripts after bone marrow transplant for CML. Lancet, 335(8680), 50. Scopus16 Europe PMC7 |
| 1990 | Hughes, T. M., & Goldman, J. M. (1990). Biological importance of residual leukaemic cells after BMT for CML: Does the polymerase chain reaction help?. Bone Marrow Transplantation, 5(1), 3-6. Scopus28 Europe PMC15 |
| 1989 | Morgan, G. J., Janssen, J. W. G., Guo, A. P., Wiedemann, L. M., Hughes, T., Gow, J., . . . Bartram, C. R. (1989). POLYMERASE CHAIN REACTION FOR DETECTION OF RESIDUAL LEUKAEMIA. Lancet, 333(8644), 928-929. Scopus142 Europe PMC82 |
| 1989 | Hughes, T. P., Economou, K., Mackinnon, S., Vlitos, M., Arthur, C. K., Guo, A. P., . . . Goldman, J. M. (1989). Slow evolution of chronic myeloid leukaemia relapsing after BMT with T‐cell depleted donor marrow. British Journal of Haematology, 73(4), 462-467. Scopus37 WoS38 Europe PMC22 |
| 1989 | Kaminski, E., Hows, J., Brookes, P., Mackinnon, S., Hughes, T., Avakian, O., . . . Batchelor, J. R. (1989). Alloreactive cytotoxic T-cell frequency analysis and HLA matching for bone marrow transplants from HLA matched unrelated donors. Transplantation Proceedings, 21(1 III), 2976-2977. Scopus11 Europe PMC3 |
| 1989 | Hughes, T. P., Jones, P., & Rozenberg, M. C. (1989). Hypergammaglobulinemia and the anticardiolipin antibody test. Arthritis Rheumatism, 32(6), 813. Scopus17 WoS16 Europe PMC16 |
| 1989 | Kaminski, E., Hows, J., Man, S., Brookes, P., Mackinnon, S., Hughes, T., . . . Batchelor, J. R. (1989). Prediction of graft versus host disease by frequency analysis of cytotoxic T cells after unrelated donor bone marrow transplantation. Transplantation, 48(4), 608-613. Scopus183 Europe PMC114 |
| 1988 | BLACK, R. E., LEVINE, M. M., CLEMENTS, M. L., HUGHES, T. P., & BLASER, M. J. (1988). EXPERIMENTAL CAMPYLOBACTER-JEJUNI INFECTION IN HUMANS. JOURNAL OF INFECTIOUS DISEASES, 157(3), 472-479. WoS912 |
| 1983 | CLEMENTS, M. L., WISSEMAN, C. L., WOODWARD, T. E., FISET, P., DUMLER, J. S., MCNAMEE, W., . . . LEVINE, M. M. (1983). REACTOGENICITY, IMMUNOGENICITY, AND EFFICACY OF A CHICK-EMBRYO CELL DERIVED VACCINE FOR ROCKY-MOUNTAIN SPOTTED-FEVER. JOURNAL OF INFECTIOUS DISEASES, 148(5), 922-930. WoS45 |
| 1983 | CLEMENTS, M. L., LEVINE, M. M., RISTAINO, P. A., DAYA, V. E., & HUGHES, T. P. (1983). EXOGENOUS LACTOBACILLI FED TO MAN - THEIR FATE AND ABILITY TO PREVENT DIARRHEAL DISEASE. PROGRESS IN FOOD AND NUTRITION SCIENCE, 7(3-4), 29-37. WoS76 Europe PMC32 |
| 1982 | HOBBINS, T. E., HUGHES, T. P., RENNELS, M. B., MURPHY, B. R., & LEVINE, M. M. (1982). BRONCHIAL REACTIVITY IN EXPERIMENTAL INFECTIONS WITH INFLUENZA-VIRUS. JOURNAL OF INFECTIOUS DISEASES, 146(4), 468-471. WoS9 |
| 1982 | LEVINE, M. M., BLACK, R. E., BRINTON, C. C., CLEMENTS, M. L., FUSCO, P., HUGHES, T. P., . . . YOUNG, C. R. (1982). REACTOGENICITY, IMMUNOGENICITY AND EFFICACY STUDIES OF ESCHERICHIA-COLI TYPE-1 SOMATIC PILI PARENTERAL VACCINE IN MAN. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 83-95. WoS41 |
| 1981 | LEVINE, M. M., YOUNG, C. R., HUGHES, T. P., ODONNELL, S., BLACK, R. E., CLEMENTS, M. L., . . . LIM, Y. L. (1981). DURATION OF SERUM ANTITOXIN RESPONSE FOLLOWING VIBRIO-CHOLERAE INFECTION IN NORTH AMERICANS - RELEVANCE FOR SEROEPIDEMIOLOGY. AMERICAN JOURNAL OF EPIDEMIOLOGY, 114(3), 348-354. WoS14 |
| 1980 | LEVINE, M. M., RENNELS, M. B., CISNEROS, L., HUGHES, T. P., NALIN, D. R., & YOUNG, C. R. (1980). LACK OF PERSON-TO-PERSON TRANSMISSION OF ENTERO-TOXIGENIC ESCHERICHIA-COLI DESPITE CLOSE CONTACT. AMERICAN JOURNAL OF EPIDEMIOLOGY, 111(3), 347-355. WoS46 |
| 1980 | CLEMENTS, M. L., LEVINE, M. M., BLACK, R. E., HUGHES, T. P., RUST, J., & TOME, F. C. (1980). POTASSIUM SUPPLEMENTS FOR ORAL DIARRHEA REGIMENS. LANCET, 2(8199), 854. WoS6 |
| 1980 | CLEMENTS, M. L., LEVINE, M. M., BLACK, R. E., HUGHES, T. P., NALIN, D. R., PIZARRO, D., & HIRSCHHORN, N. (1980). ORAL-THERAPY WITH GLUCOSE ELECTROLYTE SOLUTION. LANCET, 2(8184), 34. WoS4 |
| 1980 | LEVINE, M. M., RENNELS, M. B., DAYA, V., & HUGHES, T. P. (1980). HEMAGGLUTINATION AND COLONIZATION FACTORS IN ENTERO-TOXIGENIC AND ENTEROPATHOGENIC ESCHERICHIA-COLI THAT CAUSE DIARRHEA. JOURNAL OF INFECTIOUS DISEASES, 141(6), 733-737. WoS65 |
| 1978 | LEVINE, M. M., HUGHES, T. P., YOUNG, C. R., ODONNELL, S., CRAIG, J. P., HOLLEY, H. P., & BERGQUIST, E. J. (1978). ANTIGENICITY OF PURIFIED GLUTARALDEHYDE-TREATED CHOLERA TOXOID ADMINISTERED ORALLY. INFECTION AND IMMUNITY, 21(1), 158-162. WoS20 |
| 1978 | NALIN, D. R., LEVINE, M. M., RHEAD, J., BERGQUIST, E., RENNELS, M., HUGHES, T., . . . HORNICK, R. B. (1978). CANNABIS, HYPOCHLORHYDRIA, AND CHOLERA. LANCET, 2(8095), 859-862. WoS43 Europe PMC29 |
| 1977 | CAPLAN, E. S., HUGHES, T. P., ODONNELL, S., LEVINE, M. M., & HORNICK, R. B. (1977). REACTOGENICITY AND IMMUNOGENICITY OF PARENTERAL MONO-VALENT INFLUENZA-A-VICTORIA-3-75 (H3N2) VIRUS-VACCINE IN HEALTHY ADULTS. JOURNAL OF INFECTIOUS DISEASES, 136(Supplement 3), S484-S490. WoS13 |
| 1977 | LEVINE, M. M., HUGHES, T. P., SIMON, P., ODONNELL, S., GRAUEL, S., & LEVINE, S. G. (1977). MONO-VALENT INACTIVATED A-NEW-JERSEY-8-76 (HSW1N1) VACCINE IN HEALTHY CHILDREN AGED 3 TO 5 YEARS. JOURNAL OF INFECTIOUS DISEASES, 136(Supplement 3), S571-S574. WoS10 |
| 1940 | Davies, D. R., & Hughes, T. P. E. (1940). Faulty detoxication in mental disorder. LANCET, 1, 403-405. WoS11 |
| 1938 | Hughes, T. P., Pickels, E. G., & Horsfall, F. L. (1938). A method for determining the differential sedimentation of proteins in the high speed concentration centrifuge. JOURNAL OF EXPERIMENTAL MEDICINE, 67(6), 941-952. WoS29 |
| 1936 | Lynch, C. J., & Hughes, T. P. (1936). The inheritance of susceptibility to yellow fever encephalitis in mice. GENETICS, 21(2), 104-112. WoS34 |
| 1935 | Hughes, T. P., Parker, R. F., & Rivers, T. M. (1935). Immunological and chemical investigations of vaccine virus II. Chemical analysis of elementary bodies of vaccinia. JOURNAL OF EXPERIMENTAL MEDICINE, 62(3), 349-352. WoS25 |
| 1933 | Irwin, M. R., & Hughes, T. P. (1933). Inheritance as a factor in resistance to an infectious disease VI. The correlation between resistance and the bactericidal power of the whole blood. JOURNAL OF IMMUNOLOGY, 24(4), 343-348. WoS8 |
| 1932 | Hughes, T. P., & Sawyer, W. A. (1932). Significance of immunity tests in epidemiology as illustrated in yellow fever. JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 99(12), 978-982. WoS9 |
| 1931 | Irwin, M. R., & Hughes, T. P. (1931). Differences in bactericidal power of the blood within an inbred strain of rats.. PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, 29(3), 0295-0297. WoS6 |
| 1930 | Hughes, T. P. (1930). Acid agglutination zones of typical and variant pneumococci. PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, 27(8), 804-805. WoS2 |
| 1930 | Pritchett, I. W., Beaudette, F. R., & Hughes, T. P. (1930). The epidemiology of fowl cholera IV. Field observations of the "spontaneous" disease. JOURNAL OF EXPERIMENTAL MEDICINE, 51(2), 249-258. WoS16 |
| 1930 | Pritchett, I. W., Beaudette, F. R., & Hughes, T. P. (1930). The epidemiology of fowl cholera V. Further field observations of the spontaneous disease. JOURNAL OF EXPERIMENTAL MEDICINE, 51(2), 259-274. WoS12 |
| 1930 | Hughes, T. P. (1930). The epidemiology of fowl cholera II. Biological properties of P. avicida. JOURNAL OF EXPERIMENTAL MEDICINE, 51(2), 225-U61. WoS26 |
| 1930 | Hughes, T. P., & Pritchett, I. W. (1930). The epidemiology of fowl cholera III. Portal of entry of P. avicida; Reaction of the host. JOURNAL OF EXPERIMENTAL MEDICINE, 51(2), 239-U72. WoS12 |
| 1927 | Webster, L. T., Hughes, T. P., Pritchett, I. W., & Beaudette, F. R. (1927). Pasteurella avisepticurn* - Infection of poultry. PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, 25(2), 119-121. WoS1 |
| 1925 | Petersen, W. F., & Hughes, T. P. (1925). Mineral metabolism of the lymph following injections of levo- and dextro- suprarenin, pituitrin, and pilocarpine.. JOURNAL OF BIOLOGICAL CHEMISTRY, 66(1), 229-246. WoS9 |
| 1925 | Petersen, W. F., & Hughes, T. P. (1925). Inorganic alterations of the lymph in canine anaphylactic shock.. JOURNAL OF BIOLOGICAL CHEMISTRY, 63(2), 179-196. WoS12 |
| Year | Citation |
|---|---|
| 2007 | Hughes, T., & Rusten, T. E. (2007). Origin and evolution of self-consumption: Autophagy (Vol. 607). G. Jekely (Ed.), SPRINGER-VERLAG BERLIN. WoS33 |
| 2000 | Nicola, M., Suttle, J., Beerworth, J., Dobrovic, A., Hughes, T., & Moore, S. (2000). A new rare t(9;11)(p22;p15) in acute leukaemia. |
| Year | Citation |
|---|---|
| 2025 | Yeung, D. T. O., & Hughes, T. P. (2025). Chronic myeloid leukaemia. In Hoffbrand S Postgraduate Haematology Eighth Edition (pp. 630-651). Wiley. DOI |
| 2021 | Branford, S., Shanmuganathan, N., & Hughes, T. P. (2021). Response-related predictors of survival and of treatment-free remission in CML. In R. Hehlmann (Ed.), Source details - Title: Chronic Myeloid Leukemia (pp. 245-264). Switzerland: Springer. DOI |
| 2016 | Ross, D., & Hughes, T. (2016). Discontinuation of therapy and treatment-free remission in CML. In M. Kizaki (Ed.), Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia (pp. 183-193). Japan: Springer. DOI Scopus1 |
| 2016 | Yeung, D., & Hughes, T. (2016). Chronic Myeloid Leukaemia. In A. V. Hoffbrand, & D. R. Higgs (Eds.), Postgraduate Haematology: Seventh Edition (pp. 419-437). Wiley. DOI Scopus2 |
| 2011 | Hiwase, D. K., & Hughes, T. P. (2011). Therapy of Advanced-Stage and Resistant Chronic Myeloid Leukemia. In Leukemias Principles and Practice of Therapy (pp. 281-295). Wiley. DOI |
| 2008 | Hiwase, D. K., & Hughes, T. (2008). Monitoring response to therapy for patients with chronic myeloid leukemia. In Chronic Myeloproliferative Disorders (pp. 103-117). |
| 2007 | Hughes, T., & Branford, S. (2007). Monitoring disease response. In J. Melo, & J. Goldman (Eds.), Myeloproliferative disorders. Hematologic Malignancies (pp. 143-164). Berlin: Springer. |
| Year | Citation |
|---|---|
| 2025 | Hughes, T. P. (2025). Is Targeting BCR::ABL1 Alone Sufficient? NO. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 25 (pp. S103-S105). CIG MEDIA GROUP, LP. |
| 2024 | Hughes, T. (2024). Next Questions: Chronic Myeloid Leukemia. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 24 (pp. S140-S141). CIG MEDIA GROUP, LP. |
| 2024 | Jabbour, E., Rea, D., Cortes, J., Hochhaus, A., Hughes, T., Kim, D. -W., . . . Mauro, M. (2024). CARDINAL: A Phase 1, Multicenter, Open-Label, Dose-Escalation and Dose-Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Chronic Myeloid Leukemia. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 24 (pp. S370-S371). CIG MEDIA GROUP, LP. |
| 2023 | Hughes, T. P., Saglio, G., Geissler, J., Kim, D. -W., Lomaia, E., Mayer, J., . . . Cortes, J. (2023). Asciminib (ASC) Add-on to Imatinib (IMA) Demonstrates Sustained High Rates of Ongoing Therapy and Deep Molecular Responses (DMRs) with Prolonged Follow-up in the ASC4MORE Study. In BLOOD Vol. 142 (pp. 4 pages). CA, San Diego: ELSEVIER. DOI WoS4 |
| 2023 | Apperley, J., Cortes, J., Jabbour, E., Hochhaus, A., Hughes, T., Chuah, C., . . . Rosti, G. (2023). Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Patients With Treatment-Resistant Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Treated With Ponatinib From the Phase 2 OPTIC Trial. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 23 (pp. S339). CIG MEDIA GROUP, LP. |
| 2023 | Mueller, M. C., Cortes, J., Chuah, C., DeAngelo, D. J., Deininger, M., Guilhot, F., . . . Kantarjian, H. M. (2023). Early Cytogenetic or Molecular Landmark Response to Ponatinib Treatment Predicts Outcomes in Heavily Pretreated Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in PACE: 5-Year Data. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 23 (pp. S336-S337). CIG MEDIA GROUP, LP. |
| 2023 | Mauro, M., Hochhaus, A., Hughes, T., Rea, D., Boquimpani, C., Minami, Y., . . . Cortes, J. (2023). Responses With Asciminib Continue to Deepen Over Time in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase III ASCEMBL Study. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 23 (pp. S340). CIG MEDIA GROUP, LP. |
| 2023 | Hiwase, D., Ross, D., Lane, S., Yong, A., Sharplin, K., Yeung, D., . . . Thomas, D. (2023). A phase 2/3, multicenter trial of lenzilumab and azacitidine in chronic myelomonocytic leukemia: The PREACH-M trial. In CANCER RESEARCH Vol. 83 (pp. 3 pages). FL, Orlando: AMER ASSOC CANCER RESEARCH. DOI |
| 2023 | Ostovaneh, M., Hughes, T., Wu, C. O., McClelland, R., Casanova, R., Bluemke, D. A., . . . Venkatesh, B. A. (2023). DEEP PHENOTYPING OF DEMENTIA IN A MULTI-ETHNIC CARDIOVASCULAR COHORT: THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA). In JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY Vol. 81 (pp. 4021). LA, New Orleans: ELSEVIER SCIENCE INC. |
| 2023 | Ding, X., Dalen, K., Hughes, T., & Rasband, M. (2023). Oligodendroglial Ank3 in paranodal maintenance and etiology of bipolar disorder. In JOURNAL OF NEUROCHEMISTRY Vol. 166 (pp. 74-75). WILEY. |
| 2023 | Carpanini, S., Torvell, M., Watkins, L., Byrne, R., Hughes, T., Zelek, W., & Morgan, B. P. (2023). Roles of complement dysregulation and membrane attack complex formation in developmental synapse loss. In IMMUNOBIOLOGY Vol. 228 (pp. 72). ELSEVIER GMBH. DOI |
| 2023 | Mizuzo, M., Kamiya, T., Miyasaka, Y., Kim, H., Fukui, S., Ishigami, M., . . . Morgan, B. P. (2023). Prevention of terminal pathway activation improves survival in a lethal malarial infection mouse model associated with multiple organ failure. In IMMUNOBIOLOGY Vol. 228 (pp. 3). ELSEVIER GMBH. DOI |
| 2023 | Andreassen, O., Osete, J., Akkouh, I., Ievglevskyi, O., Vandenberghe, M., De Assis, D., . . . Djurovic, S. (2023). Transcriptional and Functional Effects of Lithium in Bipolar Disorder iPSC-Derived Cortical Spheroids. In BIOLOGICAL PSYCHIATRY Vol. 93 (pp. S19). ELECTR NETWORK: ELSEVIER SCIENCE INC. |
| 2022 | Apperley, J. F., Cortes, J. E., Jabbour, E., Hochhaus, A., Hughes, T., Chuah, C., . . . Rosti, G. (2022). Molecular Response of ≤10% <i>BCR::ABL1</i><SUP>IS</SUP> Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial. In BLOOD Vol. 140 (pp. 6760-6762). LA, New Orleans: ELSEVIER. DOI WoS1 |
| 2022 | Cortes, J. E., Hughes, T., Geissler, J., Kim, D. -W., Lomaia, E., Mayer, J., . . . Saglio, G. (2022). Efficacy and Safety Results from ASC4MORE, a Randomized Study of Asciminib (ASC) Add-on to Imatinib (IMA), Continued IMA, or Switch to Nilotinib (NIL) in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Not Achieving Deep Molecular Responses (DMRs) with ≥1 Year of IMA. In BLOOD Vol. 140 (pp. 3 pages). LA, New Orleans: ELSEVIER. DOI WoS1 |
| 2022 | Hughes, T., Rea, D., Boquimpani, C., Minami, Y., Mauro, M., Cortes, J. E., . . . Hochhaus, A. (2022). Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study. In BLOOD Vol. 140 (pp. 6757-6759). LA, New Orleans: ELSEVIER. DOI WoS4 |
| 2022 | Hughes, T., Cortes, J. E., Takahashi, N., Larson, R. A., Issa, G. C., Bombaci, F., . . . Hochhaus, A. (2022). ASC4FIRST: A Phase III Study of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitor in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP). In BLOOD Vol. 140 (pp. 6767-6768). LA, New Orleans: ELSEVIER. DOI WoS4 |
| 2021 | Cortes, J. E., Hochhaus, A., Takahashi, N., Larson, R. A., Issa, G. C., Bombaci, F., . . . Hughes, T. P. (2021). Trial in Progress: A Multicenter, Open Label, Randomized, Phase III Study of Asciminib (80 mg Once Daily) Vs Investigator-Selected TKI in Newly Diagnosed Adult Patients with Chronic Myeloid Leukemia in Chronic Phase. In BLOOD Vol. 138 (pp. 4 pages). GA, Atlanta: ELSEVIER. DOI |
| 2021 | Lassalle, P. P., Meyer, M. L., Heffernan, K. S., Kiefer, A. W., Bates, L. C., Hanson, E. D., . . . Stoner, L. (2021). Associations Between Carotid-femoral And Estimated Pulse Wave Velocity In Older Adults: The Atherosclerosis Risk In Communities (ARIC) Study. In CIRCULATION Vol. 143 (pp. 3 pages). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. DOI |
| 2020 | Cortes, J. E., Hughes, T. P., Mauro, M. J., Hochhaus, A., Rea, D., Goh, Y. T., . . . Kim, D. -W. (2020). Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial. In BLOOD Vol. 136 (pp. 5 pages). ELECTR NETWORK: ELSEVIER. DOI WoS43 |
| 2020 | Mahon, F. -X., Clementino, N. D., Fominykh, M., Lipton, J. H., Turkina, A. G., Moiraghi, B., . . . Hughes, T. P. (2020). ENESTop 5-Year Update: Durability of Treatment-Free Remission Following Second-Line Nilotinib and Exploratory Analysis of Molecular Response Regain after Nilotinib Re-Initiation in Patients with Chronic Myeloid Leukemia. In BLOOD Vol. 136 (pp. 4 pages). ELECTR NETWORK: ELSEVIER. DOI WoS3 |
| 2020 | Rea, D., Mauro, M. J., Cortes, J. E., Jiang, Q., Pagnano, K. B., Ongondi, M., . . . Hughes, T. P. (2020). COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study. In BLOOD Vol. 136 (pp. 4 pages). ELECTR NETWORK: ELSEVIER. DOI WoS25 |
| 2020 | Radich, J., Hochhaus, A., Giles, F., Ross, D., Saglio, G., Hughes, T., . . . Mahon, F. -X. (2020). Predictors of Durable Treatment-Free Remission After Frontline or Second-Line Nilotinib Treatment in Patients with Chronic Phase Chronic Myeloid Leukemia. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 20 (pp. S233-S234). CIG MEDIA GROUP, LP. |
| 2020 | Hughes, T., Mauro, M., Kim, D. -W., Cortes, J., Rea, D., Minami, H., . . . Talpaz, M. (2020). Efficacy and Safety of Asciminib in Heavily Pretreated Patients with Philadelphia Chromosome-Positive (Ph plus ) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with Sensitivity to Tyrosine Kinase Inhibitors (TKIs). In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 20 (pp. S235). CIG MEDIA GROUP, LP. WoS1 |
| 2019 | Bevan, R., Hughes, T., Good, M., Morgan, P., & Morgan, J. (2019). RETINAL GANGLION CELL MORPHOLOGY ABNORMALITIES IN ALZHEIMER'S DISEASE AND COMPLEMENT ANIMAL MODELS. In MOLECULAR IMMUNOLOGY Vol. 114 (pp. 440). SPAIN, Madrid: PERGAMON-ELSEVIER SCIENCE LTD. |
| 2019 | Szabo, A., Akkouh, I. A., Hansson, L., Inderhaug, E., Hughes, T., Ueland, T., . . . Djurovic, S. (2019). Reduced IL-1beta-induced chemokine response in human iPSC-astrocytes in schizophrenia revealed by RNA-sequencing. In BRAIN BEHAVIOR AND IMMUNITY Vol. 81 (pp. 50-51). ACADEMIC PRESS INC ELSEVIER SCIENCE. DOI |
| 2019 | Branford, S., Wadham, C., Shanmuganathan, N., Thomson, D., Shahrin, N. U. R. H., Feng, J., . . . Hughes, T. P. (2019). An RNA-Based Next Generation Sequencing (NGS) Strategy Detects More Cancer Gene Mutations Than a DNA-Based Approach for the Prediction and Assessment of Resistance in CML. In BLOOD Vol. 134 (pp. 4 pages). FL, Orlando: ELSEVIER. DOI |
| 2019 | Saglio, G., Hughes, T. P., Geissler, J., Kapoor, S., Longin, A. -S., Mukherjee, A., & Cortes, J. E. (2019). Randomized, Open-Label, Multicenter, Phase 2 Study of Asciminib (ABL001) As an Add-on to Imatinib Versus Continued Imatinib Versus Switch to Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase Who Have Not Achieved a Deep Molecular Response with Frontline Imatinib. In BLOOD Vol. 134 (pp. 3 pages). FL, Orlando: ELSEVIER. DOI WoS4 |
| 2019 | Radich, J. P., Hochhaus, A., Giles, F. J., Ross, D. M., Saglio, G., Hughes, T. P., . . . Mahon, F. -X. (2019). Analyses of Predictors of Durable Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Frontline or Second-Line Nilotinib. In BLOOD Vol. 134 (pp. 3 pages). FL, Orlando: ELSEVIER. DOI WoS1 |
| 2019 | Hughes, T. P., Saglio, G., Larson, R. A., Kantarjian, H. M., Kim, D. -W., Issaragrisil, S., . . . Hochhaus, A. (2019). Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis. In BLOOD Vol. 134 (pp. 4 pages). FL, Orlando: ELSEVIER. DOI WoS19 |
| 2019 | Shanmuganathan, N., Thomson, D., Wadham, C., Saunders, V. A., Shahrin, N. H., Yeung, D. T., . . . Branford, S. (2019). RNA Splicing Defects in Cancer-Linked Genes Indicate Mutation or Focal Gene Deletion and Are Associated with TKI Resistance in CML. In BLOOD Vol. 134 (pp. 4 pages). FL, Orlando: ELSEVIER. DOI WoS1 |
| 2019 | Kok, C. H., Liu, L., Yeung, D. T., Saunders, V. A., Dang, P., & Hughes, T. P. (2019). A Combination of <i>CD302</i> gene Expression and 3-Months <i>BCR</i>-<i>ABL1 Level</i> Predicts Inferior Achievement of Deep Molecular Response in CP-CML Patients Treated with Imatinib. In BLOOD Vol. 134 (pp. 3 pages). FL, Orlando: ELSEVIER. DOI WoS1 |
| 2019 | Deininger, M. W., Rea, D., Lang, F., Kim, D. -W., Cortes, J. E., Hughes, T. P., . . . Mauro, M. J. (2019). Efficacy and Safety of Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor Targeting the Myristoyl-Binding Site, in Patients with Chronic Myeloid Leukemia (CML) Carrying the T315I Mutation. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 19 (pp. S289-S290). CIG MEDIA GROUP, LP. DOI |
| 2018 | Mahon, F. -X., Boquimpani, C., Takahashi, N., Benyamini, N., Clementino, N. C. D., Shuvaev, V., . . . Hughes, T. P. (2018). Long-term treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib: ENESTop 144-wk results.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 2 pages). LIPPINCOTT WILLIAMS & WILKINS. DOI WoS5 |
| 2018 | Leow, B. C., Eadie, L., Pagani, I. S., Yeung, D. T., Hughes, T. P., & White, D. L. (2018). Clonal Selection Determines Resultant Dominance of Tyrosine Kinase Inhibitor-Resistant Cells in Chronic Myeloid Leukaemia. In HemaSphere Vol. 2 (pp. 503). Stockholm, Sweden: Lippincott, Williams & Wilkins. DOI |
| 2018 | Shanmuganathan, N., Branford, S., Yong, A., Hiwase, D., Yeung, D., Ross, D., & Hughes, T. (2018). Predictors of Success in Treatment-Free Remission: A Single Centre Experience. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 18 (pp. S224). CIG MEDIA GROUP, LP. DOI |
| 2018 | Mauro, M. J., Lang, F., Kim, D. -W., Cortes, J. E., Hughes, T. P., Hochhaus, A., . . . DeAngelo, D. J. (2018). Clinical Development of Asciminib (ABL001): A Randomized Phase 3 Study of Asciminib vs Bosutinib in Patients with Chronic Myeloid Leukemia (CML). In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 18 (pp. S223). CIG MEDIA GROUP, LP. DOI WoS1 |
| 2018 | Cortes, J. E., Hughes, T. P., Geissler, J., Hois, S., Quenet, S., Hourcade-Potelleret, F., . . . Saglio, G. (2018). Asciminib (ABL001) in Combination with Imatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase Who Have Not Achieved a Deep Molecular Response with Long-Term Frontline Imatinib: A Randomized, Open-Label, Multicenter, Phase 2 Study. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 18 (pp. S222-S223). CIG MEDIA GROUP, LP. DOI WoS1 |
| 2018 | Hughes, T. P., Boquimpani, C., Takahashi, N., Benyamini, N., Clementino, N. C. D., Shuvaev, V., . . . Mahon, F. -X. (2018). ENESTop 144-Week Update: Long-Term Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 18 (pp. S222). CIG MEDIA GROUP, LP. DOI WoS3 |
| 2018 | Yeung, D. T., Grigg, A. P., Shanmuganathan, N., Cunningham, I., Shortt, J., Rowling, P., . . . Hughes, T. P. (2018). Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study. In BLOOD Vol. 132 (pp. 5 pages). San Diego, CA: AMER SOC HEMATOLOGY. DOI WoS7 |
| 2018 | Tvorogov, D., Thomas, D., Liau, N. P. D., Dottore, M., Barry, E. F., Lathi, M., . . . Lopez, A. F. (2018). Accumulation of JAK Activation-Loop Phosphorylation Promotes Type I JAK Inhibitor Withdrawal Syndrome in Myelofibrosis. In BLOOD Vol. 132 (pp. 4 pages). San Diego, CA: AMER SOC HEMATOLOGY. DOI |
| 2018 | Rea, D., Lang, F., Kim, D. -W., Cortes, J. E., Hughes, T. P., Minami, H., . . . Mauro, M. J. (2018). Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial. In BLOOD Vol. 132 (pp. 4 pages). San Diego, CA: AMER SOC HEMATOLOGY. DOI WoS6 |
| 2018 | Mauro, M. J., Lang, F., Kim, D. -W., Cortes, J. E., Hughes, T. P., Hochhaus, A., . . . Rea, D. (2018). Clinical development of asciminib (ABL001) in chronic myeloid leukemia (CML): A randomized phase 3 study vs. bosutinib.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 1 page). AMER SOC CLINICAL ONCOLOGY. DOI |
| 2018 | Yong, A. S., Shanmuganathan, N., & Hughes, T. (2018). Treatment-Free Remission in CML: Selecting the Best Candidates. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 18 (pp. S3-S5). CIG MEDIA GROUP, LP. DOI |
| 2018 | Thomson, D., Shahrin, H., Wang, P., Wadham, C., Hughes, T. P., Schreiber, A., & Branford, S. (2018). High Recombination Activating Gene (RAG) Expression and RAG Mediated Recombination Is Associated with Oncogenic Rearrangement Observed with Tyrosine Kinase Inhibitor Resistant CML. In BLOOD Vol. 132 (pp. 4 pages). CA, San Diego: AMER SOC HEMATOLOGY. DOI WoS2 |
| 2017 | Hughes, T., Boquimpani, C., Takahashi, N., Benyamini, N., Clementino, N. C., Shuvaev, V., . . . Mahon, F. -X. (2017). DURABLE TREATMENT-FREE REMISSION AFTER STOPPING SECOND-LINE NILOTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: ENESTOP 96-WK UPDATE. In HAEMATOLOGICA Vol. 102 (pp. 75). Madrid, SPAIN: FERRATA STORTI FOUNDATION. WoS9 |
| 2017 | Cortes, J. E., Hochhaus, A., Kantarjian, H. M., Guilhot, F., Kota, V. K., Hughes, T. P., . . . Jabbour, E. (2017). Impact of dose reductions on 5-year efficacy in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) from DASISION.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 6 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS16 |
| 2017 | Kantarjian, H. M., Pinilla-Ibarz, J., Le Coutre, P. D., Paquette, R., Chuah, C., Nicolini, F. E., . . . Cortes, J. E. (2017). Five-year results of the ponatinib phase II PACE trial in heavily pretreated CP-CML patients (pts).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 5 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS5 |
| 2017 | Mueller, M., Baccarani, M., Deininger, M. W. N., Guilhot, F., Hochhaus, A., Hughes, T. P., . . . Cortes, J. E. (2017). Impact of early landmark responses with ponatinib on 4-yr outcomes in CP-CML patients (pts) in PACE, a pivotal phase II trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 6 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS1 |
| 2017 | Ross, D. M., Pagani, I. S., Shanmuganathan, N., Seymour, J. F., Mills, A. K., Filshie, R. J., . . . Hughes, T. P. (2017). Long-term Follow-up of the ALLG CML8 TWISTER Study of Treatment-free Remission (TFR) in Patients With Chronic Myeloid Leukemia (CML).. In Blood Vol. 130 (pp. 1597). Atlanta: American Society of Hematology. |
| 2017 | Pagani, I., Dang, P., Kommers, I., Goyne, J., Saunders, V., Prime, J., . . . Ross, D. (2017). Comparison of genomic and reverse transcriptase Q-PCR for the monitoring of first-line imatinib treatment: an ALLG CML9 sub-study. In Haematologica. Madrid: Ferrata Storti Foundation. |
| 2017 | Shanmuganathan, N., Branford, S., Yeung, D., Hiwase, D. K., Yong, A. S. M., Ross, D. M., & Hughes, T. P. (2017). Cumulative Incidence of Treatment-Free Remission (TFR) for Patients with Chronic Myeloid Leukemia (CML): The Adelaide Experience. In BLOOD Vol. 130 (pp. 3 pages). Atlanta, GA: AMER SOC HEMATOLOGY. |
| 2017 | Cortes, J. E., Nicolini, F. E., Hochhaus, A., le Coutre, P. D., Kim, D. -W., Pinilla-Ibarz, J., . . . Kantarjian, H. M. (2017). Arterial Occlusive Events (AOEs) in the Phase 2 Ponatinib PACE Trial: 5-Year Update in Heavily Treated Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CP-CML). In BLOOD Vol. 130 (pp. 4 pages). GA, Atlanta: AMER SOC HEMATOLOGY. WoS1 |
| 2017 | Hughes, T. P., Hochhaus, A., Kim, D. -W., Mahon, F. -X., Giles, F. J., Radich, J. P., . . . Saglio, G. (2017). Treatment-Free Remission (TFR) Among Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Not Initially Eligible for Treatment Discontinuation Due to Unstable Deep Molecular Response (DMR): Enestfreedom and Enestop. In BLOOD Vol. 130 (pp. 4 pages). GA, Atlanta: AMER SOC HEMATOLOGY. |
| 2017 | Hochhaus, A., Cortes, J. E., Kim, D. -W., Pinilla-Ibarz, J., le Coutre, P. D., Paquette, R., . . . Kantarjian, H. M. (2017). Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study. In BLOOD Vol. 130 (pp. 4 pages). GA, Atlanta: AMER SOC HEMATOLOGY. WoS4 |
| 2017 | Saglio, G., Hughes, T. P., Hochhaus, A., Kim, D. -W., Giles, F. J., Radich, J. P., . . . Mahon, F. -X. (2017). Impact of Treatment Cessation on Overall Disease Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Attempting Treatment-Free Remission (TFR): Findings from Enestfreedom and Enestop. In BLOOD Vol. 130 (pp. 3 pages). GA, Atlanta: AMER SOC HEMATOLOGY. |
| 2017 | Cortes, J. E., Kantarjian, H. M., Pinilla-Ibarz, J., le Coutre, P. D., Paquette, R., Chuah, C., . . . Mueller, M. C. (2017). 5-Year Updates from the Pivotal Phase 2 Ponatinib PACE Trial: Efficacy, Safety and Landmark Analysis in Heavily Pretreated Patients with Chronic-Phase Chronic Myeloid Leukemia. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 17 (pp. S307-S308). CIG MEDIA GROUP, LP. DOI |
| 2017 | Cortes, J. E., Hochhaus, A., Kantarjian, H., Guilhot, F., Kota, V., Hughes, T. P., . . . Jabbour, E. (2017). Effect of Dose Modifications on 5-Year Efficacy of Dasatinib and Imatinib in Newly Diagnosed Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) From DASISION. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 17 (pp. S308-S309). CIG MEDIA GROUP, LP. DOI |
| 2017 | Branford, S., Wang, P., Yeung, D., Purins, A., Marum, J. E., Nataren, N., . . . Hughes, T. P. (2017). Integrative Genomics Reveals Cancer Associated Mutations Are Common at Diagnosis of CML in Patients with Poor Response to TKI Therapy. In BLOOD Vol. 130 (pp. 4 pages). GA, Atlanta: AMER SOC HEMATOLOGY. |
| 2017 | Radich, J., Mahon, F. -X., Hochhaus, A., Hughes, T., Ailawadhi, S., Lipton, J., . . . Saglio, G. (2017). ENESTfreedom and ENESTop Update: Durable Treatment-Free Remission (TFR) at 96 Weeks after Nilotinib Treatment Cessation in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP). In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 17 (pp. S314-S315). CIG MEDIA GROUP, LP. DOI WoS2 |
| 2016 | Marum, J. E., Wang, P. P. S., Stangl, D., Yeung, D. T., Mueller, M. C., Dietz, C. T., . . . Branford, S. (2016). Novel Fusion Genes at CML Diagnosis Reveal a Complex Pattern of Genomic Rearrangements and Sequence Inversions Associated with the Philadelphia Chromosome in Patients with Early Blast Crisis. In BLOOD Vol. 128 (pp. 6 pages). CA, San Diego: AMER SOC HEMATOLOGY. DOI WoS2 |
| 2016 | Pagani, I. S., Kok, C. H., Saunders, V., Goyne, J., McLean, J., VanderHoek, M., . . . Ross, D. M. (2016). The genomic landscape of mitochondrial DNA mutations in chronic myeloid leukaemia.. In European Journal of Human Genetics. Barcelona: Natue Publishing Group. |
| 2016 | Mahon, F. -X., Boquimpani, C. M., Takahashi, N., Benyamini, N., Clementino, N. C. D., Shuvaev, V., . . . Hughes, T. P. (2016). Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTop Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase. In BLOOD Vol. 128 (pp. 6 pages). CA, San Diego: AMER SOC HEMATOLOGY. DOI WoS2 |
| 2016 | Hughes, T. P., Boquimpani, C. M., Takahashi, N., Benyamini, N., Clementino, N. C. D., Shuvaev, V., . . . Mahon, F. -X. (2016). Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop. In BLOOD Vol. 128 (pp. 6 pages). CA, San Diego: AMER SOC HEMATOLOGY. DOI WoS5 |
| 2016 | Asari, K., Heatley, S. L., Sadras, T., Leclercq, T. M., Fitter, S., Kok, C. H., . . . White, D. L. (2016). <i>In Vitro</i> Modeling of Ph-like ALL Fusions Identifies Novel Kinase-Domain Mutations As Mode of TKI-Resistance Implications for Targeted Therapy. In BLOOD Vol. 128 (pp. 5 pages). San Diego, CA: AMER SOC HEMATOLOGY. DOI WoS1 |
| 2016 | Shanmuganathan, N., Branford, S., Braley, J., Hiwase, D., Yeung, D. T., Ross, D. M., & Hughes, T. P. (2016). For Patients with Sustained MR4-MR4.5, Less Frequent Molecular Monitoring during the First 12 Months after Tyrosine Kinase Inhibitor Cessation Is Viable for Timely Detection of Loss of MMR. In BLOOD Vol. 128 (pp. 7 pages). CA, San Diego: AMER SOC HEMATOLOGY. DOI |
| 2016 | Yeung, D. T., Osborn, M. P., White, D. L., Branford, S., Gerber, T., Butcher, B., . . . Hughes, T. P. (2016). Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study. In BLOOD Vol. 128 (pp. 6 pages). San Diego, CA: AMER SOC HEMATOLOGY. DOI |
| 2016 | Hughes, T. P., Goh, Y. -T., Ottmann, O. G., Minami, H., Rea, D., Lang, F., . . . Kim, D. -W. (2016). Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy. In BLOOD Vol. 128 (pp. 6 pages). San Diego, CA: AMER SOC HEMATOLOGY. DOI WoS5 |
| 2016 | Jabbour, E. J., Cortes, J. E., Talpaz, M., Baccarani, M., Mauro, M. J., Hochhaus, A., . . . Kantarjian, H. M. (2016). Long-Term Follow-up of the Efficacy and Safety of Ponatinib in Philadelphia Chromosome-Positive Leukemia Patients with the T315I Mutation. In BLOOD Vol. 128 (pp. 7 pages). San Diego, CA: AMER SOC HEMATOLOGY. DOI |
| 2016 | Hiwase, D. K., Tan, P., D'Rozario, J., Taper, J., Powell, A. R., Irving, I., . . . Hughes, T. P. (2016). Efficacy and Safety of Nilotinib 300 Mg Twice Daily (BD) in Patients with CML in Chronic Phase (CML-CP) Who Are Intolerant to Prior BCR-ABL Tyrosine Kinase Inhibitors (TKIs): Results from the Randomized, Phase IIIb ENES Tswift Study. In BLOOD Vol. 128 (pp. 6 pages). CA, San Diego: AMER SOC HEMATOLOGY. DOI |
| 2016 | Hughes, T. P., Boquimpani, C., Kim, D. -W., Benyamini, N., Clementino, N. C. D., Shuvaev, V., . . . Mahon, F. -X. (2016). Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with second-line nilotinib (NIL): First results from the ENESTop study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 4 pages). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. DOI WoS5 |
| 2016 | Muller, M. C., Baccarani, M., Deininger, M. W. N., Guilhot, F., Hochhaus, A., Hughes, T. P., . . . Cortes, J. E. (2016). Impact of landmark responses on 3-year (yr) outcomes with ponatinib in heavily pretreated CP-CML patients (pts).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 4 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2016 | Cortes, J. E., Pinilla-Ibarz, J., Le Coutre, P. D., Paquette, R., Chuah, C., Nicolini, F. E., . . . Kantarjian, H. M. (2016). 4-year results of the ponatinib phase II PACE trial in patients (pts) with heavily pretreated leukemia.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 4 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS3 |
| 2016 | Pagani, I. S., Kok, C. H., Wang, J., Saunders, V., Goyne, J., McLean, J., . . . Ross, D. M. (2016). MITOCHONDRIAL DNA MUTATIONS IDENTIFY CLONAL HETEROGENEITY IN CHRONIC MYELOID LEUKAEMIA. In HAEMATOLOGICA Vol. 101 (pp. 234). Copenhagen, DENMARK: FERRATA STORTI FOUNDATION. |
| 2016 | Lu, L., Saunders, V., Kok, C., Leclercq, T., Hughes, T., & White, D. (2016). MODELLING PONATINIB RESISTANCE IN BCR-ABL1+CELL LINES: IMPLICATIONS FOR PONATINIB THERAPY. In HAEMATOLOGICA Vol. 101 (pp. 182-183). Copenhagen, DENMARK: FERRATA STORTI FOUNDATION. |
| 2015 | Pritchard, J., Lustgarten, S., Hodgson, J. G., Baccarani, M., Cortes, J. E., Deininger, M. W., . . . Rivera, V. M. (2015). ANALYSIS OF THE RELATIONSHIP BETWEEN DOSE AND BCR-ABL HALVING TIME IN CP-CML PATIENTS TREATED WITH PONATINIB OR IMATINIB. In HAEMATOLOGICA Vol. 100 (pp. 448-449). Vienna, AUSTRIA: FERRATA STORTI FOUNDATION. |
| 2015 | Hochhaus, A., Saglio, G., Hughes, T. P., Larson, R. A., Taningco, L., Deng, W., . . . Kantarjian, H. M. (2015). Impact of Treatment with Frontline Nilotinib (NIL) vs Imatinib (IM) on Sustained Deep Molecular Response (MR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP). In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY. |
| 2015 | Ottmann, O. G., Alimena, G., DeAngelo, D. J., Goh, Y. -T., Heinrich, M. C., Hochhaus, A., . . . Dong-Wook, K. (2015). ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY. DOI WoS20 |
| 2015 | Hughes, T. P., Cervantes, F., Spector, N., Leber, B., Branford, S., Glynos, T. A., . . . Lipton, J. H. (2015). Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL). In BLOOD Vol. 126 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY. |
| 2015 | Cortes, J. E., Kim, D. G., Pinilla-Ibarz, J., Le Coutre, P. D., Paquette, R., Chuah, C., . . . Kantarjian, H. M. (2015). Efficacy and safety of ponatinib in heavily pretreated leukemia patients in the PACE trial: 3-year results.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2015 | Khoury, H. J., Baccarani, M., Guilhot, F., Hochhaus, A., Hughes, T. P., Lipton, J. H., . . . Mauro, M. J. (2015). Elevated blood pressure (BP) and adverse events (AEs) of hypertension (HTN) in ponatinib (PON) leukemia trials.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. |
| 2015 | Hochhaus, A., Cortes, J. E., Kim, D. -W., Pinilla-Ibarz, J., le Coutre, P. D., Paquette, R., . . . Kantarjian, H. M. (2015). Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial. In BLOOD Vol. 126 (pp. 5 pages). Orlando, FL: AMER SOC HEMATOLOGY. WoS4 |
| 2015 | Hughes, T. P., Larson, R. A., Kim, D. W., Issaragrisil, S., le Coutre, P. D., Lobo, C., . . . Kantarjian, H. M. (2015). EFFICACY AND SAFETY OF NILOTINIB VS IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: 6-YEAR FOLLOW-UP OF ENESTND. In HAEMATOLOGICA Vol. 100 (pp. 61). Vienna, AUSTRIA: FERRATA STORTI FOUNDATION. |
| 2015 | Eadie, L. N., Hughes, T. P., & White, D. L. (2015). The Clinical Significance of Early Imatinib Induced ABCB1 Overexpression in Chronic Phase CML Patients: A TIDEL II Sub-Study. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY. DOI WoS2 |
| 2015 | Marum, J. E., Purins, L., Yeung, D. T., Parker, W. T., Price, D. J., Wang, P. P. S., . . . Branford, S. (2015). Germline Genetic Variation of ASXL1 and BIM Predicts Response to Imatinib and Identifies a Subset of High Sokal Risk Patients with the Greatest Risk of Treatment Failure and Disease Progression. In BLOOD Vol. 126 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY. DOI |
| 2015 | Kok, C. H., Leclercq, T. M., Watkins, D., Yeung, D. T., Saunders, V. A., White, D. L., & Hughes, T. P. (2015). A 20 Gene Expression Signature That Predicts Early Molecular Response Failure in Chronic Phase CML Patients Treated with Frontline Imatinib. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY. |
| 2015 | Hughes, A., Tang, C., Clarson, J., Vidovic, L., Hughes, T. P., & Yong, A. S. (2015). Chronic Myeloid Leukemia Patients with Deep Molecular Responses to Tyrosine Kinase Inhibitors Have Increased Effector Natural Killer and Cytotoxic T Cell Immune Responses to Leukaemia-Associated Antigens and Concomitant Reduced Immune Suppressors. In BLOOD Vol. 126 (pp. 2 pages). Orlando, FL: AMER SOC HEMATOLOGY. DOI WoS4 |
| 2015 | Nicolini, F. E., Basak, G. W., Kim, D. -W., Olavarria, E., Pinilla-Ibarz, J., Apperley, J. F., . . . Cortes, J. E. (2015). The Impact of Ponatinib Versus Allogeneic Stem Cell Transplant (SCT) on Outcomes in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL) with the T315I Mutation. In BLOOD Vol. 126 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY. |
| 2015 | Hughes, T. P., Salvino, M. A., Chuan, O. T., Elhaddad, A., Abdulkadyrov, K., Shortt, J., . . . Lipton, J. H. (2015). Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results from ENESTxtnd Study. In BLOOD Vol. 126 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY. |
| 2015 | Eadie, L. N., Saunders, V. A., Leclercq, T. M., Branford, S., White, D. L., & Hughes, T. P. (2015). The Allosteric Inhibitor ABL001 Is Susceptible to Resistance in Vitro Mediated By Overexpression of the Drug Efflux Transporters ABCB1 and ABCG2. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY. |
| 2015 | Yeung, D. T., Parker, W. T., Phillis, S., Georgievski, J., Scott, H. S., Hughes, T. P., & Branford, S. (2015). BCR-ABL Assay Sensitivity of MR4.5 Achieved in >90%, and MR5 in >75% of Samples, through mRNA Selection before qRT-PCR. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY. |
| 2015 | Hughes, T. P., Cervantes, F., Leber, B., Spector, N., Lipton, J. H., Pasquini, R., . . . Branford, S. (2015). ENESTCMR 4-Y RESULTS: PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AND RESIDUAL DISEASE MORE LIKELY TO ACHIEVE DEEP MOLECULAR RESPONSE FOLLOWING SWITCH TO NILOTINIB (NIL). In HAEMATOLOGICA Vol. 100 (pp. 61-62). Vienna, AUSTRIA: FERRATA STORTI FOUNDATION. |
| 2015 | Branford, S., Wang, P. P. S., Parker, W. T., Yeung, D., Marum, J. E., Stangl, D., . . . Hughes, T. P. (2015). High Incidence of Mutated Cancer-Associated Genes at Diagnosis in CML Patients with Early Transformation to Blast Crisis. In BLOOD Vol. 126 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY. |
| 2015 | Cortes, J. E., Kim, D. -W., Pinilla-Ibarz, J., le Coutre, P. D., Paquette, R., Chuah, C., . . . Shah, N. P. (2015). Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study. In BLOOD Vol. 126 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY. |
| 2015 | Pritchard, J. R., Lustgarten, S., Hodgson, G., Baccarani, M., Cortes, J. E., Deininger, M. W., . . . Rivera, V. M. (2015). High-Resolution Analysis of the Relationship Between Ponatinib Dose and Molecular Response in CP-CML Patients in the PACE Trial. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 15 (pp. S212). CIG MEDIA GROUP, LP. DOI |
| 2015 | Lipton, J. H., Chuah, C., Guerci-Bresler, A., Rosti, G., Simpson, D., Lustgarten, S., . . . Deininger, M. W. (2015). EPIC: A Phase 3 Trial of Ponatinib Compared With Imatinib in CP-CML Patients. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 15 (pp. S211). CIG MEDIA GROUP, LP. DOI |
| 2015 | Baccarani, M., Mauro, M. J., Cortes, J. E., Hochhaus, A., Hughes, T. P., Guilhot, F., . . . Talpaz, M. (2015). LONG-TERM FOLLOW-UP OF PONATINIB EFFICACY AND SAFETY IN PATIENTS (PTS) WITH THE T315I MUTATION IN THE PHASE 1 AND PHASE 2 (PACE) TRIALS. In HAEMATOLOGICA Vol. 100 (pp. 65). Vienna, AUSTRIA: FERRATA STORTI FOUNDATION. WoS2 |
| 2015 | Mueller, M., Baccarani, M., Deininger, M. W., Guilhot, F., Hochhaus, A., Hughes, T. P., . . . Cortes, J. E. (2015). RESPONSES AT EARLY LANDMARK TIME POINTS ARE ASSOCIATED WITH OUTCOMES IN HEAVILY PRETREATED CP-CML PATIENTS (PTS) TREATED WITH PONATINIB. In HAEMATOLOGICA Vol. 100 (pp. 65). Vienna, AUSTRIA: FERRATA STORTI FOUNDATION. |
| 2014 | Mauro, M. J., Cortes, J. E., Hochhaus, A., Baccarani, M., Hughes, T. P., Guilhot, F., . . . Talpaz, M. (2014). Ponatinib Efficacy and Safety in Patients with the T315I Mutation: Long-Term Follow-up of Phase 1 and Phase 2 (PACE) Trials. In BLOOD Vol. 124 (pp. 4 pages). AMER SOC HEMATOLOGY. WoS2 |
| 2014 | Cortes, J. E., Kim, D. -W., Pinilla-Ibarz, J., Le Coutre, P., Paquette, R., Chuah, C., . . . Kantarjian, H. M. (2014). Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial. In BLOOD Vol. 124 (pp. 5 pages). San Francisco, CA: AMER SOC HEMATOLOGY. WoS4 |
| 2014 | Nicolini, F. E., Cortes, J. E., Kim, D. W., Pinilla-Ibarz, J., le Coutre, P. D., Paquette, R., . . . Hochhaus, A. (2014). CLINICAL IMPACT OF DOSE MODIFICATION AND DOSE INTENSITY ON RESPONSE TO PONATINIB IN PATIENTS (PTS) WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) LEUKEMIAS. In HAEMATOLOGICA Vol. 99 (pp. 334). Milan, ITALY: FERRATA STORTI FOUNDATION. |
| 2014 | le Coutre, P. D., Kim, D. W., Pinilla-Ibarz, J., Paquette, R., Chuah, C., Nicolini, F. E., . . . Cortes, J. E. (2014). PONATINIB IN PATIENTS (PTS) WITH PHILADELPHIA CHROMOSOME- POSITIVE (PH plus ) LEUKEMIAS RESISTANT OR INTOLERANT TO DASATINIB OR NILOTINIB, OR WITH THE T315I MUTATION: LONGER-TERM FOLLOW-UP OF THE PACE TRIAL. In HAEMATOLOGICA Vol. 99 (pp. 334). Milan, ITALY: FERRATA STORTI FOUNDATION. |
| 2014 | Chuah, C., Guerci-Bresler, A., Rosti, G., Simpson, D., Lustgarten, S., Trede, N., . . . Lipton, J. H. (2014). EPIC: A PHASE 3 TRIAL OF PONATINIB VS IMATINIB IN PATIENTS (PTS) WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CP-CML). In HAEMATOLOGICA Vol. 99 (pp. 238). Milan, ITALY: FERRATA STORTI FOUNDATION. WoS7 |
| 2014 | Ma, H., Li, L., Hao, X., Hughes, T., & Chen, H. (2014). Cross-linking Bovine lens capsule as a potential corneal endothelium carrier. In INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE Vol. 55 (pp. 2 pages). ASSOC RESEARCH VISION OPHTHALMOLOGY INC. |
| 2014 | Larson, R. A., Kim, D. -W., Issaragrilsil, S., le Coutre, P., Dorlhiac Llacer, P. E., Etienne, G., . . . Hughes, T. P. (2014). Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd. In BLOOD Vol. 124 (pp. 4 pages). San Francisco, CA: AMER SOC HEMATOLOGY. DOI WoS2 |
| 2014 | Hughes, T. P., Munhoz, E. C., Elhaddad, A., Chuan, O. T., Abdulkadyrov, K., Shortt, J., . . . Lipton, J. H. (2014). Efficacy and Safety of Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTxtnd Interim Analysis. In BLOOD Vol. 124 (pp. 4 pages). San Francisco, CA: AMER SOC HEMATOLOGY. |
| 2014 | Mahon, F. -X., Baccarani, M., Mauro, M. J., Hughes, T. P., Sagilo, G., Savona, M., . . . Hochhaus, A. (2014). Treatment-free remission (TER) following nilotinib (NIL) in patients (pis) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. DOI WoS11 |
| 2014 | Larson, R. A., Kim, D. -W., Jootar, S., Pasquini, R., Clark, R. E., Lobo, C., . . . Hughes, T. P. (2014). ENESTnd 5-year (y) update: Long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. DOI WoS10 |
| 2014 | Spector, N., Clementino, N. C. D., Dorlhiac-Llacer, P. E., Leber, B., Hughes, T. P., Cervantes, F., . . . Lipton, J. H. (2014). Effect of continued imatinib (IM) in pts with detectable BCR-ABL after ≥ 2 years on study on deep molecular responses (MR): 36-month update from ENESTcmr.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. DOI |
| 2014 | Deininger, M. W., Shah, N. P., Cortes, J. E., Kim, D. W., Nicolini, F. E., Talpaz, M., . . . Branford, S. (2014). LONGER-TERM FOLLOW-UP OF THE IMPACT OF BASELINE (BL) MUTATIONS ON PONATINIB RESPONSE AND END OF TREATMENT (EOT) MUTATION ANALYSIS IN PATIENTS (PTS) WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CP-CML). In HAEMATOLOGICA Vol. 99 (pp. 533). Milan, ITALY: FERRATA STORTI FOUNDATION. |
| 2014 | Branford, S., Kamel-Reid, S., Bendit, I., Etienne, G., Guerci-Bresler, A., Hughes, T. P., . . . Cervantes, F. (2014). EARLY MOLECULAR RESPONSE PREDICTS ACHIEVEMENT OF UNDETECTABLE BCR-ABL IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) TREATED WITH NILOTINIB: 3-YEAR FOLLOW-UP OF ENESTCMR. In HAEMATOLOGICA Vol. 99 (pp. 532). Milan, ITALY: FERRATA STORTI FOUNDATION. WoS3 |
| 2014 | Hughes, T. P., le Coutre, P. D., Jootar, S., Reiffers, J., Turkina, A. G., Saglio, G., . . . Larson, R. A. (2014). ENESTND 5-YEAR FOLLOW-UP: CONTINUED BENEFIT OF FRONTLINE NILOTINIB (NIL) COMPARED WITH IMATINIB (IM) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP). In HAEMATOLOGICA Vol. 99 (pp. 236-237). Milan, ITALY: FERRATA STORTI FOUNDATION. WoS10 |
| 2014 | Lipton, J. H., Chuah, C., Guerci-Bresler, A., Rosti, G., Simpson, D., Lustgarten, S., . . . Deininger, M. W. N. (2014). EPIC: A phase III trial of ponatinib (PON) versus imatinib (IM) in patients (pts) with newly diagnosed CP-CML.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. DOI WoS3 |
| 2014 | Eadie, L. N., Hughes, T. P., & White, D. L. (2014). Increasing expression of the efflux transporter ABCB1 may predispose CML cells to over TKI resistance. In NDLR Abstract Handbook Vol. 122 (pp. 2 pages). Noosa, QLD: AMER SOC HEMATOLOGY. DOI WoS1 |
| 2014 | Hochhaus, A., Pinilla-Ibarz, J., Kim, D. -W., Le Coutre, P. D., Paquette, R., Chuah, C., . . . Cortes, J. E. (2014). Clinical impact of dose modification and dose intensity on response to ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph plus ) leukemias.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. DOI WoS7 |
| 2014 | Mueller, M. C., Baccarani, M., Deininger, M. W., Guilhot, F., Hochhaus, A., Hughes, T. P., . . . Cortes, J. E. (2014). Achieving Early Landmark Response Is Predictive of Outcomes in Heavily Pretreated Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib. In BLOOD Vol. 124 (pp. 4 pages). San Francisco, CA: AMER SOC HEMATOLOGY. DOI WoS1 |
| 2014 | Moad, G., Barlow, K., Hao, X., Hughes, T. C., Hutt, O. E., Polyzos, A., & Turner, K. A. (2014). RAFT-synthesized porous polymer monoliths for flow. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 248 (pp. 1 page). CA, San Francisco: AMER CHEMICAL SOC. |
| 2013 | Hughes, T., Cortese, J., Kim, D., Nicolini, F., Talpaz, M., Baccarani, M., . . . Deininger, M. (2013). IMPACT OF BASELINE MUTATIONS ON RESPONSE TO PONATINIB AND END OF TREATMENT MUTATION ANALYSIS IN PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ( PH plus ) LEUKEMIAS. In HAEMATOLOGICA Vol. 98 (pp. 57). FERRATA STORTI FOUNDATION. |
| 2013 | Larson, R. A., Hochhaus, A., Saglio, G., Kim, D. -W., Jootar, S., Le Coutre, P. D., . . . Kantarjian, H. M. (2013). Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 4-year (y) update. In JOURNAL OF CLINICAL ONCOLOGY Vol. 31 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. WoS12 |
| 2013 | Lipton, J. H., Deininger, M. W. N., Lustgarten, S., Turner, C. D., Rivera, V. M., Clackson, T., . . . Haluska, F. G. (2013). EPIC: A phase III randomized, open-label study of ponatinib versus imatinib in adult patients with newly diagnosed chronic myeloid leukemia in chronic phase.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 31 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. |
| 2013 | Saglio, G., Hughes, T. P., Larson, R. A., Issaragrilsil, S., Turkina, A. G., Steegmann, J. L., . . . Hochhaus, A. (2013). Impact of early molecular response to nilotinib (NIL) or imatinib (IM) on the long-term outcomes of newly diagnosed patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): Landmark analysis of 4-year (y) data from ENESTnd. In JOURNAL OF CLINICAL ONCOLOGY Vol. 31 (pp. 2 pages). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. |
| 2013 | Hochhaus, A., Saglio, G., Larson, R., Rosti, G., Flinn, I., Goh, Y., . . . Hughes, T. (2013). NILOTINIB SHOWS SUSTAINED BENEFIT COMPARED WITH IMATINIB IN PATIENTS (PTS) WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTND 4-YEAR FOLLOW-UP (F/U). In HAEMATOLOGICA Vol. 98 (pp. 298-299). FERRATA STORTI FOUNDATION. |
| 2013 | Hughes, T., Saglio, G., Quintas-Cardama, A., Mauro, M., Kim, D., Lipton, J., . . . Hochhaus, A. (2013). RESPONSE DYNAMICS AND OUTCOMES IN PATIENTS DEVELOPING MUTATIONS DURING FIRST-LINE TREATMENT WITH DASATINIB OR IMATINIB FOR CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): DASISION 3-YEAR FOLLOW-UP. In HAEMATOLOGICA Vol. 98 (pp. 296-297). FERRATA STORTI FOUNDATION. |
| 2013 | Cervantes, F., Hughes, T., Etienne, G., Guerci-Bresler, A., De Souza, C., Moiraghi, B., . . . Leber, B. (2013). CONTINUED DEEPER MOLECULAR RESPONSE WITH NILOTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WITH DETECTABLE DISEASE ON LONG-TERM IMATINIB: ENESTCMR 24-MONTH RESULTS. In HAEMATOLOGICA Vol. 98 (pp. 56-57). FERRATA STORTI FOUNDATION. |
| 2013 | Leber, B., Cervantes, F., Spector, N., Lipton, J. H., Etienne, G., Pasquini, R., . . . Hughes, T. P. (2013). Achievement and Maintenance Of Deeper Molecular Response By Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Residual Disease On Long-Term Imatinib: ENESTcmr 36-Month Follow-Up. In BLOOD Vol. 122 (pp. 2 pages). New Orleans, LA: AMER SOC HEMATOLOGY. DOI WoS4 |
| 2013 | Gordon, J. E. A., Bailey, C. G., Rasko, J., Ritchie, W., Watkins, D. B., White, D. L., . . . Hughes, T. P. (2013). MicroRNA Dysregulation in Newly Diagnosed Chronic Myeloid Leukaemia Patients. In BLOOD Vol. 122 (pp. 1 page). New Orleans, LA: AMER SOC HEMATOLOGY. DOI |
| 2013 | Kantarjian, H. M., Cortes, J. E., Kim, D. -W., Pinilla-Ibarz, J., le Coutre, P. D., Paquette, R., . . . Shah, N. P. (2013). Efficacy and Safety Of Ponatinib Following Failure Of Nilotinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial. In BLOOD Vol. 122 (pp. 2 pages). New Orleans, LA: AMER SOC HEMATOLOGY. DOI WoS5 |
| 2013 | Hochhaus, A., Cortes, J. E., Kim, D. -W., Pinilla-Ibarz, J., le Coutre, P. D., Paquette, R., . . . Guilhot, F. (2013). Efficacy and Safety Of Ponatinib Following Failure Of Dasatinib In Patients (pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial. In BLOOD Vol. 122 (pp. 2 pages). New Orleans, LA: AMER SOC HEMATOLOGY. DOI WoS3 |
| 2013 | Le Coutre, P. D., Kim, D. -W., Pinilla-Ibarz, J., Paquette, R., Chuah, C., Nicolini, F. E., . . . Cortes, J. E. (2013). Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs). In BLOOD Vol. 122 (pp. 3 pages). New Orleans, LA: AMER SOC HEMATOLOGY. DOI WoS3 |
| 2013 | le Coutre, P. D., Hughes, T. P., Mahon, F. -X., Kim, D. -W., Steegmann, J. L., Shah, N. P., . . . Cortes, J. E. (2013). Peripheral Arterial Occlusive Disease (PAOD) In Patients (Pts) Receiving Dasatinib: Experience Across Multiple Clinical Trials. In BLOOD Vol. 122 (pp. 2 pages). New Orleans, LA: AMER SOC HEMATOLOGY. DOI WoS21 |
| 2013 | Cortes, J. E., Kim, D. -W., Pinilla-Ibarz, J., le Coutre, P. D., Paquette, R., Chuah, C., . . . Kantarjian, H. M. (2013). Ponatinib In Patients (pts) With Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL) Resistant Or Intolerant To Dasatinib Or Nilotinib, Or With The T315I BCR-ABL Mutation: 2-Year Follow-Up Of The PACE Trial. In BLOOD Vol. 122 (pp. 2 pages). New Orleans, LA: AMER SOC HEMATOLOGY. DOI WoS4 |
| 2013 | Branford, S., Roberts, N., Yeung, D. T., Altamura, H., Parker, W. T., & Hughes, T. P. (2013). Any BCR-ABL Reduction Below 10% At 6 Months Of Therapy Significantly Improves Outcome For CML Patients With a Poor Response At 3 Months. In BLOOD Vol. 122 (pp. 2 pages). New Orleans, LA: AMER SOC HEMATOLOGY. WoS9 |
| 2013 | Saglio, G., Hochhaus, A., Hughes, T. P., Clark, R. E., Nakamae, H., Kim, D. -W., . . . Larson, R. A. (2013). ENESTnd Update: Nilotinib (NIL) Vs Imatinib (IM) In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) and The Impact Of Early Molecular Response (EMR) and Sokal Risk At Diagnosis On Long-Term Outcomes. In BLOOD Vol. 122 (pp. 2 pages). New Orleans, LA: AMER SOC HEMATOLOGY. DOI WoS16 |
| 2013 | White, D., Saunders, V., Eadie, L., David, Y., & Hughes, T. P. (2013). The Depth Of In Vivo Kinase Inhibition Achieved Over The First Month Of Nilotinib Therapy Predicts For Subsequent Molecular Response, and Is Closely Related To Nilotinib Plasma Levels. In Blood Vol. 122 (pp. 256). American Society of Hematology. DOI |
| 2013 | Eadie, L., Hughes, T. P., & White, D. L. (2013). Increasing expression of the efflux transporter ABCB1 may predispose CML cells to overt TKI resistance. In Blood Vol. 122 (pp. 5157). New Orleans, Louisiana: American Society of Hematology. DOI |
| 2013 | Tan, K. J., Moad, G., Turner, K. A., Polyzos, A., Hughes, T. C., Hutt, O. E., & Hao, X. (2013). Monoliths for flow processes synthesised by RAFT polymerization. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 245 (pp. 1 page). LA, New Orleans: AMER CHEMICAL SOC. |
| 2013 | Gautier, J. -F., Rea, D., Saglio, G., Hughes, T. P., Kantarjian, H. M., Kemp, C., . . . Breccia, M. (2013). Glucose Metabolism (GM) Changes in Nondiabetic Patients (Pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated With Nilotinib (NIL) or Imatinib (IM). In DIABETES Vol. 62 (pp. A704-A705). AMER DIABETES ASSOC. |
| 2012 | Cervantes, C., Hughes, T., Etienne, G., De Souza, C. A., Dorlhiac Llacer, P. E., Schwarer, A., . . . Rea, D. (2012). NILOTINIB INDUCES DEEPER MOLECULAR RESPONSES VS CONTINUED IMATINIB IN PATIENTS WITH PH plus CHRONIC MYELOID LEUKEMIA (CML) WITH DETECTABLE DISEASE AFTER=2 YEARS ON IMATINIB: ENESTCMR 12-MONTH RESULTS. In HAEMATOLOGICA Vol. 97 (pp. 239). FERRATA STORTI FOUNDATION. WoS1 |
| 2012 | Ossenkoppele, G., Le Coutre, P., Steegmann, J. L., Turkina, A., Lobo, C., Shibayama, H., . . . Saglio, G. (2012). RESULTS FROM THE ENESTND EXTENSION STUDY: EFFICACY AND SAFETY OF NILOTINIB 400 MG BID IN PATIENTS WITH PH plus CML-CP AFTER SUBOPTIMAL RESPONSE OR TREATMENT FAILURE TO IMATINIB OR NILOTINIB 300 MG BID. In HAEMATOLOGICA Vol. 97 (pp. 308). FERRATA STORTI FOUNDATION. |
| 2012 | Hochhaus, A., Guilhot, F., Al-Ali, K. H., Rosti, G., Nakaseko, C., De Souza, C. A., . . . Hughes, T. (2012). EARLY BCR-ABL TRANSCRIPT LEVELS PREDICT FUTURE MOLECULAR RESPONSE AND LONG-TERM OUTCOMES IN NEWLY-DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: ANALYSIS OF ENESTND 3-YEAR DATA. In HAEMATOLOGICA Vol. 97 (pp. 237-238). FERRATA STORTI FOUNDATION. WoS4 |
| 2012 | Gorospe, G., Kantarjian, H. H., Hochhaus, A., Larson, R., Saglio, G., & Hughes, T. (2012). EFFICACY AND SAFETY OF NILOTINIB IN OLDER (≥65 YEARS) PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): RESULTS FROM THE PHASE 3 ENESTND (EVALUATING NILOTINIB EFFICACY AND SAFETY IN CLINICAL TRIALS OF NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE CML PATIENTS) STUDY.. In ONCOLOGY NURSING FORUM Vol. 39 (pp. E191-E192). ONCOLOGY NURSING SOC. |
| 2012 | Peng, S., Hughes, T. C., Hartley, P. G., & Guo, Q. (2012). Capturing nanostructure evolution of polymerizable microemulsion by in situ synchrotron SAXS. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 243 (pp. 1 page). CA, San Diego: AMER CHEMICAL SOC. |
| 2012 | Ross, M., Branford, S., Seymour, J., Arthur, C., Schwarer, A., Dang, P., . . . Hughes, T. (2012). FREQUENT AND SUSTAINED DRUG-FREE REMISSION IN THE AUSTRALASIAN CML8 TRIAL OF IMATINIB WITHDRAWAL. In HAEMATOLOGICA Vol. 97 (pp. 74-75). FERRATA STORTI FOUNDATION. WoS2 |
| 2012 | Clark, R., Reiffers, J., Kim, D. W., Rosti, G., Kurokawa, M., Moiraghi, B., . . . Hochhaus, A. (2012). SUPERIOR EFFICACY OF NILOTINIB COMPARED WITH IMATINIB IN NEWLY DIAGNOSED PATIENTS WITH PH plus CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTND 3-YEAR FOLLOW-UP. In HAEMATOLOGICA Vol. 97 (pp. 237). FERRATA STORTI FOUNDATION. |
| 2012 | Kantarjian, H. M., Kim, D. -W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., . . . Cortes, J. E. (2012). Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial. In BLOOD Vol. 120 (pp. 3 pages). GA, Atlanta: AMER SOC HEMATOLOGY. |
| 2012 | Mauro, M. J., Cortes, J. E., Kim, D. -W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., . . . Kantarjian, H. M. (2012). Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL) Treated with Ponatinib in the PACE Trial. In BLOOD Vol. 120 (pp. 3 pages). Atlanta, GA: AMER SOC HEMATOLOGY. DOI WoS7 |
| 2012 | Cortes, J. E., Kim, D. -W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., . . . Kantarjian, H. M. (2012). A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial. In BLOOD Vol. 120 (pp. 3 pages). GA, Atlanta: AMER SOC HEMATOLOGY. DOI WoS23 |
| 2012 | Kantarjian, H. M., Kim, D. -W., Issaragrisil, S., Clark, R. E., Reiffers, J., Nicolini, F. E., . . . Larson, R. A. (2012). Enestnd 4-Year (y) Update: Continued Superiority of Nilotinib Vs Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph plus ) Chronic Myeloid Leukemia in Chronic Phase (CML-CP). In BLOOD Vol. 120 (pp. 3 pages). Atlanta, GA: AMER SOC HEMATOLOGY. DOI WoS15 |
| 2012 | Kantarjian, H., Flinn, I. W., Goldberg, S., Bunworasate, U., Zanichelli, M. A., Nakamae, H., . . . Larson, R. A. (2012). Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 3-year (yr) follow-up (f/u). In JOURNAL OF CLINICAL ONCOLOGY Vol. 30 (pp. 2 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. WoS2 |
| 2012 | Lipton, J. H., Hughes, T. P., Leber, B., De Souza, C., Dorlhiac-Llacer, P. E., Steegmann, J. L., . . . Spector, N. (2012). Switch to nilotinib versus continued imatinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with detectable BCR-ABL after 2 or more years on imatinib: ENESTcmr 12-month (mo) follow-up. In JOURNAL OF CLINICAL ONCOLOGY Vol. 30 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. WoS2 |
| 2012 | Kim, D. -W., Cortes, J. E., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., . . . Kantarjian, H. M. (2012). Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial. In BLOOD Vol. 120 (pp. 3 pages). Atlanta, GA: AMER SOC HEMATOLOGY. DOI WoS6 |
| 2012 | Hochhaus, A., Kim, D. -W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., . . . Cortes, J. E. (2012). Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph plus ) Leukemia: Results From the PACE Trial. In BLOOD Vol. 120 (pp. 3 pages). Atlanta, GA: AMER SOC HEMATOLOGY. DOI |
| 2012 | Morley, A., Bartley, P., Latham, S., Budgen, B., Ross, D., Hughes, E., . . . Hughes, T. (2012). DNA-qPCR vs RT-qPCR for Monitoring MRD in Chronic Myeloid Leukemia. In JOURNAL OF MOLECULAR DIAGNOSTICS Vol. 14 (pp. 662-663). Long Beach, CA: ELSEVIER SCIENCE INC. |
| 2011 | le Coutre, P. D., Giles, F. J., Pinilla-Ibarz, J., Larson, R. A., Gattermann, N., Ottmann, O. G., . . . Kantarjian, H. M. (2011). Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study. In BLOOD Vol. 118 (pp. 1610). San Diego, CA: AMER SOC HEMATOLOGY. WoS1 |
| 2011 | Nieborowska-Skorska, M., Kopinski, P., Ray, R., Hoser, G., Ngaba, D., Flis, S., . . . Skorski, T. (2011). Targeting Rac2-Mitochondrial Respiratory Chain Complex III Signaling to Prevent Genomic Instability in Leukemia Stem and Progenitor Cells. In BLOOD Vol. 118 (pp. 1176-1177). San Diego, CA: AMER SOC HEMATOLOGY. |
| 2011 | Pasquini, R., Cortes, J. E., Kantarjian, H. M., Joske, D., Meillon, L. A., Zernovak, O., . . . Kim, D. -W. (2011). Survey of the Frontline Treatment and Management of Chronic Myeloid Leukemia (CML) in a Real-Word Setting: The 3rd Annual Update of the Worldwide Observational Registry Collecting Longitudinal Data on Management of Chronic Myeloid Leukemia Patients (The WORLD CML Registry). In BLOOD Vol. 118 (pp. 738). San Diego, CA: AMER SOC HEMATOLOGY. |
| 2011 | Parker, W. T., Ho, M., Scott, H. S., Hughes, T. P., & Branford, S. (2011). Multiple Low Level Mutations Identifies Imatinib Resistant CML Patients At Risk of Poor Response to Second-Line Inhibitor Therapy, Irrespective of the Resistance Profile of the Mutations. In BLOOD Vol. 118 (pp. 54). San Diego, CA: AMER SOC HEMATOLOGY. WoS1 |
| 2011 | Watkins, D. B., Kok, C. H., Hughes, T. P., Slader, C., D'Andrea, R., & White, D. L. (2011). Differential Lineage Involvement Between Very Low and Higher OCT-1 Activity Chronic-Phase CML Patients. In BLOOD Vol. 118 (pp. 727). San Diego, CA: AMER SOC HEMATOLOGY. |
| 2011 | Hughes, T. P., Lipton, J. H., Leber, B., Spector, N., Cervantes, F., Pasquini, R., . . . Branford, S. (2011). Complete Molecular Response (CMR) Rate with Nilotinib in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) without CMR, After ≥ 2 Years on Imatinib: Preliminary Results From the Randomized ENESTcmr Trial of Nilotinib 400 Mg Twice Daily (BID) Vs Imatinib. In BLOOD Vol. 118 (pp. 278). San Diego, CA: AMER SOC HEMATOLOGY. WoS1 |
| 2011 | Yeung, D. T., Osborn, M., White, D. L., Branford, S., Kornhauser, M., Slader, C., . . . Hughes, T. P. (2011). Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial. In BLOOD Vol. 118 (pp. 208). San Diego, CA: AMER SOC HEMATOLOGY. WoS1 |
| 2011 | White, D. L., Saunders, V. A., Frede, A., GrootObbink, K., Slader, C., Yeung, D. T., . . . Hughes, T. P. (2011). The Strategy of Early Nilotinib Switch Based on Failure to Achieve Optimal Molecular Targets on Imatinib May Not Overcome the Negative Impact of a Low OCT-1 Activity in De-Novo CP-CML Patients. In BLOOD Vol. 118 (pp. 735). San Diego, CA: AMER SOC HEMATOLOGY. |
| 2011 | Nievergall, E., White, D. L., Ramshaw, H., Lopez, A. F., Hughes, T. P., & Hiwase, D. K. (2011). Antibody-Targeting of IL-3 Receptor-α Increases the Susceptibility of CD34<SUP>+</SUP> CML Progenitors to Dasatinib-Induced Cell Death. In BLOOD Vol. 118 (pp. 1599). San Diego, CA: AMER SOC HEMATOLOGY. DOI WoS1 |
| 2011 | Wang, J., Hughes, T. P., Kok, C. H., Saunders, V. A., Frede, A., GrootObbink, K., . . . White, D. L. (2011). Non-Steroidal Anti-Inflammatory Drugs and Imatinib; Drug Interactions That May Impact Efficacy. In BLOOD Vol. 118 (pp. 1493-1494). San Diego, CA: AMER SOC HEMATOLOGY. |
| 2011 | Branford, S., Yeung, D. T., Prime, J., Ross, D., & Hughes, T. P. (2011). Imatinib Dose Interruption in Responding CML Patients Is Associated with Characteristic BCR-ABL Kinetics, Which Could Help to Differentiate Non-Adherence From Drug Resistance. In BLOOD Vol. 118 (pp. 55). San Diego, CA: AMER SOC HEMATOLOGY. WoS1 |
| 2011 | White, D. L., Lu, L., Clackson, T. P., Saunders, V. A., & Hughes, T. P. (2011). ATP Dependent Efflux Transporters ABCB1 and ABCG2 Are Unlikely to Impact the Efficacy, or Mediate Resistance to the Tyrosine Kinase Inhibitor, Ponatinib. In BLOOD Vol. 118 (pp. 1180). San Diego, CA: AMER SOC HEMATOLOGY. WoS1 |
| 2011 | Alexander, W., & Shah, N. (2011). American Society of Hematology, 52nd Annual Meeting and Exposition: Dasatinib (Sprycel) versus imatinib (Gleevec) in newly diagnosed chronic-phase chronic myeloid leukemia: The DASISION trial, 18-month follow-up. In P and T Vol. 36 (pp. 100). Scopus3 |
| 2011 | Tuch, B. E., Hughes, T. C., & Evans, M. D. M. (2011). Encapsulated pancreatic progenitors derived from human embryonic stem cells as a therapy for insulin-dependent diabetes. In Diabetes Metabolism Research and Reviews Vol. 27 (pp. 928-932). Incheon, SOUTH KOREA: WILEY. DOI Scopus33 WoS32 Europe PMC26 |
| 2011 | Gorospe, G., Kantarjian, H., Hochhaus, A., Larson, R., Saglio, G., & Hughes, T. (2011). DURABLE RESPONSES WITH NILOTINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): 18-MONTH RESULTS FROM THE ENESTND STUDY. In ONCOLOGY NURSING FORUM Vol. 38 (pp. E137). ONCOLOGY NURSING SOC. |
| 2011 | Garcia, R., Larson, R., Kantarjian, H., Hughes, T., & Gorospe, G. (2011). SUMMARY OF CARDIAC EFFECTS OF NILOTINIB AND IMATINIB IN PATIENTS ENROLLED IN ENESTND (EVALUATING NILOTINIB EFFICACY AND SAFETY IN CLINICAL TRIALS OF NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE CML PATIENTS) TRIAL: IMPLICATIONS FOR ONCOLOGY NURSES. In ONCOLOGY NURSING FORUM Vol. 38 (pp. E146-E147). ONCOLOGY NURSING SOC. |
| 2010 | Klumpen, H., Eechoute, K., Hertzberg, M. S., Schwarer, A. A., Goldstein, D., Hughes, T. P., . . . Gurney, H. (2010). Pharmacogenetic factors predicting the need for a higher dose of imatinib. In JOURNAL OF CLINICAL ONCOLOGY Vol. 28 (pp. 1 page). AMER SOC CLINICAL ONCOLOGY. DOI |
| 2010 | Hughes, T. P. (2010). EVOLUTION OF CML TREATMENT: WORKING TOWARDS CURE. In EXPERIMENTAL HEMATOLOGY Vol. 38 (pp. S103). Melbourne, AUSTRALIA: ELSEVIER SCIENCE INC. |
| 2010 | Hochhaus, A., Lobo, C., Pasquini, R., Clark, R., Kim, D. W., Issaragrisil, S., . . . Hughes, T. (2010). CONTINUED SUPERIORITY OF NILOTINIB VS IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTND BEYOND 1 YEAR. In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 95 (pp. 459). FERRATA STORTI FOUNDATION. WoS3 |
| 2010 | le Coutre, P., Hino, M., Nobile, F., Hochhaus, A., Hughes, T., Kantarjian, H., . . . Clark, R. (2010). RESULTS FROM ENESTND: POPULATION PHARMACOKINETIC (PK) AND EXPOSURE-RESPONSE ANALYSIS OF NILOTINIB IN PATIENTS WITH NEWLY DIAGNOSED PH<SUP>+</SUP> CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP). In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 95 (pp. 59-60). Barcelona, SPAIN: FERRATA STORTI FOUNDATION. WoS1 |
| 2010 | Hiwase, D. K., Eadie, L., Saunders, V., Hughes, T., & White, D. L. (2010). Proton Pump Inhibitors Augment Nilotinib and Dasatinib Mediated Bcr-Abl Kinase Inhibition. In Blood Vol. 116 (pp. 3991). American Society of Hematology. DOI |
| 2010 | White, E., Matejtschuk, P., Rigsby, P., Gabert, J., Wang, Y., Branford, S., . . . Cross, N. (2010). ESTABLISHMENT OF THE 1ST WORLD HEALTH ORGANIZATION INTERNATIONAL GENETIC REFERENCE PANEL FOR QUANTITATION OF BCR-ABL MRNA. In HAEMATOLOGICA Vol. 95 (pp. 84-85). Barcelona, SPAIN: FERRATA STORTI FOUNDATION. |
| 2010 | White, D. L., Saunders, V., Frede, A., GrootObbink, K., Slader, C., Yeung, D. T., . . . Hughes, T. (2010). Early Switching From Imatinib to Nilotinib In CML Patients Failing to Achieve Early Molecular Targets May Not Be An Effective Approach In Patients with Very Low OCT-1 Activity: A TIDEL II Sub-Study. In BLOOD Vol. 116 (pp. 160-161). Orlando, FL: AMER SOC HEMATOLOGY. |
| 2010 | Yeung, D. T., Osborn, M., White, D. L., Branford, S., Haswell, L., Slader, C., . . . Hughes, T. (2010). Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II Trial. In BLOOD Vol. 116 (pp. 96). Orlando, FL: AMER SOC HEMATOLOGY. DOI WoS10 |
| 2010 | White, D. L., Saunders, V., Andrew, M., Rofe, A., Slader, C., Yeung, D. T., . . . Hughes, T. (2010). Imatinib PK: Observations From the TIDEL II Study.. In BLOOD Vol. 116 (pp. 943). Orlando, FL: AMER SOC HEMATOLOGY. |
| 2010 | Parker, W., Ho, M., Lawrence, R., Irwin, D., Scott, H., Hughes, T., & Branford, S. (2010). Detection of low level nilotinib or dasatinib resistant BCR-ABL mutations by mass spectrometry in CML patients who fail Imatinib is highly predivtive of their subsequent clonal expansion when treated with the drug for which their mutation confers resistance. In Proceedings of 2010 american society of hematology meeting Vol. 116 (pp. 0 pages). Florida, USA: AMER SOC HEMATOLOGY. |
| 2010 | Prime, H., Romeo, G., Phillis, S., Field, C., Jamison, B., Prime, J., . . . Branford, S. (2010). Contrasting response of patients with chronic myeloid leukaemia (CML) and the highly imatinib resistant L248V mutation that may be related to an increased propensity of some patients to form an associated deletion mutant with increased imatinib sensitivity. In Proceedings of Haematology association of australasia annual meeting (pp. 0 pages). Auckland, New Zealand. |
| 2010 | Branford, S., Goh, H., Izzo, B., Beppu, L., Ortmann, C., Duniec, K., . . . Hughes, T. (2010). A Review of Mutation Analysis In the TOPS Trial of Standard Dose Versus High Dose IM In CML Suggests That Refinements to the ELN Recommendations for Mutation Screening May Be Appropriate. In Proceedings of 52nd American Society of Hematology Meeting (ASH), as published in Blood Vol. 116 (pp. 389-390). Washington, DC: American Society of Hematology. WoS1 |
| 2010 | Fletcher, L., Prime, J., Phillis, S., Jamison, B., Field, C., Prime, H., . . . Branford, S. (2010). Limiting the variability within a BCR-ABL quantitative PCR (RQ-PCR) assay is essential for optimal concordance of results between laboratories generating BCR-ABL values on an international reporting scale. In Proceedings of Haematology association of australasia annual meeting (pp. 0 pages). New Zealand. |
| 2010 | Morley, A., Bartley, P., Ross, D., Latham, S., Budgen, B., Branford, S., & Hughes, T. (2010). Towards DNA-based monitoring of therapy in chronic myeloid leukemia. In Proceedings of 2010 American society of hematology meeting Vol. 116 (pp. 0 pages). Orlando, FL: AMER SOC HEMATOLOGY. |
| 2010 | Kim, D., Kim, D., Kim, S., Goh, H., Pane, F., Hughes, T., . . . Hochhaus, A. (2010). Mutation analysis of BCR-ABL tyrosine kinase domain in new chronic phase-chronic myeloid leukemia patients with suboptimal response or treatment failure from imatinib treatment. In Proceedings of 2010 American society of hematology meeting Vol. 116 (pp. 0 pages). Orlando, FL: AMER SOC HEMATOLOGY. |
| 2010 | Yeung, D., Osborn, M., White, D., Branford, S., Haswell, L., Slader, C., . . . Hughes, T. (2010). Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: interim results from the TIDELL-II trial. In Proceedings of 2010 American Society of Hematology conference (pp. 1-2). Florida. |
| 2010 | Saglio, G., Larson, R. A., Hughes, T. P., Issaragrisil, S., Turkina, A. G., Marin, D., . . . Hochhaus, A. (2010). Efficacy and Safety of Nilotinib In Chronic Phase (CP) Chrome Myeloid Leukemia (CML) Patients (Pts) with Type 2 Diabetes In the ENESTnd Trial. In BLOOD Vol. 116 (pp. 1405-1406). Orlando, FL: AMER SOC HEMATOLOGY. WoS4 |
| 2010 | Pasquini, R., Cortes, J., Kantarjian, H. M., Joske, D., Meillon, L. A., Mongay, L., . . . Kim, D. -W. (2010). A Worldwide Observational Registry Collecting Longitudinal Data on Management of Chronic Myeloid Leukemia Patients (The WORLD CML Registry)-2nd Annual Interim Analysis.. In BLOOD Vol. 116 (pp. 945). Orlando, FL: AMER SOC HEMATOLOGY. WoS3 |
| 2010 | Hughes, T. P., Hochhaus, A., Saglio, G., Kim, D. -W., Jootar, S., le Coutre, P. D., . . . Kantarjian, H. M. (2010). ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP). In BLOOD Vol. 116 (pp. 94-95). Orlando, FL: AMER SOC HEMATOLOGY. WoS16 |
| 2010 | Hochhaus, A., Saglio, G., Larson, R. A., Kim, D. -W., Flinn, I. W., Goh, Y. -T., . . . Hughes, T. P. (2010). Nilotinib Lowers the Incidence of BCR-ABL Mutations and Improves the Molecular Response Kinetics Compared with Imatinib in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia (CML). In BLOOD Vol. 116 (pp. 1406-1407). Orlando, FL: AMER SOC HEMATOLOGY. WoS1 |
| 2010 | Soverini, S., Angelini, S., Turrini, E., Burnett, M., Ravegnini, G., Thornquist, M., . . . Martinelli, G. (2010). Specific Drug Transporter Genotypes Are Significantly Associated with Increased Rates of Major and Complete Molecular Responses In Newly Diagnosed Chronic Myeloid Leukemia Patients Treated with Imatinib - A TOPS Correlative Substudy. In BLOOD Vol. 116 (pp. 293-294). Orlando, FL: AMER SOC HEMATOLOGY. |
| 2010 | Larson, R. A., Hochhaus, A., Saglio, G., Rosti, G., Lopez, J. L., Stenke, L., . . . Kantarjian, H. M. (2010). Cardiac Safety Profile of Imatinib and Nilotinib In Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Results From ENESTnd.. In BLOOD Vol. 116 (pp. 944-945). Orlando, FL: AMER SOC HEMATOLOGY. WoS1 |
| 2010 | Stein, A., Shou, Y., Bottino, D., Chia, Y., Woodman, R., Martinelli, G., . . . Radich, J. (2010). RAPID INITIAL DECLINE IN BCR-ABL LEVELS IS ASSOCIATED WITH SUPERIOR RESPONSES IN IMATINIB-RESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA PATIENTS IN CHRONIC PHASE (CML-CP) TREATED WITH NILOTINIB. In HAEMATOLOGICA Vol. 95 (pp. 56). Barcelona, SPAIN: FERRATA STORTI FOUNDATION. |
| 2010 | Morley, A., Bartley, P., Ross, D., Latham, S., Budgen, B., Hughes, E., . . . Hughes, T. (2010). Monitoring of CML by DNA qPCR. In JOURNAL OF MOLECULAR DIAGNOSTICS Vol. 12 (pp. 868). San Jose, CA: AMER SOC INVESTIGATIVE PATHOLOGY, INC. |
| 2010 | Martinelli, G., Hochhaus, A., Radich, J., Soverini, S., Branford, S., Erben, P., . . . Kim, D. (2010). DETECTION OF NEW MUTATIONS IN NILOTINIB-TREATED PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE. In HAEMATOLOGICA Vol. 95 (pp. 62). Barcelona, SPAIN: FERRATA STORTI FOUNDATION. |
| 2010 | Saglio, S., Hughes, T., Kim, D., Hanfstein, B., Gottardi, E., Branford, S., . . . Martinelli, G. (2010). RESPONSE TO NILOTINIB IN PATIENTS WITH IMATINIB-RESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WITH DIFFERENT BCR-ABL TRANSCRIPT TYPES. In HAEMATOLOGICA Vol. 95 (pp. 342-343). FERRATA STORTI FOUNDATION. |
| 2010 | Hughes, T., Kim, D., Martinelli, G., Branford, S., Mueller, M., Beppu, L., . . . Hochhaus, A. (2010). EARLY MOLECULAR RESPONSE TO NILOTINIB IN PATIENTS WHO FAILED IMATINIB IS ASSOCIATED WITH A HIGHER PROBABILITY OF CYTOGENETIC RESPONSE IN CHRONIC MYELOID LEUKEMIA (CML). In HAEMATOLOGICA Vol. 95 (pp. 54). Barcelona, SPAIN: FERRATA STORTI FOUNDATION. WoS1 |
| 2010 | Kim, D., Kim, S., Goh, H., Pane, F., Hughes, T., Radich, J., . . . Kim, D. (2010). BCR-ABL MUTATION ANALYSIS USING BOTH ASO-PCR AND DIRECT SEQUENCING IN NEW CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS WITH SUBOPTIMAL RESPONSE OR TREATMENT FAILURE FROM IMATINIB TREATMENT. In HAEMATOLOGICA Vol. 95 (pp. 344-345). FERRATA STORTI FOUNDATION. |
| 2010 | Hiwase, D. K., Engler, J., Saunders, V., White, D. L., & Hughes, T. (2010). In Contrast to Imatinib, Dasatinib Intracellular Concentration In CML-CD34<SUP>+</SUP> Progenitors Is Not Significantly Different Than That Observed In CD34<SUP>-</SUP> Mature Cells.. In BLOOD Vol. 116 (pp. 517). Orlando, FL: AMER SOC HEMATOLOGY. |
| 2010 | Hiwase, D. K., Eadie, L., Saunders, V., Hughes, T., & White, D. L. (2010). Proton Pump Inhibitors Augment Nilotinib and Dasatinib Mediated Bcr-Abl Kinase Inhibition.. In BLOOD Vol. 116 (pp. 1626-1627). Orlando, FL: AMER SOC HEMATOLOGY. WoS1 |
| 2010 | Tang, C., Schafranek, L., Watkins, D., Parker, W. T., Prime, J., White, D. L., & Hughes, T. (2010). Modelling of TKI Resistance In CML Cell Lines: Kinase Domain Mutations Usually Arise In the Setting of BCR-ABL Overexpression. In BLOOD Vol. 116 (pp. 1385). Orlando, FL: AMER SOC HEMATOLOGY. WoS1 |
| 2009 | White, D. L., Saunders, V. A., Frede, A., Dang, P., Zrim, S., Osborn, M. P., . . . Hughes, T. (2009). The Functional Activity of the OCT-1 Protein Is Predictive of Molecular Response and Survival in CP-CML Patients Treated with Imatinib: A 5 Year Update of the TIDEL Trial. In BLOOD Vol. 114 (pp. 209-210). New Orleans, LA: AMER SOC HEMATOLOGY. |
| 2009 | Osborn, M. P., White, D. L., Saunders, V. A., Cambareri, B., Branford, S., Menelaou, A., . . . Hughes, T. P. (2009). Early Dose-Escalation in Chronic Myeloid Leukaemia Patients with Low Plasma Imatinib Levels Leads to Equivalent BCR-ABL Values and Drug Levels at 6 Months to Those with Optimal Drug Levels: First Analysis From the TIDEL II Trial of De-Novo Patients Treated with 600mg Imatinib.. In BLOOD Vol. 114 (pp. 465). New Orleans, LA: AMER SOC HEMATOLOGY. |
| 2009 | Martinelli, G., Kim, D. W., Saglio, G., Branford, S., Erben, P., Gottardi, E., . . . Radich, J. (2009). RESPONSE TO NILOTINIB IS SIMILAR IN IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA PATIENTS IN ACCELERATED PHASE (CML-AP) WITH AND WITHOUT BCR-ABL MUTATIONS EXCEPT E25SK/V, Y253H, AND F359C/V. In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 94 (pp. 258-259). Berlin, GERMANY: FERRATA STORTI FOUNDATION. WoS1 |
| 2009 | Saglio, G., Hochhaus, A., Martinelli, G., Gottardi, E., Soverini, S., Branford, S., . . . Kim, D. (2009). DYNAMICS OF CYTOGENETIC AND MOLECULAR RESPONSE TO NILOTINIB IS SIMILAR IN IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA PATIENTS IN CHRONIC PHASE (CML-CP) WITH AND WITHOUT BCR-ABL MUTATIONS EXCEPT E255K/V, Y253H, AND F359C/V. In HAEMATOLOGICA Vol. 94 (pp. 261). Berlin, GERMANY: FERRATA STORTI FOUNDATION. |
| 2009 | Kantarjian, H. M., Giles, F. J., Bhalla, K. N., Pinilla-Ibarz, J., Larson, R. A., Gattermann, N., . . . le Coutre, P. D. (2009). Update On Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) On Nilotinib Therapy at 24 Months: Clinical Response, Safety, and Long-Term Outcomes.. In BLOOD Vol. 114 (pp. 464). New Orleans, LA: AMER SOC HEMATOLOGY. WoS14 |
| 2009 | Larson, R. A., Chia, Y. L., Granvil, C., Guilhot, F., Druker, B. J., O'Brien, S. G., . . . Wang, Y. (2009). Steady-State Imatinib Trough Levels as Well as Dose Interruptions Are Associated with Clinical Response (CCyR and MMR) and Adverse Events (AEs) in Patients with Chronic Myeloid Leukemia (CML) Receiving IM as Frontline Therapy. In BLOOD Vol. 114 (pp. 872). New Orleans, LA: AMER SOC HEMATOLOGY. WoS2 |
| 2009 | Soverini, S., Angelini, S., Turrini, E., Pane, F., Quarantelli, F., Hughes, T. P., . . . Martinelli, G. (2009). Association Between Imatinib (IM) Transporters and Metabolizing Enzymes Genotype and Response in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients (Pts) Is Influenced by Ethnicity. In BLOOD Vol. 114 (pp. 1271). New Orleans, LA: AMER SOC HEMATOLOGY. |
| 2009 | Deininger, M., O'Brien, S. G., Guilhot, F., Goldman, J. M., Hochhaus, A., Hughes, T. P., . . . Druker, B. J. (2009). International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.. In BLOOD Vol. 114 (pp. 462). New Orleans, LA: AMER SOC HEMATOLOGY. WoS69 |
| 2009 | Branford, S., Kim, D. -W., Soverini, S., Gottardi, E., Beppu, L., Mueller, M. C., . . . Hochhaus, A. (2009). Molecular Response at 3 Months On Nilotinib Therapy Predicts Response and Long-Term Outcomes in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP). In BLOOD Vol. 114 (pp. 1275-1276). New Orleans, LA: AMER SOC HEMATOLOGY. WoS1 |
| 2009 | Radich, J. P., Martinelli, G., Hochhaus, A., Gottardi, E., Soverini, S., Branford, S., . . . Saglio, G. (2009). Response and Outcomes to Nilotinib at 24 Months in Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) and Accelerated Phase (CML-AP) with and without BCR-ABL Mutations.. In BLOOD Vol. 114 (pp. 464-465). New Orleans, LA: AMER SOC HEMATOLOGY. WoS1 |
| 2009 | Branford, S., Hochhaus, A., Mueller, M., Bahceci, E., Ploughman, L., Mukhopadhyay, J., & Hughes, T. (2009). Analysis of Molecular Data and the Emergence of Mutations for Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) Patients Treated with Dasatinib After Imatinib Failure.. In BLOOD Vol. 114 (pp. 1270-1271). New Orleans, LA: AMER SOC HEMATOLOGY. |
| 2009 | Hughes, T. (2009). Reduction of bcr-abl transcript levels with imatinib (Gleevec) in chronic myeloid leukemia (Chronic Phase). In P and T Vol. 34 (pp. 96-97). |
| 2009 | Kim, D. -W., Granvil, C., Demirhan, E., Reynolds, J., Jin, Y., Wang, Y., . . . Guilhot, F. (2009). Comparison of Steady-State Imatinib (IM) Trough Levels, Clinical Response, and Safety Between Caucasian and Asian Patients with Chronic Lyeloid Leukemia in Chronic Phase (CML-CP) Treated with 400mg and 800mg Daily Doses of IM in the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) Study.. In BLOOD Vol. 114 (pp. 462-463). New Orleans, LA: AMER SOC HEMATOLOGY. WoS1 |
| 2009 | Baccarani, M., Druker, B. J., Cortes-Franco, J., Hughes, T. P., Kim, D. -W., Pane, F., . . . Guilhot, F. (2009). 24 Months Update of the TOPS Study: a Phase III, Randomized, Open-Label Study of 400mg/d (SD-IM) Versus 800mg/d (HD-IM) of Imatinib Mesylate (IM) in Patients (Pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP). In BLOOD Vol. 114 (pp. 142-143). New Orleans, LA: AMER SOC HEMATOLOGY. WoS12 |
| 2009 | Hiwase, D. K., White, D. L., Powell, J. A., Saunders, V. A., Zrim, S., Frede, A., . . . Hughes, T. (2009). Blocking of Cytokine Survival Signals along with Intense Bcr-Abl Kinase Inhibition May Eradicate CML Progenitor Cells. In BLOOD Vol. 114 (pp. 1258-1259). New Orleans, LA: AMER SOC HEMATOLOGY. |
| 2009 | Osborn, M. P., Branford, S., White, D. L., Seymour, J. F., Columbus, R., Taylor, K., . . . Hughes, T. P. (2009). Maintaining Imatinib ≥600 Mg Daily in the First 12 Months of Chronic Phase CML Treatment Is Associated with Superior Event-Free Survival at 5 Years.. In BLOOD Vol. 114 (pp. 461-462). New Orleans, LA: AMER SOC HEMATOLOGY. |
| 2009 | Esposito, N., Quintarelli, C., Colavita, I., Izzo, B., Peluso, A. L., Ruoppolo, M., . . . Pane, F. (2009). Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph plus Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pretreatment Predictor of Major Molecular Response Achievement in CML Patients. In BLOOD Vol. 114 (pp. 871-872). New Orleans, LA: AMER SOC HEMATOLOGY. |
| 2009 | Engler, J. R., Frede, A., Saunders, V. A., Zannettino, A. C. W., White, D. L., & Hughes, T. P. (2009). OCT-1 Activity in CML CD34+Cells Is Not Predictive of Molecular Response to Imatinib Treatment in CP-CML Patients, Despite the Strong Predictive Value of MNC OCT-1 Activity. In BLOOD Vol. 114 (pp. 861). New Orleans, LA: AMER SOC HEMATOLOGY. |
| 2009 | Angelini, S., Soverini, S., Turrini, E., Perini, G., Pane, F., Hughes, T., . . . Baccarani, M. (2009). ASSOCIATION BETWEEN GENOTYPES AND RESPONSE TO THE TREATMENT IN A SUBSET OF PREVIOUSLY UNTREATED CHRONIC MYELOID LEUKEMIA PATIENTS ENROLLED INTO THE TOPS TRIAL. In BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY Vol. 105 (pp. 78). WILEY-BLACKWELL PUBLISHING, INC. |
| 2008 | Modur, V., Bottino, D. C., Branford, S., Krahnke, T., Pane, F., Rudoltz, M., . . . Barrett, J. C. (2008). Mathematical Simulation of BCR-ABL Real Time Quantitative Polymerase Chain Reaction (RQ-PCR) for Chronic Myeloid Leukemia (CML) Response Monitoring Provides Insight on the Basis of International Standardization. In BLOOD Vol. 112 (pp. 740). San Francisco, CA: AMER SOC HEMATOLOGY. |
| 2008 | Hochhaus, A., Mueller, M. C., Cortes, J., Kim, D. W., Matloub, Y., Ploughman, L., & Hughes, T. (2008). DASATINIB EFFICACY AFTER IMATINIB FAILURE BY DOSING SCHEDULE AND BASELINE BCR-ABL MUTATION STATUS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP). In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 93 (pp. 371-372). Copenhagen, DENMARK: FERRATA STORTI FOUNDATION. WoS6 |
| 2008 | Hughes, T. (2008). Molecular diagnosis and monitoring of CML: a paradigm for haematological malignancy. In INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY Vol. 30 (pp. 3-4). WILEY-BLACKWELL. |
| 2008 | Heaney, N. B., Drummond, M., Kaeda, J., Nicolini, F., Clark, R., Wilson, G., . . . Holyoake, T. (2008). A pilot study of continuous imatinib versus pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 141 (pp. 50-51). Glasgow, SCOTLAND: BLACKWELL PUBLISHING. |
| 2008 | Hughes, T., Bates, J., Beattie, D., Hao, X., Jarrett, R., Jeffery, J., . . . Rajapaksha, J. (2008). Property optimisation of a fluoropolymer corneal inlay by factorial design. In 8th World Biomaterials Congress 2008 Vol. 3 (pp. 1282). |
| 2008 | Hao, X., Donovan, L., Ho, A., Hughes, T. C., Jeffery, J. L., Le, T., . . . Fernandez, V. (2008). Polysiloxane soft gels as in-situ curable accommodating implant. In 8th World Biomaterials Congress 2008 Vol. 3 (pp. 1288). |
| 2008 | Hughes, T., Bates, J., Beattie, D., Hao, X., Johnson, G., Le, T., . . . Wilkie, J. (2008). Control of topography of porous perfluoropolyethers using radical concentration during polymerisation. In 8th World Biomaterials Congress 2008 Vol. 3 (pp. 1281). |
| 2008 | Hao, X., Aly, M., Ho, A., Hughes, T. C., Jeffery, J. L., Le, T., . . . Ziebarth, N. (2008). High refractive index polysiloxanes as in-situ curable accommodating implant. In 8th World Biomaterials Congress 2008 Vol. 3 (pp. 1287). |
| 2008 | White, D. L., Saunders, V. A., Dang, P., Frede, A., Eadie, L., Soverini, S., . . . Hughes, T. (2008). CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study. In Blood Vol. 112 (pp. 3187). American Society of Hematology. DOI |
| 2008 | Engler, J. R., Frede, A., Zannettino, A. C. W., White, D. L., & Hughes, T. P. (2008). Reduced Activity of the OCT-1 Protein in Primitive CML Cells: A Likely Determinant of Stem Cell Resistance in Imatinib Treated CML Patients. In BLOOD Vol. 112 (pp. 80). San Francisco, CA: AMER SOC HEMATOLOGY. WoS2 |
| 2008 | Hiwase, D. K., White, D. L., Saunders, V. A., Melo, J. V., Kumar, S., & Hughes, T. P. (2008). Short-Term Intense Bcr-Abl Kinase Inhibition Is Adequate to Trigger Cell Death in CML Cell Lines but Not in CML-CD34+Cells Unless They Are Growth Factor Deprived. In BLOOD Vol. 112 (pp. 397). San Francisco, CA: AMER SOC HEMATOLOGY. |
| 2008 | Esposito, N., Colavita, I., Quarantelli, F., Izzo, B., Luciano, L., Del Vecchio, L., . . . Pane, F. (2008). A decreased Level of Shp1 provides an additive survival advantage to the Ph plus Cells of CML Patients and may account for Resistance to Imatinib Treatment. In BLOOD Vol. 112 (pp. 1093). San Francisco, CA: AMER SOC HEMATOLOGY. |
| 2008 | White, D., Dang, P., Obbink, K. G., Frede, A., Kok, C., Hughes, T. P., & D'Andrea, R. (2008). Enhancing the Functional Activity of the OCT-1 Influx Pump May Overcome the Negative Impact of Low OCT-1 Activity in Imatinib Treated CML Patients. In BLOOD Vol. 112 (pp. 268-269). San Francisco, CA: AMER SOC HEMATOLOGY. WoS1 |
| 2008 | Cross, C., Hochhaus, A., Mueller, M., Saglio, G., Branford, S., Hughes, T., . . . White, H. (2008). DEVELOPMENT OF PROTOTYPE REFERENCE MATERIALS FOR BCR-ABL QUANTITATIVE RT-PCR. In HAEMATOLOGICA Vol. 93 (pp. 54). Copenhagen, DENMARK: FERRATA STORTI FOUNDATION. |
| 2008 | Cortes, J., Baccarani, M., Guilhot, F., Druker, B. J., Branford, S., Kim, D. -W., . . . Hughes, T. P. (2008). A Phase III, Randomized. Open-Label Study of 400 Mg Versus 800 Mg of Imatinib Mesylate (1M) in Patients (pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Using Molecular Endpoints: 1-Year Results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) Study. In BLOOD Vol. 112 (pp. 130-131). San Francisco, CA: AMER SOC HEMATOLOGY. WoS14 |
| 2008 | White, D., Saunders, V., Quinn, S., & Hughes, T. (2008). PATIENT-SPECIFIC IC50 ASSAYS IN IMATINIB-RESISTANT CIVIL PATIENTS ARE HIGHLY VARIABLE AND MAY BE CLINICALLY RELEVANT. In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 93 (pp. 41). Copenhagen, DENMARK: FERRATA STORTI FOUNDATION. |
| 2008 | Cortes, J. G., Baccarani, M., Guilhot, F., Druker, B. J., Yu, R., Rudoltz, M., . . . Hughes, T. (2008). FIRST REPORT OF THE TOPS STUDY: A RANDOMIZED PHASE III TRIAL OF 400MG VS 800MG IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED, PREVIOUSLY UNTREATED CML IN CHRONIC PHASE USING MOLECULAR ENDPOINTS. In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 93 (pp. 160). Copenhagen, DENMARK: FERRATA STORTI FOUNDATION. WoS6 |
| 2008 | Mullighan, C. G., Radtke, I., Zhang, J., Phillips, L. A., Su, X., Ma, J., . . . Downing, J. R. (2008). Genome-Wide Analysis of Genetic Alterations in Chronic Myelogenous Leukemia. In BLOOD Vol. 112 (pp. 397-398). San Francisco, CA: AMER SOC HEMATOLOGY. WoS9 |
| 2008 | Vandyke, K., Dewar, A., Diamond, P., Fitter, S., Farrugia, A. N., To, L. B., . . . Zannettino, A. C. W. (2008). Dasatinib (Sprycel™) Inhibits Oteoclast Activity <i>in Vitro</i> and <i>in Vivo</i> Via a C-Fms-Dependent and C-Src-Independent Mechanism. In BLOOD Vol. 112 (pp. 1102-1103). San Francisco, CA: AMER SOC HEMATOLOGY. |
| 2008 | Morley, A. A., Bartley, P., Ross, D. M., Latham, S., Martin-Harris, H., Budgen, B., . . . Hughes, T. (2008). DNA-Based Monitoring of Minimal Residual Disease(MRD) in Chronic Myeloid Leukemia(CML). In BLOOD Vol. 112 (pp. 406). San Francisco, CA: AMER SOC HEMATOLOGY. |
| 2008 | Shah, N. P., Kantarjian, H. M., Kim, D. W., Réa, D., Dorlhiac-Llacer, P. E., Milone, J. H., . . . Hochhaus, A. (2008). Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. In Journal of Clinical Oncology Vol. 26 (pp. 3204-3212). Vienna, AUSTRIA: AMER SOC CLINICAL ONCOLOGY. DOI Scopus455 WoS407 Europe PMC365 |
| 2008 | Esposito, N., Quarantelli, F., Luciano, L., Izzo, B., Peluso, A. L., Picardi, M., . . . Pane, F. (2008). The Expression of shp-1 and SHP-2: A Novel Powerful Predictor of Major Molecular Response (MMR) Achievement in Chronic Myeloid Leukemia Gleevec-Treated Patients Enrolled into the TOPS Clinical Trial. In BLOOD Vol. 112 (pp. 404). San Francisco, CA: AMER SOC HEMATOLOGY. |
| 2008 | O'Brien, S. G., Guilhot, F., Goldman, J. M., Hochhaus, A., Hughes, T. P., Radich, J. P., . . . Larson, R. A. (2008). International Randomized Study of Interferon Versus ST1571 (IRIS) 7-year Follow-up: Sustained Survival, Low Rate of Transformation and Increased Rate of Major Molecular Response (MMR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib (IM). In BLOOD Vol. 112 (pp. 76). San Francisco, CA: AMER SOC HEMATOLOGY. WoS130 |
| 2008 | Guilhot, F., Hughes, T. P., Cortes, J., Wang, Y., Hayes, M., Gichangi, A., . . . Baccarani, M. (2008). Imatinib (IM) Pharmacokinetic (PK) Exposure and Its Correlation with Clinical Outcome in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) for 400 Mg and 800 Mg Daily Doses (Tyrosine Kinase Dose Optimization Study [TOPS]). In BLOOD Vol. 112 (pp. 170-171). San Francisco, CA: AMER SOC HEMATOLOGY. WoS4 |
| 2008 | Hochhaus, A., Mueller, M. C., Radich, J., Branford, S., Hanfstein, B., Rousselot, P., . . . Hughes, T. P. (2008). Dasatinib-Associated Major Molecular Responses Are Rapidly Achieved in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Following Resistance, Suboptimal Response, or Intolerance on Imatinib. In BLOOD Vol. 112 (pp. 400). San Francisco, CA: AMER SOC HEMATOLOGY. WoS4 |
| 2008 | Hochhaus, A., Kim, D. -W., Martinelli, G., Hughes, T. P., Soverini, S., Branford, S., . . . Radich, J. P. (2008). Nilotinib Efficacy According to Baseline BCR-ABL Mutations in Patients with Imatinib-Resistant Chronic Myeloid Leukemia in Chronic Phase (CML-CP). In BLOOD Vol. 112 (pp. 1103-1104). San Francisco, CA: AMER SOC HEMATOLOGY. WoS2 |
| 2008 | Hughes, T. P., Hochhaus, A., Branford, S., Mueller, M. C., Foroni, L., Druker, B. J., . . . Goldman, J. M. (2008). Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP). In BLOOD Vol. 112 (pp. 129-130). San Francisco, CA: AMER SOC HEMATOLOGY. WoS11 |
| 2008 | Mueller, M. C., Cortes, J., Kim, D. -W., Druker, B. J., Erben, P., Pasquini, R., . . . Hochhaus, A. (2008). Dasatinib Efficacy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Pre-Existing BCR-ABL Mutations. In BLOOD Vol. 112 (pp. 171-172). San Francisco, CA: AMER SOC HEMATOLOGY. WoS5 |
| 2008 | Radich, J., Kim, D. -W., Martinelli, G., Soverini, S., Branford, S., Mueller, M., . . . Saglio, G. (2008). RESPONSE TO NILOTINIB IN CHRONIC MYELOGENOUS LEUKEMIA PATIENTS IN CHRONIC PHASE (CML-CP) ACCORDING TO BCR-ABL MUTATIONS AT BASELINE. In HAEMATOLOGICA Vol. 93 (pp. 55). Copenhagen, DENMARK: FERRATA STORTI FOUNDATION. WoS3 |
| 2008 | Branford, S., Lawrence, R., Fletcher, L., Field, C., Rudzki, Z., & Hughes, T. (2008). The Initial Molecular Response of Chronic Phase CML Patients Treated with Second Generation ABL Inhibitor Therapy after Imatinib Failure Can Predict Inadequate Response and Provide Indications for Rational Mutation Screening. In BLOOD Vol. 112 (pp. 128). San Francisco, CA: AMER SOC HEMATOLOGY. WoS2 |
| 2008 | White, D. L., Saunders, V. A., Kalebic, T., & Hughes, T. P. (2008). The IC50 Assay Is Predictive of Molecular Response, and Indicative of Optimal Dose in De-Novo CML Patients. In BLOOD Vol. 112 (pp. 405). San Francisco, CA: AMER SOC HEMATOLOGY. WoS1 |
| 2008 | White, D. L., Saunders, V. A., Dang, P., Frede, A., Eadie, L., Soverini, S., . . . Hughes, T. (2008). CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study. In BLOOD Vol. 112 (pp. 1093-1094). San Francisco, CA: AMER SOC HEMATOLOGY. WoS3 |
| 2008 | Branford, S., Lawrence, R., Grigg, A., Seymour, J. F., Schwarerl, A., Arthur, C., . . . Hughes, T. (2008). Long Term Follow up of Patients with CML in Chronic Phase Treated with First-Line Imatinib Suggests That Earlier Achievement of a Major Molecular Response Leads to Greater Stability of Response. In BLOOD Vol. 112 (pp. 735-736). San Francisco, CA: AMER SOC HEMATOLOGY. WoS3 |
| 2007 | Ross, D., Bartley, P. A., Morley, A. A., Seymour, J. F., Branford, S., & Hughes, T. P. (2007). Detection of patient-specific BCR-ABL genomic dna in cml patients with no detectable BCR-ABL by quantitative reverse transcriptase PCR. In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 92 (pp. 212). Vienna, AUSTRIA: FERRATA STORTI FOUNDATION. WoS1 |
| 2007 | Toplin, J., Fuller, C., Fletcher, L., Wong, S., Maslak, P., Cortes, J., . . . Beillard, E. (2007). An MMR control RNA for reliable monitoring of BCR-ABL transcripts in treated CML patients. In BLOOD Vol. 110 (pp. 863A-864A). Atlanta, GA: AMER SOC HEMATOLOGY. DOI |
| 2007 | Hughes, T., Saglio, G., Martinelli, G., Kim, D. -W., Soverini, S., Mueller, M., . . . Hochhaus, A. (2007). Responses and disease progression in CML-CP patients treated with nilotinib after imatinib failure appear to be affected by the BCR-ABL mutation status and types. In BLOOD Vol. 110 (pp. 101A). Atlanta, GA: AMER SOC HEMATOLOGY. DOI WoS13 |
| 2007 | Branford, S., Fletcher, L., Cross, N. C. P., Hochhaus, A., Mueller, M. C., Kim, D. -W., . . . Hughes, T. (2007). Validation of the international scale for measurement of BCR-ABL by RQ-PCR based on deriving laboratory-specific conversion factors. In BLOOD Vol. 110 (pp. 307A). Atlanta, GA: AMER SOC HEMATOLOGY. DOI WoS1 |
| 2007 | Stone, R. M., Kantarjian, H. M., Baccarani, M., Lipton, J. H., Hughes, T., Ezzeddine, R., . . . Hochhaus, A. (2007). Efficacy of dasatinib in patients with chronic-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-C (CA180-013). In BLOOD Vol. 110 (pp. 225A). Atlanta, GA: AMER SOC HEMATOLOGY. DOI WoS14 |
| 2007 | Morley, A., Bartley, P., Martin-Harris, H., Latham, S., Ross, D., & Hughes, T. (2007). DNA-based measurement of BCR ABL in chronic myeloid leukemia (CML). In BLOOD Vol. 110 (pp. 865A-866A). Atlanta, GA: AMER SOC HEMATOLOGY. DOI |
| 2007 | Saglio, G., Kim, D. -W., Hochhaus, A., Soverini, S., Erben, P., Branford, S., . . . Radich, J. (2007). Correlation of clinical response to nilotinib with BCR-ABL mutation status in advanced phase chronic myelogenous leukemia (CML-AP) patients with imatinib-resistance or intolerance. In BLOOD Vol. 110 (pp. 576A-577A). Atlanta, GA: AMER SOC HEMATOLOGY. WoS4 |
| 2007 | Hiwase, D. K., White, D. L., Saunders, V. A., Dang, P., Venables, A., Eadie, L., . . . Hughes, T. P. (2007). In contrast to imatinib, OCT-1 mediated influx has minimal impact on cellular uptake of dasatinib in CML patients at diagnosis. In BLOOD Vol. 110 (pp. 575A-576A). Atlanta, GA: AMER SOC HEMATOLOGY. WoS7 |
| 2007 | Hiwase, D. K., White, D. L., Saunders, V. A., Dang, P., Venables, A., Eadie, L., . . . Hughes, T. P. (2007). In Contrast to Imatinib, OCT-1 Mediated Influx Has Minimal Impact on Cellular Uptake of Dasatinib in CML Patients at Diagnosis.. In Blood Vol. 110 (pp. 1937). American Society of Hematology. DOI |
| 2007 | Heaney, N., Drummond, M., Kaeda, J., Nicolini, F., Clark, R., Wilson, G., . . . Holyoake, T. L. (2007). A phase 3 pilot study of continuous imatinib versus pulsed imatinib with or without G-CSF in patients with chronic phase CML who have achieved a complete cytogenetic response to imatinib. In BLOOD Vol. 110 (pp. 313A). Atlanta, GA: AMER SOC HEMATOLOGY. DOI WoS1 |
| 2007 | Lewis, R. D., Jackson, C. L., Morgan, B. P., & Hughes, T. (2007). A role for CD59a in the progression of atherosclerosis: The first direct evidence from an in vivo study. In MOLECULAR IMMUNOLOGY Vol. 44 (pp. 3939). Cardiff, WALES: PERGAMON-ELSEVIER SCIENCE LTD. DOI |
| 2007 | White, D., Saunders, V. A., Dang, P., Lynch, K., Manley, P., & Hughes, T. P. (2007). The intracellular concentrations of imatinib and nilotinib, can be substantially altered by interaction with other drugs: Studies with proton pump inhibitors. In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 92 (pp. 339). Vienna, AUSTRIA: FERRATA STORTI FOUNDATION. |
| 2006 | Hochhaus, A., Ottmann, O. G., Lauber, S., Hughes, T., Verhoef, G., Schwarer, A. P., . . . Gattermann, N. (2006). A phase II study of nilotinib, a novel inhibitor of c-kit, PDGFR, and Bcr-Abl, administered to patients with systemic mastocytosis.. In BLOOD Vol. 108 (pp. 764A). Orlando, FL: AMER SOC HEMATOLOGY. DOI WoS2 |
| 2006 | Seymour, J. F., Grigg, A., Reynolds, J., Schwarer, A. P., Hermann, R., Taylor, K. M., . . . Hughes, T. (2006). Two year data from a prospective safety study analyzing the consequences of imatinib mesylate inhibition of sensitive kinases other than bcr-abl in patients with previously untreated chronic phase CML.. In BLOOD Vol. 108 (pp. 609A). Orlando, FL: AMER SOC HEMATOLOGY. DOI WoS1 |
| 2006 | White, D., Saunders, V., Dang, P., Venables, A., Zrim, S., Reynolds, J., . . . Hughes, T. (2006). Molecular response to imatinib is dependent on dose in CML patients with low OCT-1 influx activity. Patients with high activity may respond equally well to standard or increased dose imatinib.. In BLOOD Vol. 108 (pp. 222A). Orlando, FL: AMER SOC HEMATOLOGY. |
| 2006 | White, D., Dang, P., Venables, A., Saunders, V., Zrim, S., Zannettino, A., . . . Hughes, T. (2006). ABCB1 overexpression may predispose imatinib treated CML patients to the development of Abl kinase domain mutations, and may be an important contributor to acquired resistance.. In BLOOD Vol. 108 (pp. 608A). Orlando, FL: AMER SOC HEMATOLOGY. DOI WoS2 |
| 2006 | Branford, S., Hughes, T., Stylian, S., Schwarer, A. P., Arthur, C., Filshie, R., . . . Taylor, K. M. (2006). Significant reduction of BCR-ABL transcripts after switching to imatinib therapy in patients with CML and complete or near-complete cytogenetic responses to interferon-alpha (IFN).. In BLOOD Vol. 108 (pp. 607A-608A). Orlando, FL: AMER SOC HEMATOLOGY. DOI WoS1 |
| 2006 | Shah, N. P., Skaggs, B., Branford, S., Hughes, T. P., Nicoll, J. M., Paquette, R. L., & Sawyers, C. L. (2006). The most common dasatinib-resistant BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia are sensitive to VX-680: Rationale for early combination kinase inhibitor therapy.. In BLOOD Vol. 108 (pp. 617A). Orlando, FL: AMER SOC HEMATOLOGY. DOI WoS2 |
| 2006 | Hochhaus, A., Erben, P., Branford, S., Radich, J., Kim, D. W., Martinelli, G., . . . Baccarani, M. (2006). Hematologic and cytogenetic response dynamics to nilotinib (AMN107) depend on the type of BCR-ABL mutations in patients with chronic myelogeneous leukemia (CML) after imatinib failure.. In BLOOD Vol. 108 (pp. 225A). Orlando, FL: AMER SOC HEMATOLOGY. WoS4 |
| 2006 | Branford, S., Cross, N. C. P., Hochhaus, A., Radich, J., Saglio, G., Kim, D. W., . . . Hughes, T. (2006). First results from a collaborative initiative to develop an international scale for the measurement of BCR-ABL by RQ-PCR based on deriving laboratory-specific conversion factors.. In BLOOD Vol. 108 (pp. 221A). Orlando, FL: AMER SOC HEMATOLOGY. WoS1 |
| 2006 | Shah, N. P., Skaggs, B., Branford, S., Hughes, T. P., Nicoll, J. M., Paquette, R. L., & Sawyers, C. L. (2006). Sequential kinase inhibitor therapy in CML patients can select for cells harboring compound BCR-ABL kinase domain mutations with increased oncogenic potency: Rationale for early combination therapy of ABL kinase inhibitors.. In BLOOD Vol. 108 (pp. 225A-226A). Orlando, FL: AMER SOC HEMATOLOGY. WoS4 |
| 2006 | Ross, D. M., Hughes, T. P., & Branford, S. (2006). Reverse transcription with a random pentadecamer primer increases the sensitivity of quantitative PCR for BCR-ABL.. In BLOOD Vol. 108 (pp. 662A-663A). Orlando, FL: AMER SOC HEMATOLOGY. DOI |
| 2006 | Branford, S., Seymour, J. F., Grigg, A., Arthur, C., Lynch, K., & Hughes, T. (2006). Increasing frequency and marked stability of complete molecular response is observed in imatinib-treated CML patients with long-term follow up.. In BLOOD Vol. 108 (pp. 131A). Orlando, FL: AMER SOC HEMATOLOGY. WoS4 |
| 2006 | Kaeda, J., Hochhaus, A., Radich, J., Branford, S., So, C., Gathmann, I., . . . Hughes, T. (2006). Patients with chronic phase CML in the IRIS study who receive imatinib mesylate (IM) 2nd line after prior IFN/Ara-C have sustained complete cytogenetic and major molecular response rates similar to 1st line IM patients.. In BLOOD Vol. 108 (pp. 607A). Orlando, FL: AMER SOC HEMATOLOGY. DOI WoS2 |
| 2005 | Hughes, T. P., Branford, S., Reynolds, J., Koelmeyer, R., Seymour, J., Taylor, K., . . . Grigg, A. (2005). Maintenance of imatinib dose intensity in the first six months of therapy for newly diagnosed patients with CML is predictive of molecular response, independent of the ability to increase dose at a later point.. In BLOOD Vol. 106 (pp. 51A). Atlanta, GA: AMER SOC HEMATOLOGY. WoS4 |
| 2005 | Shah, N. P., Nicoll, J. M., Branford, S., Hughes, T. P., Paquette, R. L., Talpaz, M., . . . Sawyers, C. L. (2005). Molecular analysis of dasatinib resistance mechanisms in CML patients identifies novel BCR-ABL mutations predicted to retain sensitivity to imatinib: Rationale for combination tyrosine kinase inhibitor therapy.. In BLOOD Vol. 106 (pp. 318A). Atlanta, GA: AMER SOC HEMATOLOGY. WoS11 |
| 2005 | Lyons, A. B., Hughes, T. P., & Viboonjuntra, P. (2005). Production of GM-CSF by CML cells can modulate the anti-proliferative and pro-apoptotic effects of imatinib on CML CD34<SUP>+</SUP> cells. In BLOOD Vol. 106 (pp. 803A). Atlanta, GA: AMER SOC HEMATOLOGY. WoS1 |
| 2005 | Roberts, M. M., Ross, D. M., Hughes, T. P., & To, L. B. (2005). Lymphoid foci in bone marrow of patients with chronic myeloid leukaemia treated with imatinib.. In BLOOD Vol. 106 (pp. 568A). Atlanta, GA: AMER SOC HEMATOLOGY. DOI WoS1 |
| 2005 | White, D. L., Branford, S., Saunders, V. A., Lynch, K., Grigg, A., To, L. B., & Hughes, T. P. (2005). In imatinib treated CML patients with low baseline IC50, early molecular response is highly predictive of longer term molecular outcome. in patients with high IC50, other prognostic indicators are needed. In BLOOD Vol. 106 (pp. 918A). GA, Atlanta: AMER SOC HEMATOLOGY. |
| 2005 | Sweeney, D. F., Sridhar, M. S., Vannas, A., Pravin, V. K., Kala, R., Hughes, T. C., . . . Xie, R. Z. (2005). Corneal inlays: Results of a 6 month phase 1 clinical trial. In INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE Vol. 46 (pp. 1 page). Ft Lauderdale, FL: ASSOC RESEARCH VISION OPHTHALMOLOGY INC. |
| 2004 | Sweeney, D. F., Xie, R. Z., Evans, M. D. M., Bojarski, B., Vannas, A., Hughes, T. C., . . . McLean, K. M. (2004). Long-term corneal biocompatibility to Pfpe polymers - Histological findings. In INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE Vol. 45 (pp. U306). Ft Lauderdale, FL: ASSOC RESEARCH VISION OPHTHALMOLOGY INC. |
| 2004 | Evans, M. D. M., Xie, R. Z., Bojarski, B., Hughes, T. C., McLean, K. M., Wilkie, J. S., . . . Sweeney, D. F. (2004). Long-term corneal biocompatibility of PFPE for an implantable contact lens. In Transactions 7th World Biomaterials Congress (pp. 116). |
| 2004 | Shah, N. P., Branford, S., Hughes, T. P., Nicoll, J. M., Decillis, A. P., & Sawyers, C. L. (2004). Major cytogenetic responses to BMS-354825 in patients with chronic myeloid leukemia are associated with a one to two log reduction in <i>BCR</i>-<i>ABL</i> transcript.. In BLOOD Vol. 104 (pp. 288A). San Diego, CA: AMER SOC HEMATOLOGY. WoS4 |
| 2004 | Hughes, T. C., Chan, G. Y. N., Evans, M. D. M., Johnson, G., Le, T. P. T., McFarland, G., . . . Xie, R. Z. (2004). Perfluoropolyether corneal onlays: Adhesive development. In Transactions 7th World Biomaterials Congress (pp. 1653). |
| 2004 | Hughes, T. C., Chan, G. Y. N., Evans, M. D. M., Johnson, G., Knower, W. S., Le, T. P. T., . . . Xie, R. Z. (2004). Hydrogel-like perfluoropolyethers. In Transactions 7th World Biomaterials Congress (pp. 1607). Scopus1 |
| 2004 | McLean, K. M., Beumer, G. J., Bojarski, B., Chan, G. Y. N., Chaouk, H., Evans, M. D. M., . . . Xie, R. Z. (2004). Corneal implants for refractive error correction. In Transactions 7th World Biomaterials Congress (pp. 1605). |
| 2003 | Branford, S., Rudzki, Z., Miller, B., Grigg, A., Seymour, J. F., Schwarer, A., . . . Hughes, T. P. (2003). Mutations in the catalytic core (P-Loop) of the BCR-ABL kinase domain of imatinib-treated chronic myeloid leukemia patients in chronic phase are strongly associated with imminent progression to blast crisis.. In BLOOD Vol. 102 (pp. 71A). SAN DIEGO, CALIFORNIA: AMER SOC HEMATOLOGY. WoS3 |
| 2003 | Branford, S., Rudzki, Z., Grigg, A., Seymour, J. F., Taylor, K., Herrmann, R., . . . Hughes, T. P. (2003). The incidence of BCR-ABL kinase mutations in chronic myeloid leukemia patients is as high in the second year of imatinib therapy as the first but survival after mutation detection is significantly longer for patients with mutations detected in the second year of therapy.. In BLOOD Vol. 102 (pp. 414A). SAN DIEGO, CALIFORNIA: AMER SOC HEMATOLOGY. WoS6 |
| 2003 | Hughes, T. P., Branford, S., Matthews, J., Seymour, J., Taylor, K., Guzzo-Pernell, N., . . . Grigg, A. (2003). Trial of higher dose imatinib with selective intensification in newly diagnosed CML patients in the chronic phase.. In BLOOD Vol. 102 (pp. 31A). SAN DIEGO, CALIFORNIA: AMER SOC HEMATOLOGY. WoS16 |
| 2003 | Baccarani, M., Cortes, J., Daley, G. Q., Druker, B. J., Guilhot, F., Hochhaus, A., . . . Mahon, F. X. (2003). Comments on the hammersmith policy. In Seminars in Hematology Vol. 40 (pp. 104-113). Elsevier BV. DOI |
| 2003 | Seymour, J. F., Grigg, A. P., Matthews, J., Taylor, K., Guzzo-Pernell, N., Mills, A. K., . . . Hughes, T. P. (2003). A prospective analysis of the consequences of imatinib mesylate inhibition of sensitive kinases other than BCR-ABL in patients with previously untreated early chronic phase CML.. In BLOOD Vol. 102 (pp. 911A). CALIFORNIA, SAN DIEGO: AMER SOC HEMATOLOGY. |
| 2003 | Hui, C. H., Goh, K., White, D., Branford, S., Grigg, A., Seymour, J., . . . Hughes, T. P. (2003). Mobilization of CD34+ cells from chronic myeloid leukemia patients achieving CCR on imatinib; safety and efficacy using filgrastim with or without continuation of imatinib. In BONE MARROW TRANSPLANTATION Vol. 31 (pp. S50). ISTANBUL, TURKEY: NATURE PUBLISHING GROUP. |
| 2001 | Ferrao, P. T., Frost, M. J., Coles, C. J., Domaschenz, R. M., Hughes, T. P., & Ashman, L. K. (2001). Activated mutant D816VKit confers resistance to chemotherapeutic drugs, irradiation and STI 571.. In CLINICAL CANCER RESEARCH Vol. 7 (pp. 3742S). AMER ASSOC CANCER RESEARCH. |
| 2001 | Hughes, T. C., Meijs, G. F., Chaouk, H., Steele, J. G., & Johnson, G. (2001). Porous perfluoroalkyl acrylates: A potential ophthalmic biomaterial.. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 222 (pp. U318). AMER CHEMICAL SOC. |
| 2000 | Bensinger, W., Cornetta, K., Carabasi, M., Yanovich, S., Hughes, T., Skikne, B., . . . Mills, B. (2000). T cell depleted allogeneic PBSC transplantation using CD34+cell selection.. In BLOOD Vol. 96 (pp. 199A). AMER SOC HEMATOLOGY. |
| 2000 | Bardy, P., Grigg, A. P., Szer, J., Roberts, A., Schwarer, A. P., Spencer, A., . . . Hughes, T. P. (2000). Successful engraftment with disease response following sibling allograft with reduced conditioning, T-cell depletion and delayed incremental DLI in CML and MM.. In BLOOD Vol. 96 (pp. 783A). AMER SOC HEMATOLOGY. |
| 1997 | Moore, S., Levesque, J. P., Haylock, D. N., McDiarmid, L., Samels, L., To, L. B., . . . Hughes, T. P. (1997). Kit ligand as the sole stimulatory agent induces marked proliferation of CD34+ CML cells without a concomitant increase in adhesion.. In BLOOD Vol. 90 (pp. 1746). W B SAUNDERS CO. WoS1 |
| 1996 | Hughes, T. P., Grigg, A., Szer, J., Ho, J., Ma, D., Dale, B. M., . . . Arthur, C. (1996). Mobilization of predominantly Ph-negative blood progenitors using cyclophosphamide and lenograstim in early chronic phase CML: Correlation with Sokal prognostic index and hematological control pre-mobilisation.. In BLOOD Vol. 88 (pp. 927). W B SAUNDERS CO. |
| 1995 | Juttner, C. A., To, L. B., Haylock, D. N., Dyson, P. G., Simmons, P. J., Bayly, J., . . . Thorp, D. (1995). Blood progenitor cells: Biologic and clinical issues. In Bone Marrow Transplantation Vol. 15 (pp. S15-S20). |
| 1995 | Lewis, L. D., Haylock, D. N., Moore, S., To, L. B., Juttner, C. A., & Hughes, T. P. (1995). Identification of normal primitive progenitors in blood and mobilised blood in chronic myeloid leukaemia.. In BLOOD Vol. 86 (pp. 2085). W B SAUNDERS CO. WoS1 |
| 1993 | Cullis, J. O., Szydlo, R. M., Cross, N. C. P., Marks, D. I., Schwarer, A. P., Hughes, T. P., . . . Goldman, J. M. (1993). Matched unrelated donor bone marrow transplantation for chronic myeloid leukaemia in chronic phase: Comparison of ex vivo and in vivo T-cell depletion. In Bone Marrow Transplantation Vol. 11 (pp. 107-111). ITALY, PAVIA: STOCKTON PRESS. Scopus12 WoS10 Europe PMC4 |
| 1991 | Goldman, J. M., & Hughes, T. (1991). Detection and significance of minimal residual disease in patients with leukaemia and lymphoma. In Bone Marrow Transplantation Vol. 7 (pp. 66-69). England. Scopus3 Europe PMC2 |
| 1991 | Hughes, T. P., O'Shea, P., Morgan, G., Martiat, P., & Goldman, J. M. (1991). Persistence of BCR/ABL transcripts after BMT for CML detected by PCR reflects a high risk of relapse. In Bone Marrow Transplantation Vol. 7 (pp. 23). England. Scopus5 |
| Year | Citation |
|---|---|
| 2021 | Eadie, L., Heatley, S., McClure, B., Rehn, J., Schutz, C., Breen, J., . . . White, D. (2021). Next Generation Genomic Analyses Inform Druggable Targets In T-All Patients. Poster session presented at the meeting of 4th International T-ALL/T-NHL conference: T-ALL2020: Omics, genetics and therapy. |
| 2021 | Eadie, L., Heatley, S., McClure, B., Rehn, J., Schutz, C., Breen, J., . . . White, D. (2021). Next Generation Genomic Analyses Inform Druggable Targets In T-All Patients. Poster session presented at the meeting of 12th Biennial Childhood Leukemia and Lymphoma Symposium (CLLS). |
| 2020 | Poudel, G., Yeung, D., White, D., Hughes, T., & Pagani, I. (2020). Understanding the mechanisms of imatinib resistance in a Ph+ acute lymphoblastic leukaemia cell line. Poster session presented at the meeting of The 59th ASMR National Scientific Conference. |
| 2020 | Eadie, L., Heatley, S., McClure, B., Schutz, C., Breen, J., Hughes, T., . . . White, D. (2020). Next Generation Genomic Analyses Inform Druggable Targets In T-All Patients. Poster session presented at the meeting of Australian & New Zealand Children’s Haematology/Oncology Group. |
| 2020 | Eadie, L. N., Rehn, J., Heatley, S. L., McClure, B. J., Schutz, C. S., Breen, J., . . . White, D. L. (2020). Next Generation Genomic Analyses in T-ALL Patients Identify Recurrent and Novel Genomic Abnormalities. Poster session presented at the meeting of BLOOD. ELECTR NETWORK: ELSEVIER. DOI WoS1 |
| 2019 | Eadie, L., Heatley, S. L., McClure, B. J., Rehn, J. A., Breen, J., Hughes, T. P., . . . White, D. L. (2019). Exploration of the Genomic Diversity in T-ALL Patients Using mRNA Sequencing. Poster session presented at the meeting of 1st European Society of Haematology (ESH) Translational Conference on ALL. Berlin, Germany. |
| 2019 | Eadie, L., Heatley, S. L., McClure, B. J., Rehn, J. A., Breen, J., Hughes, T. P., . . . White, D. L. (2019). Exploration of the Genomic Diversity in T-ALL Patients Using mRNA Sequencing. Poster session presented at the meeting of ASMR Annual Scientific Meeting. Adelaide, South Australia. |
| 2019 | Heatley, S. L., McClure, B. J., Eadie, L. N., Rehn, J. A., Breen, J., Hughes, T. P., . . . White, D. L. (2019). Exploring the genomic diversity of AYA and adult high-risk B-ALL cases by mRNA sequencing. Poster session presented at the meeting of SAHMRI Annual Scientific Meeting. Adelaide, South Australia. |
| 2019 | Yeung, D. T., Shanmuganathan, N., Grigg, A., Cunningham, I., Shortt, J., Rowling, P., . . . Hughes, T. P. (2019). Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study. Poster session presented at the meeting of BLOOD. FL, Orlando: ELSEVIER. DOI WoS3 |
| 2019 | Yeung, D. T., Grigg, A., Shanmuganathan, N., Solterbeck, A. C., White, D. L., Branford, S., . . . Hughes, T. P. (2019). Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct Study. Poster session presented at the meeting of BLOOD. FL, Orlando: ELSEVIER. DOI WoS1 |
| 2019 | El Khawanky, N., Hughes, A., Yu, W., Taromi, S., Clarson, J., Lopez, A. F., . . . Zeiser, R. (2019). Azacytidine Sensitizes AML Cells for Effective Elimination By CD123 CAR T-Cells. Poster session presented at the meeting of BLOOD. Orlando, FL: AMER SOC HEMATOLOGY. DOI WoS4 |
| 2019 | Talpaz, M., Cortes, J., Lang, F., Kim, D. -W., Rea, D., Mauro, M. J., . . . Hughes, T. P. (2019). Combination of Asciminib, a Novel and Specific BCR-ABL1 Inhibitor, Plus Imatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results. Poster session presented at the meeting of CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP. DOI WoS3 |
| 2019 | Hughes, T. P. (2019). CML Case Studies: Impact of Comorbidities. Poster session presented at the meeting of CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP. DOI |
| 2019 | DeAngelo, D. J., Mauro, M. J., Kim, D. -W., Cortes, J., Rea, D., Hughes, T. P., . . . Lang, F. (2019). Combination of Asciminib plus Nilotinib or Asciminib plus Dasatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results. Poster session presented at the meeting of CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP. DOI WoS4 |
| 2019 | Mahon, F. -X., Boquimpani, C., Takahashi, N., Benyamini, N., Clementino, N. C. D., Shuvaev, V., . . . Hughes, T. P. (2019). ENESTop 192-Weeks Results: Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib. Poster session presented at the meeting of CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP. DOI WoS4 |
| 2019 | Hughes, T. P., Boquimpani, C., Takahashi, N., Benyamini, N., Clementino, N. C. D., Shuvaev, V., . . . Mahon, F. -X. (2019). ENESTop 192-week results: Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib (NIL).. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. WoS8 |
| 2018 | Asari, K., Leclercq, T., Srihari, S., Fitter, S., Yeung, D., Hughes, T., . . . White, D. L. (2018). in vitro modelling of Ph-like ALL uncovers novel genomic alterations associated with TKI-resistance as a consequence of targeted therapy. Poster session presented at the meeting of Childhood Leukaemia and Lymphoma Symposium. Helsinki, Finland. |
| 2018 | Heatley, S. L., Mayne, B. T., McClure, B. J., Kok, C., Sadras, T., Dang, P., . . . White, D. L. (2018). Exploring the genomic diversity of AYA and adult high-risk B-ALL cases by mRNA sequencing. Poster session presented at the meeting of 23rd Congress of European Hematology Association. Stockholm, Sweden. |
| 2018 | Heatley, S. L., McClure, B. J., Kok, C., Sadras, T., Dang, P., Galbraith, K., . . . White, D. L. (2018). Exploring the genomic diversity of adult and AYA cases with high-risk B-ALL by mRNA sequencing. Poster session presented at the meeting of NDLR. |
| 2018 | Pagani, I. S., Kok, C., Saunders, V., Schwarer, A., Hughes, T. P., White, D. L., & Ross, D. M. (2018). Association of mitochondrial DNA (mtDNA) mutations at diagnosis with treatment response in chronic myeloid leukaemia (CML) patients. Poster session presented at the meeting of NDLR. |
| 2018 | Lu, L., Kok, C., Saunders, V., Nievergall, E., White, D. L., & Hughes, T. P. (2018). TGF-α predicts TKI treated CML patients who fail to achieve early molecular response. Poster session presented at the meeting of NDLR. |
| 2018 | Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification and computational modelling of ruxolitinib resistant mutations in JAK2-rearranged B-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of Poster, Adelaide Protein Group (APG) Student Awards. |
| 2018 | Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification of ruxolitinib resistance mutations in Pro-B cells driven by a high-risk JAK2 fusion in B-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of Oral, Australian Society for Medical Research (ASMR) SA Meeting. |
| 2018 | Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification and Characterisation of Ruxolitinib Resistant Mutations in JAK2-rearranged B-cell Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of Poster, Australasian Genomic Technologies Association (AGTA) Annual Conference. |
| 2018 | Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification of ruxolitinib resistance mutations in Pro-B cells driven by a high-risk B-ALL JAK2-fusion. Poster session presented at the meeting of Poster, Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG) Annual Scientific Meeting. |
| 2018 | Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification and computational modelling of ruxolitinib resistant mutations in JAK2-rearranged B-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of Poster, South Australian Health and Medical Research Institute (SAHMRI) Annual Scientific Meeting. |
| 2018 | Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification and computational modelling of ruxolitinib resistant mutations in JAK2-rearranged B-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of Poster, European Molecular Biology Laboratory (EMBL) Australia Postgraduate Symposium. |
| 2018 | Shanmuganathan, N., Branford, S., Yong, A. S. M., Hiwase, D. K., Yeung, D. T., Ross, D. M., & Hughes, T. P. (2018). The e13a2 BCR-ABL1 Transcript Is Associated with Higher Rates of Molecular Recurrence after Treatment-Free Remission Attempts: Retrospective Analysis of the Adelaide Cohort. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY. DOI WoS8 |
| 2017 | El-Khawanky, N., Hughes, A., Yu, W., Clarson, J., Lopez, A. F., Brown, M., . . . Yong, A. (2017). CD123 Chimeric Antigen Receptor T-cells in Chronic and Acute Myeloid Leukaemia: pre-clinical in vitro studies. Poster session presented at the meeting of HAA. |
| 2017 | El-Khawanky, N., Hughes, T. P., Clarson, J., Yu, W., White, D. L., & Yong, A. (2017). Anti-CD123 Chimeric Antigen Receptor (CAR) T-cells in Chronic and Acute Myeloid Leukaemia: pre-clinical in vitro studies. Poster session presented at the meeting of ASMR. |
| 2017 | McClure, B. J., Heatley, S. L., Kok, C., Sadras, T., An, J., Quek, K., . . . White, D. L. (2017). EP300-ZNF384 is a recurrent fusion gene with distinct gene expression in adolescent/young adult pre-B-ALL patients. Poster session presented at the meeting of ANZCHOG. |
| 2017 | Heatley, S. L., Sadras, T., Kok, C., Nievergall, E., Quek, K., Dang, P., . . . White, D. L. (2017). High Prevalence of Relapse in Australian Children with Ph-like Acute Lymphoblastic Leukemia Despite Risk-Adapted Treatment. Poster session presented at the meeting of ANZCHOG. |
| 2017 | Asari, K., Sadras, T., Srihari, S., Fitter, S., An, J., Zannettino, A. C., . . . White, D. L. (2017). in vitro Modelling of Ph-like ALL Fusions Uncovers Novel Kinase-domain Mutations as a Mode of TKI-resistance and Potential Consequence of Targeted TKI Therapy. Poster session presented at the meeting of ANZCHOG. |
| 2017 | Ross, D. M., Pagani, I. S., Shanmuganathan, N., Seymour, J. F., Mills, A., Filshie, R., . . . Hughes, T. P. (2017). Long-Term Follow-up of the ALLG CML8 Twister Study of Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia (CML). Poster session presented at the meeting of 59th ASH Annual Meeting & Exposition. |
| 2017 | Hughes, A., Clarson, J., White, D. L., Yeung, D., Hughes, T. P., & Yong, A. S. M. (2017). Nilotinib/Interferon-α Combination Rapidly Enhances Leukaemia-Associated Antigen Specific Cytotoxic T-Lymphocyte Immune Responses, Limits Natural Killer Cell Maturation and Triggers B Cell Remodelling. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY. WoS4 |
| 2017 | Yeung, D., Grigg, A., Shanmuganathan, N., Cunningham, I., Shortt, J., Rowling, P., . . . Hughes, T. P. (2017). Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY. |
| 2017 | Pagani, I. S., Dang, P., Kommers, I. O., Goyne, J., Saunders, V. A., Prime, J. A., . . . Ross, D. M. (2017). COMPARISON OF GENOMIC DNA AND REVERSE TRANSCRIPTASE Q-PCR FOR THE MONITORING OF FIRST-LINE IMATINIB TREATMENT: AN ALLG CML9 SUB-STUDY. Poster session presented at the meeting of HAEMATOLOGICA. Madrid, SPAIN: FERRATA STORTI FOUNDATION. |
| 2017 | Cortes, J. E., Kantarjian, H. M., Pinilla-Ibarz, J., le Coutre, P. D., Paquette, R., Chuah, C., . . . Mueller, M. C. (2017). 5-YR RESULTS FROM THE PIVOTAL PHASE 2 PONATINIB PACE TRIAL: EFFICACY, SAFETY AND LANDMARK ANALYSIS IN HEAVILY PRETREATED PATIENTS (PTS) WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML). Poster session presented at the meeting of HAEMATOLOGICA. Madrid, SPAIN: FERRATA STORTI FOUNDATION. |
| 2017 | Hochhaus, A., Jabbour, E., Kantarjian, H., Guilhot, F., Kota, V., Hughes, T. P., . . . Cortes, J. E. (2017). 5-YEAR EFFICACY OF DASATINIB AND IMATINIB IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WITH DOSE MODIFICATIONS FROM DASISION. Poster session presented at the meeting of HAEMATOLOGICA. Madrid, SPAIN: FERRATA STORTI FOUNDATION. |
| 2017 | Downes, C. E., McClure, B. M., Heatley, S. H., Sadras, T. S., Hughes, T. H., Kok, C. K., . . . White, D. W. (2017). Identification and cloning of a novel GOLGA4-JAK2 fusion from an adult patient with B-cell Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of Poster, Australian Society for Medical Research (ASMR) SA Meeting. Adelaide. |
| 2017 | Heatley, S., Sadras, T., Kok, C., Nievergall, E., Quek, K., Dang, P., . . . White, D. (2017). High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment. Poster session presented at the meeting of Abstracts of the 57th Annual Meeting of the American Society of Hematology, as published in Blood. Orlando, FL: American Society of Hematology. DOI WoS2 |
| 2016 | Mueller, M., Baccarani, M., Deininger, M. W., Guilhot, F., Hochhaus, A., Hughes, T. P., . . . Cortes, J. E. (2016). LANDMARK ANALYSES IN THE PIVOTAL PONATINIB PACE TRIAL: IMPACT OF EARLY RESPONSES ON 3-YEAR OUTCOMES IN HEAVILY PRETREATED CP-CML PATIENTS. Poster session presented at the meeting of HAEMATOLOGICA. Copenhagen, DENMARK: FERRATA STORTI FOUNDATION. |
| 2016 | Kok, C. H., Watkins, D., Wang, J., Saunders, V., Goyne, J., Pagani, I., . . . White, D. (2016). HIGH GENE EXPRESSION OF HIST1H2AG AND HIST1H4A REDUCES IMATINIB UPTAKE INTO CML CELLS AND PREDICTS POOR RESPONSE TO FRONTLINE IMATINIB THERAPY. Poster session presented at the meeting of HAEMATOLOGICA. Copenhagen, DENMARK: FERRATA STORTI FOUNDATION. |
| 2016 | Hughes, T. P., Boquimpani, C., Takahashi, N., Benyamini, N., Clementino, N. C. D., Shuvaev, V., . . . Mahon, F. X. (2016). RESULTS FROM ENESTOP: TREATMENT-FREE REMISSION (TFR) FOLLOWING SWITCH TO NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP). Poster session presented at the meeting of HAEMATOLOGICA. Copenhagen, DENMARK: FERRATA STORTI FOUNDATION. WoS5 |
| 2016 | Cortes, J. E., Pinilla-Ibarz, J., le Coutre, P. D., Paquette, R., Chuah, C., Nicolini, F. E., . . . Kantarjian, H. M. (2016). LONG-TERM EFFICACY AND SAFETY OF PONATINIB IN HEAVILY PRETREATED LEUKEMIA PATIENTS: 4-YEAR RESULTS FROM THE PIVOTAL PHASE 2 PACE TRIAL. Poster session presented at the meeting of HAEMATOLOGICA. Copenhagen, DENMARK: FERRATA STORTI FOUNDATION. WoS1 |
| 2016 | Sadras, T., Heatley, S., Dang, P., Kok, C., Quek, K., Nievergall, E., . . . White, D. L. (2016). A nine-gene signature defines 2 groups of CRLF2 rearranged B-ALL patients with distinctive genetic features. Poster session presented at the meeting of .. Athens. |
| 2016 | Pagani, I. S., Kok, C., Saunders, V., Goyne, J., McLean, J., Vanderhoek, M., . . . Ross, D. (2016). The genomic landscape of mitochondrial DNA mutations in chronic myeloid leukaemia. Poster session presented at the meeting of .. Barcelona, Spain. |
| 2016 | Eadie, L., Saunders, V., Branford, S., Hughes, T., & White, D. (2016). Resistance mechanisms of the new allosteric inhibitor ABL001. Poster session presented at the meeting of ,. Houtson, USA. |
| 2016 | Eadie, L., Goyne, J., Hughes, T., & White, D. (2016). ABCC6 plays a significant role in the transport of nilotinib in both cells lines and primary patient cells, and may contribute to resistance. Poster session presented at the meeting of ,. Houston, USA. |
| 2016 | Saunders, V. A., Wang, J., Lu, L., Eadie, L. N., McLean, J. A., Goyne, J. M., . . . Hughes, T. P. (2016). A Low Concentration of ABL001 Potentiates <i>In Vitro</i> TKI-Induced Bcr-Abl Kinase Inhibition in CML Cells. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY. DOI WoS1 |
| 2016 | Eadie, L. N., Goyne, J., Hughes, T., & White, D. L. (2016). The ABCC6 Transporter Plays a Significant Role in the Efflux of Nilotinib and Dasatinib, and May Contribute to Tyrosine Kinase Inhibitor Resistance. Poster session presented at the meeting of .. San Diego, USA: AMER SOC HEMATOLOGY. DOI |
| 2016 | Eadie, L., Hughes, T., & White, D. (2016). ABCB1 overexpression predicts outcome of CML patients undergoing first-line imatinib treatment. Poster session presented at the meeting of Abstract presented at the New Directions in Leukaemia Research 2016 Meeting. Noosa, QLD. |
| 2016 | Eadie, L., Saunders, V., Leclercq, T., Branford, S., White, D. L., & Hughes, T. (2016). Abl001 Is Susceptible To Resistance Mediated By Overexpression Of Drug Transporters Abcb1 and Abcg2. Poster session presented at the meeting of .. Noosa, QLD. |
| 2016 | Sadras, T., Heatley, S., Kok, C., Quek, K., Dang, P., Nievergall, E., . . . White, D. L. (2016). CRLF2 rearranged B-ALL cases with a Ph-like gene signature are enriched for JAK2 mutations. Poster session presented at the meeting of .. Noosa, QLD. |
| 2016 | Lu, L., Saunders, V., Kok, C., Leclercq, T., Hughes, T., & White, D. (2016). Modelling ponatinib resistance in BCR-ABL1+ cell lines: implications for ponatinib therapy. Poster session presented at the meeting of New Directions in Leukaemia Research 2016. Noosa, QLD. |
| 2016 | McClure, B., Heatley, S., Sadras, T., Nievergall, E., Kok, C., Dang, P., . . . White, D. L. (2016). Identification of a significantly high prevalence of relapse in Australian children with Ph-like ALL. Poster session presented at the meeting of .. Noosa, QLD. |
| 2016 | Asari, K., Heatley, S., Leclercq, T., Fitter, S., Zannettino, A., Hughes, T., & White, D. L. (2016). In vitro Modelling of Therapeutic Resistance to Elucidate Mechanisms of TKI-Resistant High-Risk ALL. Poster session presented at the meeting of .. Noosa, QLD. |
| 2016 | Pagani, I., Kok, C., Saunders, V., Goyne, J., McLean, J., Vanderhoek, M., . . . White, D. L. (2016). Do mitochondrial mutations in chronic myeloid leukaemia identify a pre-leukemic clone?. Poster session presented at the meeting of .. Noosa, QLD. |
| 2016 | Eadie, L., Dang, P., Saunders, V., Hughes, T., & White, D. L. (2016). The clinical significance of early imatinib induced ABCB1 overexpression in chronic phase CML patients treated sequentially with imatinib and nilotinib: A TIDEL II sub-study. Poster session presented at the meeting of ,. Adelaide, SA. |
| 2016 | White, D. L., McClure, B., Heatley, S., Sadras, T., Quek, K., & Hughes, T. (2016). Investigation of the transforming capacity of a recently identified EP300-ZNF384 fusion gene in adult acute lymphoblastic leukaemia. Poster session presented at the meeting of Poster Session. Adelaide, SA. |
| 2016 | Asari, K., Heatley, S., Leclercq, T., Fitter, S., Kok, C. H., Zannettino, A., . . . White, D. L. (2016). Investigating Modes of Therapeutic Resistance via In Vitro Modelling of TKI-resistant High-Risk Philadelphia-chromosome-positive and Philadelphia-chromosome-like Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of Poster Session. Adelaide, SA. |
| 2016 | Watts, S., Saunders, V., Wee, A., Kutyna, M., White, D. L., Hughes, T., & Hiwase, D. (2016). Understanding the mechanism of secondary resistance to Azacitidine in Myelodysplastic syndromes using the cell-line model MOLM-13. Poster session presented at the meeting of Poster Session. Adelaide, SA. |
| 2016 | Kok, C. H., Watkins, D., Wang, J., Saunders, V., Goyne, J., Pagani, I. S., . . . White, D. L. (2016). High Gene Expression of hist1h2ag and hist1h4a Reduces Imatinib Uptake into CML Cells and Predicts Poor Response to Frontline Imatinib Therapy. Poster session presented at the meeting of Poster Session. Melbourne, VIC. |
| 2016 | Heatley, S., Sadras, T., McClure, B., Kok, C. H., Dang, P., Nievergall, E., . . . White, D. L. (2016). The Incidence of Ph-like Acute Lymphoblastic Leukaemia (ALL) Increases with Age and is Characterised by Poor Outcome. Poster session presented at the meeting of Poster Session. Melbourne, VIC. |
| 2016 | Pagani, I. S., Kok, C. H., Wang, J., Saunders, V., Van der Hoek, M., Heatley, S., . . . Ross, D. (2016). Mitochondrial DNA Mutations at Diagnosis are Linked to Response in TKI treated Chronic Myeloid Leukaemia Patients. Poster session presented at the meeting of Poster Session. Melbourne, VIC. |
| 2016 | Watts, S., Wee, A., Saunders, V., Kutyna, M., White, D. L., Hughes, T., & Hiwase, D. (2016). Determining Mechanisms of Resistance to Azacitidine (Aza) in Myelodysplastic (MDS) Syndromes and Acute Myeloid Leukaemia (AML) using an in-vitro model. Poster session presented at the meeting of Poster Session. Melbourne, VIC. |
| 2016 | Lu, L., Saunders, V., Kok, C. H., Leclercq, T., Hughes, T., & White, D. L. (2016). Modelling Ponatinib Resistance In BCR-ABL1+ Cell Lines: Implications For Ponatinib Therapy. Poster session presented at the meeting of Poster Session. Adelaide, SA. |
| 2016 | Hughes, A., Clarson, J., White, D. L., Ross, D. M., Hughes, T. P., & Yong, A. S. (2016). Enhanced Natural Killer and Cytotoxic T Lymphocyte Responses, with Decreased Monocytic Myeloid Derived Suppressor Cells May Promote Treatment Free Remission in Chronic Myeloid Leukaemia Patients Following Tyrosine Kinase Inhibitor Cessation. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY. DOI WoS7 |
| 2015 | Cortes, J., Kim, D. W., Pinilla-Ibarz, J., le Coutre, P. D., Paquette, R., Chuah, C., . . . Kantarjian, H. M. (2015). PONATINIB EFFICACY AND SAFETY IN HEAVILY PRETREATED LEUKEMIA PATIENTS: 3-YEAR RESULTS OF THE PACE TRIAL. Poster session presented at the meeting of HAEMATOLOGICA. Vienna, AUSTRIA: FERRATA STORTI FOUNDATION. WoS12 |
| 2015 | Guilhot, F., Khoury, H. J., Baccarani, M., Hochhaus, A., Hughes, T. P., Lipton, J. H., . . . Mauro, M. J. (2015). ELEVATED BLOOD PRESSURE (BP) AND ADVERSE EVENTS OF HYPERTENSION (HTN) IN PHASE 1, 2, AND 3 TRIALS OF PONATINIB IN LEUKEMIA. Poster session presented at the meeting of HAEMATOLOGICA. Vienna, AUSTRIA: FERRATA STORTI FOUNDATION. WoS1 |
| 2015 | Wang, J., Kok, C. H., Leclercq, T. M., Saunders, V. A., D'Andrea, R. J., Hughes, T. P., & White, D. L. (2015). High peroxisome proliferator-activated receptor-gamma (PPAR gamma le) transcriptional activity reduces active influx of imatinib and kinase inhibition in CML cells. Poster session presented at the meeting of Blood. US: American Society of Hematology. |
| 2015 | Mueller, M. C., Baccarani, M., Deininger, M. W., Guilhot, F., Hochhaus, A., Hughes, T. P., . . . Cortes, J. E. (2015). Responses to Ponatinib at early landmark time points are associated with Progression-Free Survival (PFS) and Overall Survival (OS) in heavily pretreated Chronic-Phase (CP) Chronic Myeloid Leukemia (CML) patients (Pts). Poster session presented at the meeting of Oncology Research and Treatment. KARGER. |
| 2015 | Foreman, C., Russo, P., Davies, N., Hissaria, P., Hughes, T., Proudman, S., & Limaye, V. (2015). AN AUDIT OF IVIG USE FOR INFLAMMATORY MYOPATHIES IN SOUTH AUSTRALIA. Poster session presented at the meeting of INTERNAL MEDICINE JOURNAL. WILEY-BLACKWELL. |
| 2014 | Branford, S., Yeung, D., Ross, D., Parker, W., Braley, J., Seymour, J., & Hughes, T. (2014). The adverse effect of high sokal risk for first line imatinib treated patients is overcome by a rapid rate of BCR-ABL decline measured as early as 1 month of treatment. Poster session presented at the meeting of Abstract of power point presentation at 56th ASH Annual Meeting, published in Blood. San Francisco, California: American Society of Hematology. |
| 2014 | Yeung, D. T., Vidovic, L., Tang, C., White, D. L., Branford, S., Hughes, T. P., & Yong, A. S. M. (2014). KIR2DL5B Genotype Independently Predicts Poor Outcomes in CML-CP Patients Switched to Nilotinib after Suboptimal Responses to Imatinib and May Refine Prognosis in Patients with EMR Failure. Poster session presented at the meeting of BLOOD. San Francisco, CA: AMER SOC HEMATOLOGY. |
| 2014 | Nievergall, E., Reynolds, J., Kok, C. H., Watkins, D., Biondo, M., Busfield, S. J., . . . Hughes, T. P. (2014). High plasma levels of TGF-α and IL-6 at diagnosis predict early molecular response failure and transformation in CML. Poster session presented at the meeting of Abstract of presentation to 56th ASH Annual Meeting, published in Blood. San Francisco, California: American Society of Hematology. DOI WoS1 |
| 2014 | Parker, W. T., Phillis, S. R., Yeung, D. T., Lawrence, D., Schreiber, A., Wang, P., . . . Branford, S. (2014). Detection of BCR-ABL1 Compound and Polyclonal Mutants in Chronic Myeloid Leukemia Patients Using a Novel Next Generation Sequencing Approach That Minimises PCR and Sequencing Errors. Poster session presented at the meeting of BLOOD. San Francisco, CA: AMER SOC HEMATOLOGY. DOI WoS4 |
| 2014 | Branford, S., Yeung, D., Parker, W. T., Purins, L., Braley, J., Seymour, J. F., . . . Hughes, T. P. (2014). PROGNOSIS FOR CML PATIENTS WITH >10% BCR-ABL AFTER 3 MONTHS OF IMATINIB DEPENDS ON THE INITIAL RATE OF BCR-ABL DECLINE. Poster session presented at the meeting of HAEMATOLOGICA. Milan, ITALY: FERRATA STORTI FOUNDATION. |
| 2014 | Kantarjian, H. M., Kim, D. -W., Pinilla-Ibaz, J., Le Coutre, P. D., Paquette, R., Chuah, C., . . . Cortes, J. E. (2014). Ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph plus ) leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: Longer-term follow up of the PACE trial.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. DOI WoS5 |
| 2014 | Lu, L., Saunders, V., Kok, C. H., Leclercq, T., Hughes, T. P., & White, D. L. (2014). Modeling Ponatinib Resistance in <i>BCR-ABL1</i>+ Cell Lines: Implications for Ponatinib Resistance in TKI-Resistant and TKI-naive Patients. Poster session presented at the meeting of BLOOD. AMER SOC HEMATOLOGY. |
| 2014 | Deininger, M. W., Cortes, J. E., Kim, D. -W., Nicolini, F. E., Talpaz, M., Baccarani, M., . . . Hughes, T. P. (2014). Impact of Baseline Mutations on Response to Ponatinib and End of Treatment Mutation Analysis in Patients With Chronic Myeloid Leukemia. Poster session presented at the meeting of CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP. DOI |
| 2014 | Lipton, J. H., Chuah, C., Guerci-Bresler, A., Rosti, G., Simpson, D., Assouline, S., . . . Deininger, M. W. (2014). Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML). Poster session presented at the meeting of BLOOD. AMER SOC HEMATOLOGY. WoS6 |
| 2013 | White, D. L., Schafranek, L., Nievergall, E., Powell, J. A., Hiwase, D., Leclercq, T., & Hughes, T. (2013). STAT5 is a critical component of the time-dependent sensitivity of CML cells to TKI treatment in a Bcr-Abl-dependent, but JAK2-independent manner.. Poster session presented at the meeting of American Society of Haematology. New Orleans, USA. |
| 2013 | White, D., Saunders, V., Eadie, L., David, Y., & Hughes, T. P. (2013). The Depth Of <i>In Vivo</i> Kinase Inhibition Achieved Over The First Month Of Nilotinib Therapy Predicts For Subsequent Molecular Response, and Is Closely Related To Nilotinib Plasma Levels. Poster session presented at the meeting of BLOOD. New Orleans, LA: AMER SOC HEMATOLOGY. WoS1 |
| 2013 | Wang, J., Kok, C. H., D'Andrea, R. J., Hughes, T. P., & White, D. L. (2013). Role Of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) and Its Ligands In The Regulation Of Functional OCT-1 Activity In CML Cells. Poster session presented at the meeting of BLOOD. New Orleans, LA: AMER SOC HEMATOLOGY. DOI |
| 2013 | White, D. L., Eadie, L., & Hughes, T. (2013). Increasing Expression of the Efflux Transporter ABCB1 may Predispose CML Cells to Overt TKI Resistance.. Poster session presented at the meeting of American Society of Haematology. New Orleans, USA. |
| 2013 | Deininger, M. W. N., Cortes, J. E., Kim, D. -W., Nicolini, F. E., Talpaz, M., Baccarani, M., . . . Hughes, T. P. (2013). Impact of baseline mutations on response to ponatinib and end of treatment mutation analysis in patients with chronic myeloid leukemia.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. WoS4 |
| 2013 | Spector, N., Leber, B., Lipton, J. H., De Souza, C., Moiraghi, B., Steegmann, J. L., . . . Rea, D. (2013). Switching patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with residual disease on long-term imatinib (IM) to nilotinib (NIL): ENESTcmr 24-mo follow-up. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. |
| 2013 | Parker, W., Yeoman, A., Altamura, H., Roberts, N., Yeung, D., Jamison, B., . . . Branford, S. (2013). Additional BCR-ABL1 Mutations Identified By Sensitive Mass Spectrometry In Chronic Phase CML Patients With T315I Treated With Ponatinib Are Associated With Relatively Inferior Responses and Outcome. Poster session presented at the meeting of Blood. Amer Soc Hematology. |
| 2013 | Hiwase, D., Yeung, D., Carne, L., Ross, D., Grigg, A., & Hughes, T. (2013). Hypercholesterolemia In Imatinib Intolerant/Resistant CML-CP Patients Treated With Nilotinib: A Retrospective Analysis. Poster session presented at the meeting of Blood. Amer Soc Hematology. WoS10 |
| 2013 | Deininger, M., Shah, N., Cortes, J., Kim, D. W., Nicolini, F., Talpaz, M., . . . Branford, S. (2013). Impact Of Baseline (BL) Mutations, Including Low-Level and Compound Mutations, On Ponatinib Response and End Of Treatment (EOT) Mutation Analysis In Patients (Pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML). Poster session presented at the meeting of Blood. Amer Soc Hematology. WoS3 |
| 2013 | Parker, W., Phillis, S., Yeung, D., Hughes, T., Scott, H., & Branford, S. (2013). PCR-mediated recombination can lead to artificial chimera formation, which may pose as BCR-ABL1 compound mutations. Poster session presented at the meeting of Oral Sessions from the 55th ASH Annual Meeting and Exhibition, as published in Blood. New Orleans, Louisiana: American Society of Hematology. |
| 2012 | Branford, S., Ross, D., Prime, J., Field, C., Altamura, H., Yeoman, A., . . . Hughes, T. (2012). Early Molecular Response and Female Sex Strongly Predict Achievement of Stable Undetectable <i>BCR</i>-<i>ABL1</i>, a Criterion for Imatinib Discontinuation in Patients with CML. Poster session presented at the meeting of BLOOD. GA, Atlanta: AMER SOC HEMATOLOGY. DOI WoS6 |
| 2012 | Watkins, D. B., Kok, C. H., D'Andrea, R. J., Hughes, T. P., & White, D. L. (2012). Global DNA methylation analysis identifies key pathway differences between poor (low OCT-1 activity) and standard risk CP-CML patients at diagnosis. Poster session presented at the meeting of “Abstracts of the 54th Annual Meeting and Exposition of the American Society of Hematology, as published in Blood. Atlanta, GA: America Society of Hematology. |
| 2012 | Nievergall, E., White, D. L., Yong, A. S. M., Ramshaw, H. S., Busfield, S. J., Vairo, G., . . . Hiwase, D. K. (2012). Effective Elimination of CML Progenitor and Stem Cells Through Combination of α-CD123 Antibody-Dependent Cell-Mediated Cytotoxicity and Tyrosine Kinase Inhibitor Treatment. Poster session presented at the meeting of BLOOD. GA, Atlanta: AMER SOC HEMATOLOGY. DOI |
| 2012 | Schafranek, L., Nievergall, E., Powell, J. A., Hiwase, D. K., White, D. L., & Hughes, T. P. (2012). Commitment of CML Cells to Apoptotic Cell Death Depends On the Length of Exposure to Das and the Level of STAT5 Activity. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY. DOI WoS3 |
| 2012 | Yeung, D. T., Osborn, M. P., White, D. L., Branford, S., Kornhauser, M., Slader, C., . . . Hughes, T. P. (2012). Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY. DOI WoS8 |
| 2012 | Parker, W. T., Yeoman, A. L., Jamison, B. A., Yeung, D. T., Scott, H. S., Hughes, T. P., & Branford, S. (2012). The patient's BCR-ABL1 Kinase Domain Mutation History Is Important for Decisions Regarding Tyrosine Kinase Inhibitor Therapy. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY. DOI |
| 2012 | White, D. L., Saunders, V., Yeung, D., Grigg, A., & Hughes, T. (2012). Early Molecular Response to Imatinib in CP-CML Patients: The Significance of Early Dose Intensity and OCT-1 Activity in Responders and Efficacy of Dose Escalation and Switch to Nilotinib in Non-Responders.. Poster session presented at the meeting of American Society of Haematology. Atlanta, USA. |
| 2012 | Delphine, R., Gautier, J. -F., Breccia, M., Saglio, G., Hughes, T. P., Kantarjian, H. M., . . . Hochhaus, A. (2012). Incidence of Hyperglycemia by 3 Years in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib (NIL) or Imatinib (IM) in ENESTnd. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY. DOI WoS5 |
| 2012 | Hochhaus, A., Hughes, T. P., Saglio, G., Guilhot, F., Al-Ali, H. K., Rosti, G., . . . Kantarjian, H. M. (2012). Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Based On Early Molecular Response and Factors Associated with Early Response: 4-Year Follow-up Data From Enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients). Poster session presented at the meeting of BLOOD. GA, Atlanta: AMER SOC HEMATOLOGY. DOI WoS19 |
| 2012 | Cortes, J. E., Pasquini, R., Kantarjian, H. M., Joske, D., Meillon, L. A., Shen, Z., . . . Hughes, T. P. (2012). First-Line Treatment and Management of Chronic Myeloid Leukemia (CML) in Clinical Practice: Update of > 1800 Patients (Pts) in the WORLD CML Registry. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY. DOI |
| 2012 | Kantarjian, H. M., Kim, D. -W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., . . . Cortes, J. E. (2012). Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY. DOI WoS3 |
| 2011 | Saglio, G., Kantarjian, H., Reiffers, J., Jootar, S., Kalaycio, M. E., Shibayama, H., . . . Hochhaus, A. (2011). The incidence of BCR-ABL mutations in patients (pts) with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP) treated with nilotinib or imatinib in ENESTnd: 24-month follow-up. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. DOI WoS2 |
| 2011 | Soverini, S., Angelini, S., Barnett, M., Ravegnini, G., Pane, F., Hughes, T. P., . . . Martinelli, G. (2011). Pharmacogenetics of drug transporters may be useful to identify chronic myeloid leukemia patients who are less likely to achieve molecular responses to imatinib: Implications for treatment optimization in the era of new tyrosine kinase inhibitors. Poster session presented at the meeting of CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. DOI |
| 2011 | Yin, O. Q., Giles, F. J., Baccarani, M., le Coutre, P., Chia, Y. L., Gallagher, N., . . . Larson, R. A. (2011). CONCURRENT USE OF PROTON PUMP INHIBITORS (PPI) OR H2-BLOCKERS DID NOT ADVERSELY AFFECT NILOTINIB RESPONSE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML). Poster session presented at the meeting of CLINICAL PHARMACOLOGY & THERAPEUTICS. Dallas, TX: NATURE PUBLISHING GROUP. |
| 2011 | Larson, R. A., Kim, D., Rosti, G., Stenke, L., Pasquini, R., Hoenekopp, A., . . . Kantarjian, H. (2011). Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-month follow-up. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. DOI |
| 2011 | Hughes, T. P., Kim, D. -W., Etienne, G., De Souza, C., Kurokawa, M., Kalaycio, M., . . . Hochhaus, A. (2011). The Incidence of BCR-ABL Mutations and Their Impact on Outcome in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib or Imatinib in ENESTnd: 36-Month Follow-up. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY. WoS2 |
| 2011 | Hochhaus, A., Ossenkoppele, G., Reiffers, J., Yao, M., Shibayama, H., Gatterman, N., . . . Kantarjian, H. M. (2011). Results From the ENESTnd Extension Study: Efficacy and Safety of Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP), Treated with Nilotinib 400 Mg Twice Daily (BID) After Suboptimal Response (SoR) or Treatment Failure (TF) to Imatinib 400 Mg Once Daily (QD) or Nilotinib 300 Mg BID. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY. |
| 2011 | Larson, R. A., Bunworasate, U., Turkina, A. G., Goldberg, S. L., Dorlhiac-Llacer, P., Lopez, J. L., . . . Hughes, T. P. (2011). Nilotinib Shows Safety and Efficacy in Older Patients (≥ 65 years) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Comparable with That in Younger Patients with Chronic Myeloid Leukemia in Chronic Phase: Results From ENESTnd. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY. WoS2 |
| 2011 | Saglio, G., LeCoutre, P. D., Pasquini, R., Jootar, S., Nakamae, H., Flinn, I. W., . . . Kantarjian, H. M. (2011). Nilotinib Versus Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd 36-Month (mo) Follow-up. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY. WoS1 |
| 2008 | Vandyke, K., Dewar, A. L., Davis, A. N., Fiuer, S., Hughes, T. P., To, L. B., & Zannettino, A. C. W. (2008). The tyrosine kinase inhibitor dasatinib decreases osteoclast formation and activity in vitro. Poster session presented at the meeting of 30th Annual Meeting of the American Society for Bone and Mineral Research, as published in Journal of Bone and Mineral Research. Montreal, Canada: Wiley. DOI |
| Year | Citation |
|---|---|
| 2025 | Eadie, L. N., McDougal, D. P., Lagonik, E., Schutz, C. E., Conlin, T. S., Page, E. C., . . . White, D. L. (2025). The 5’ fusion partner modulates response to the STAMP inhibitor asciminib in <i>ABL</i> -rearranged ALL. DOI |
2021 - 2026 Medical Research Future Fund (MRFF) - Research Grants - Precision Medicine for Chronic Myelomonocytic Leukaemia: Phase II Trial Studying the Efficacy of Lenzilumab or High Dose Ascorbate plus Azacitidine Based on Molecular Profiling Compared to Risk-matched Historical Cohort.
2020 Cancer Council SA Beat Cancer Research Project Grant. Developing an artificial intelligence-based algorithm to enable a risk-adapted approach to frontline therapy in chronic myeloid leukaemia (CML)
2018 Australian Cancer Research Fund (ACRF) – Infrastructure: ACRF Centre for Integrated Cancer Systems Biology (ACRFCICSB).
2018 - 2021 NHMRC Project Grant. Chronic Myeloid Leukaemia: Changing the treatment paradigm
2018 - 2022 NHMRC. Principal Research Fellowship. Improving Leukaemia Outcomes
2016 – 2018 Leukemia & Lymphoma Society (US). Translational Research Program Grant
2015 - 2019 NHMRC Program Grant: Cytokine dysregulation in leukaemia
2015 Bristol Meyer Squibb Australia. Correlative Science Proposal Associated with the DIRECT study.
2014 - 2017 Determining the prerequisites for the achievement of treatment-free remission in chronic myeloid leukaemia to facilitate the development of new therapeutic approaches with curative intent.
2014 Bristol Meyer Squibb Australia. Correlative Science Proposal Associated with the REGALLIA clinical trial registry.
2014 Bristol Meyer Squibb Australia. Correlative Science Proposal Associated with the REGALLIA clinical trial registry.
2014 Novartis Australia. Correlative Science Proposal Associated with the ENESTxtnd clinical trial.
2013 - 2015 Screening for recently defined genetic lesions in poor risk adult and childhood ALL, and developing treatment approaches to target causative pathways
2013 - 2017 NHMRC. Practitioner Fellowship
2012 - 2014 NHMRC. Assessment of markers of genomic instability for the prediction of treatment response of chronic myeloid leukaemia
2012 – 2014 NHMRC. Characterisation of a new poor-risk sub-category of chronic phase chronic myeloid leukaemia
2012 – 2014 NHMRC. Development of a treatment algorithm for kinase inhibitor therapy in CML
2011 - 2012 Leukaemia Foundation of Australia. Developing a gene signature to predict the optimal front-line kinase inhibitor for CP-CML patients
2011 - 2013 Novartis Pharmaceuticals Australia. Correlative Science Proposal Associated with the ENESTxtnd clinical trial.
2011 Novartis Pharmaceuticals Australia. Correlative Science Associated with TIDELII Clinical Trial – expansion of patient numbers.
| Date | Role | Research Topic | Program | Degree Type | Student Load | Student Name |
|---|---|---|---|---|---|---|
| 2023 | Co-Supervisor | Investigating the role of lipid metabolism in chronic myeloid leukaemia | Doctor of Philosophy | Doctorate | Full Time | Miss Molly Gladys Tolland |
| 2023 | Co-Supervisor | Investigating the role of lipid metabolism in chronic myeloid leukaemia | Doctor of Philosophy | Doctorate | Full Time | Ms Molly Tolland |
| 2021 | Co-Supervisor | Investigation of current, innovative treatments and the roles of secondary genomic lesions in BCR-ABL1 positive leukaemias | Doctor of Philosophy | Doctorate | Part Time | Mr Elias Lagonik |
| 2021 | Co-Supervisor | Genomic Mechanisms Influencing Outcome In Chronic Myeloid Leukaemia | Doctor of Philosophy | Doctorate | Part Time | Miss Adelina Catherina B. Fernandes |
| 2021 | Co-Supervisor | Investigation of current, innovative treatments and the roles of secondary genomic lesions in BCR-ABL1 positive leukaemias | Doctor of Philosophy | Doctorate | Part Time | Mr Elias Lagonik |
| 2021 | Co-Supervisor | Genomic Mechanisms Influencing Outcome In Chronic Myeloid Leukaemia | Doctor of Philosophy | Doctorate | Part Time | Miss Adelina Catherina B. Fernandes |
| Date | Role | Research Topic | Program | Degree Type | Student Load | Student Name |
|---|---|---|---|---|---|---|
| 2019 - 2023 | Principal Supervisor | Unravelling Resistance Mechanisms in Philadelphia Positive Leukemias: Targeted Treatment Strategies to Overcome Resistance | Doctor of Philosophy | Doctorate | Full Time | Mr Govinda Poudel |
| 2012 - 2014 | Principal Supervisor | The role of cytokines in governing the expansion of the T315I mutation in Chronic myeloid leukaemia | Master of Philosophy (Medical Science) | Master | Full Time | Dr Oi-Lin Lee |
| 2012 - 2016 | Co-Supervisor | In Vitro Investigation of Intracellular Ponatinib Transport and Modeling Ponatinib Resistence in BCR-ABL1+ Cell Lines: Implications for Therapeutic Strategies | Doctor of Philosophy | Doctorate | Full Time | Ms Liu Lu |
| 2012 - 2016 | Co-Supervisor | Prognostic Markers Associated With Tyrosine Kinase Inhibitor Treatment Response and Maintenance of Treatment Free Remission in Chronic Myeloid Leukaemia | Doctor of Philosophy | Doctorate | Full Time | Prof David Yeung |
| 2010 - 2014 | Principal Supervisor | Assessment of Critical Survival Mechanisms Exploited by BCR-ABL1+ Cells to Evade Tyrosine Kinase Inhibitor-Induced Death; Determination of Novel Therapeutic Targets in Chronic Myeloid Leukaemia | Doctor of Philosophy | Doctorate | Full Time | Miss Lisa Schafranek |
| 2010 - 2014 | Co-Supervisor | Defining CP-CML patient subsets associated with poor imatinib uptake and response | Doctor of Philosophy | Doctorate | Full Time | Mr Dale Benjamin Watkins |
| 2009 - 2013 | Principal Supervisor | Nilotinib Efflux and Resistance Development: The Effects of Combination and Concomitant Therapies on the Transport and Efficacy of Nilotinib | Doctor of Philosophy | Doctorate | Full Time | Ms Laura Eadie |
| 2008 - 2013 | Principal Supervisor | Investigating Drugs that Enhance Imatinib Uptake and Factors which Contribute to the Functional Activity of OCT-1 in CML Cells | Doctor of Philosophy | Doctorate | Full Time | Miss Jueqiong Wang |
| 2008 - 2012 | Principal Supervisor | TKI Resistance in CML Cell Lines: Investigating Resistance Pathways | Doctor of Philosophy | Doctorate | Full Time | Mrs Carine Tang |
| 2007 - 2011 | Principal Supervisor | Cell Lineage, Cell Maturity and BCR-ABL: Factors Which Influence Imatinib Uptake in Chronic Myeloid Leukaemia | Doctor of Philosophy | Doctorate | Full Time | Ms Jane Engler |
| 2006 - 2009 | Principal Supervisor | Minimal Residual Disease in Chronic Myeloid Leukaemia after Imatinib Treatment | Doctor of Philosophy | Doctorate | Full Time | Dr David Ross |
| 2005 - 2009 | Co-Supervisor | Investigating the Effects of ABL Kinase Inhibitors on the Signalling and Function of Normal Leukocytes and Leukemic Cells | Doctor of Philosophy | Doctorate | Full Time | Mr Stephen Blake |
| 2004 - 2008 | Principal Supervisor | Factors which Impact on the Response of CML Patients to ABL Kinase Inhibitor Therapy: A Study of Imatinib and Nilotinib | Doctor of Philosophy | Doctorate | Part Time | Prof Deborah Lee White |
| 2001 - 2006 | Co-Supervisor | GM-CSF Protection of CML CD34+ Cells from the Inhibitory Effect of Imatinib | Doctor of Philosophy | Doctorate | Full Time | Mr Pongtep Viboonjuntra |
Connect With Me
External Profiles
